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Abstract 
 
Epilepsy is a common and serious neurological disorder to which a high proportion of patients 
continue to be considered “drug-resistant” despite the availability of a host of anti-seizure drugs. 
Investigation into new treatment strategies is therefore of great importance, one such strategy 
being the use of the nose to deliver drugs directly to the brain with the help of pharmaceutical 
formulation to overcome the physical challenges presented by this route. The overall aim of 
this thesis was to establish and apply a seizure model to the investigation of two types of 
particulate intranasal delivery systems; microparticles and cubosomes.  
Chapter One introduces the topic of intranasal delivery of anti-seizure drugs, covering the link 
between the nose and seizures, pathways from the nose to the brain, current rudimentary 
formulations in clinical use, animal seizure models and their proposed application in studying 
intranasal treatments, and a critical discussion of relevant pre-clinical studies in the literature. 
Upon this, Chapter Two begins by validating a seizure model based on the Maximal 
Electroshock Seizure Threshold (MEST) test with the intention of using it to detect the effects 
of intranasally administered therapeutics. The design attempts to address previously scarcely 
acknowledged issues of sensitivity in the MEST model and confounding by anaesthetics which 
are currently necessary to reliably and ethically perform intranasal administration to the 
olfactory region in rats. The results show that the model was able to clearly detect a change in 
seizure threshold after administration of the positive control, intravenous phenytoin, which was 
supported by therapeutic brain and plasma concentrations of the drug as determined using an 
internally developed Liquid Chromatography Mass Spectrometry (LC-MS) assay. Importantly, 
this effect was able to be detected despite the use of the inhaled anaesthetic, isoflurane, to briefly 
sedate the animals 60 minutes prior to stimulation.   
In Chapter Three, the seizure model is applied to the evaluation of tamarind seed polysaccharide 
(TSP) microparticles as a proposed intranasal delivery system for the pharmacokinetically 
troublesome anti-seizure drug phenytoin.  In this first pharmacodynamic study, to the author’s 
knowledge, of a dry powder mucoadhesive microparticle formulation for seizure treatment, the 
model identified a peak anti-seizure effect time of 120 minutes after administration, which 
coincided with peak brain concentrations and supported its utilisation in intranasal delivery 
screening. Furthermore, the complementary demonstration of a histologically intact nasal 
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epithelium and simultaneous measurement of phenytoin’s major metabolite, 5-(4-
Hydroxyphenyl)-5-phenylhydantoin (4-HPPH) in brain tissue and plasma, supported the 
hypothesis of a direct intranasal delivery to the brain and the suitability of the microparticles 
for further trials.  
In Chapter Four, the seizure model is applied to explore a potential new type of anti-seizure 
therapeutic, the endogenous endocannabinoid-like molecule, oleoylethanolamide (OEA), 
which has not yet had an effect on seizures documented. A cubosome dispersion was selected 
as the delivery vehicle, presenting one of the few pharmacodynamic in vivo studies conducted 
with this class of formulation to date. Given the unknown effects of oleoylethanolamide, it was 
firstly administered intravenously as a control, but no effect on seizure threshold was evident. 
Considering the complex nature of the hydrolysis-susceptible oleoylethanolamide and the self-
assembling cubosome dispersion, complementary in vivo pharmacokinetic studies (utilising an 
internally developed LC-MS assay) and in vitro structural stability studies (utilising Small-
angle X-ray Scattering (SAXS)) were conducted to further explore confounding factors. 
Despite presenting with complexities of their own, they overall supported the lack of 
pharmacodynamic effect seen after systemic administration. Intranasal studies were conducted 
in an attempt to bypass the challenges of systemic administration, but also demonstrated no 
measurable change in seizure threshold. Histological studies to determine a safe dose uncovered 
a toxicity of cubosomes to the nasal epithelium at the highest dose, independent of lipid type, 
which has not yet been described in any in vivo liquid crystalline nanoparticle studies to date 
and should be considered in future related work.   
In summary, this thesis presents a tailored seizure model for screening intranasal delivery 
systems, a practical template for studying these systems in vivo, and a pre-clinical evaluation 
of two such systems. Notwithstanding the discussed limitations, it concludes that dry-powder 
mucoadhesive microparticles appear to be a promising platform for future study of intranasal 
anti-seizure drug delivery, while cubosomes and oleoylethanolamide may be better suited to 
other applications until a more thorough in vivo exploration of their respective fields exists.  
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Chapter One 
 
Intranasal Treatments for Epilepsy 
                                                                         
1.1 Epilepsy and its Treatment 
Epilepsy has been defined as a disorder of the brain characterised by an enduring predisposition 
to generate epileptic seizures and by the neurobiologic, cognitive, psychological, and social 
consequences of this condition. The condition therefore requires the occurrence of more than 
one epileptic seizure, an event that is defined as a transient occurrence of signs and/or symptoms 
due to abnormal excessive or synchronous neuronal activity in the brain1. A seizure may be 
generalised, as is the most commonly recognised presentation by the layman involving 
convulsions, but in a lot of cases may be, at least initially, focal (or partial) in nature2. In this 
case, the seizure develops in a localised area of the brain (at which point a patient may 
experience an aura associated with that region – e.g. déjà vu or sensory hallucinations) and may 
or may not progress to a generalised seizure affecting the whole brain. Individuals may remain 
conscious and alert during this focal experience, in which case it is classified as a simple partial 
seizure. Alternatively, they may experience altered consciousness or lose it all together, in 
which case it is classified as a complex partial seizure.  
Epilepsy is the most common serious neurological disorder3. It is a disease of all ages, affecting 
up to 50 million people worldwide4 and comes with the huge burdens of reduced quality of life, 
high unemployment rates, reduced life expectancy and comorbidities such as depression5. 
Despite decades of international research towards developing pharmacological treatments and 
the current availability of over 22 anti-seizure drugs (ASDs)6, it is somewhat disconcerting to 
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reflect on the statistic that approximately 30% of patients still fall under the classification of 
“drug-resistant”, with temporal lobe epilepsy (i.e. focal epilepsy arising from the temporal lobe) 
thought to be the most susceptible to becoming drug resistant7. Drug resistance is defined by 
the International League Against Epilepsy (ILAE) as the failure of adequate trials of two 
tolerated and appropriately chosen and used ASD schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom8.  Proposed mechanisms of drug resistance 
have been discussed in detail elsewhere9,10 but in general, may involve genetic variation, 
disease-related mechanisms (seizure etiology, progression of disease, neural network changes, 
alterations in drug target(s), alterations in drug uptake into the brain) or drug-related 
mechanisms (tolerance or ineffective mechanism of action).  
Two phrases are important to consider in this definition of drug resistance in the context of 
developing future pharmaceutical treatments for it. The first is the endpoint of “sustained 
seizure freedom”, as quality of life does not correlate particularly well with seizure frequency 
and the constant threat of randomly having a seizure is usually more destructive than the actual 
seizure itself11. The second is “tolerated”, as side effects have a strong inverse correlation with 
quality of life12 and will often lead to discontinuation or non-compliance, resulting in a longer 
time period before resistance is recognised. The “appropriately chosen and used” and “adequate 
trials” aspects can be addressed by clinicians and patients themselves. There has been much 
discussion in recent years on how to move forward to address what appear to be the two clear 
needs as far as pharmaceuticals are concerned; increased efficacy in drug-resistant individuals 
and improved tolerability. While the latter has been significantly improved, it still remains an 
issue13. Pharmaceutical companies, however, have pulled back from the expensive process of 
developing new ASDs, as the market for them would appear to be saturated6.  
Several strategies have been suggested in order to develop better treatments. The most widely 
recognised is the need to develop and utilise more broad and goal-oriented models in screening 
protocols, given that most ASDs on the market were initially selected for development based 
on successful performance in the Maximal Electroshock Seizure (MES) and/or the 
subcutaneous pentylenetetrazole (s.c. PTZ) tests, thereby sending ASD discovery down a multi-
decade road of unearthing similar compounds to those which were already used and 
disregarding compounds that may have been effective through unique mechanisms and might 
have been of benefit to the large “drug-resistant” population14,15. As well as developing 
screening models relevant to drug resistance, there is also a focus on establishing models with 
which to identify and test disease-modifying anti-epileptogenic drugs.  
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Hitting a target pharmacologically with a rational or serendipitous therapeutic molecule is the 
simplest and most high throughput method of screening and developing new ASDs and will no 
doubt remain extremely important as the focus moves towards disease-modifying agents and 
treatments for specific types of epilepsy. However, there exists a potentially very useful 
supplementary approach that pharmacology alone cannot address and which appears to have 
therefore remained largely confined to the literature; the utilisation of pharmaceutical 
formulation. Perhaps the most interesting aspect of this is the potential it offers to exploit 
endogenous molecules16,17, which are normally subject to rapid in vivo degradation, but may 
exert important therapeutic effects where synthetic molecules fail. From another perspective, 
pharmaceutical formulation might be used to achieve more efficient targeting of drug to the 
brain to improve tolerability and efficacy (e.g. through the use of nanoparticles), or for simply 
incorporating a difficult molecule into a physiologically-friendly solution or suspension18–22. 
Finally, and perhaps most obviously, it provides a pathway to optimally deliver molecules by 
nonconventional routes and orifices.  
The following review explores the nose, a somewhat alternative approach to ASD treatment for 
which pharmaceutical formulation is intimately relevant, and while investigated from some 
angles, has not yet had its full potential explored. The nose has had longstanding and interesting 
relationships with both epilepsy and the brain and this Chapter will discuss these, along with 
the potential value of delivering ASDs to the brain through the nose as a therapeutic strategy 
for the treatment of seizures and epilepsy. 
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1.2 Relationships between the Nose and Epilepsy 
1.2.1 Historical and Epidemiological 
Historical examples of treating epilepsy through the nose can be drawn from all corners of the 
world. In Eastern countries, the smell of a shoe has been, and apparently still is, used as a first 
aid measure to arrest seizures23. In the Western world, the burning of the ammonia-based 
hartshorn under the nose as a first aid measure for treating seizures was reported in the 17th 
century24. In later times, it was suggested that the use of ammonia or amyl nitrate may arrest 
the course of a seizure25 and later still that such a stimulus may be used to condition a patient 
to inhibit seizures psychologically by thinking of it during the prodromal phase26,27. The 
commonality between these “treatments” is obviously the potent and disenchanting nature of 
the aroma. More recently, and in contrast to these reports, Betts28 proposed conditioning with 
aromatherapy as a means of controlling seizures. However, while pleasant olfactory sensations 
may have played a role in this, they could not be distinguished from effects of transdermal oil 
absorption or simply the relaxation associated with the sessions. The relationship between the 
nose and epilepsy is therefore something which science has sought to make progress on for 
centuries and explain through the apparent link between olfactory sensation networks and the 
networks involved in the generation and propagation of seizures. 
Evidence of the involvement of the olfactory sensory network with some types of epilepsies 
can be found in the symptoms experienced by some patients, namely olfactory auras and 
impaired olfactory function. An aura is the subjective experience of a simple partial seizure29, 
related to activation of a specific area (or areas) of the brain. It is usually a hallucination, but 
may also possibly be an illusion or a vaguer episode with a quality of reminiscence (e.g. déjà 
vu). The usual occurrence in an olfactory aura is the experience of an unpleasant odour, with 
the earliest influential description of an olfactory case dating back to 1889, describing a woman 
with a horrible smell of “dirty burning stuff” prior to a seizure30. It has been estimated that 19-
30% of epileptic auras are olfactory, but these occur in only 0.6-16% of people with temporal 
lobe epilepsy and 0.9-8.1% of all people with focal epilepsy30. Of note, it appears that such 
auras may be more prevalent in patients with temporal lobe epilepsy, and the involvement of 
the olfactory network in this particular condition is further supported by the occurrence of many 
abnormalities in olfactory function in these patients. These include impairment of odour 
discrimination, memory and identification, as well as temporarily altered detection thresholds, 
with an increased sensitivity before a seizure and decreased sensitivity for hours or days 
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afterwards30. The fact that temporal lobe epilepsy represents most cases of drug-resistant 
epilepsy (at least those managed surgically)31 suggests a potentially significant role for the nose 
in the treatment of this phenomenon.  
1.2.2 Neurological 
1.2.2.1 The Olfactory System 
The olfactory system is remarkably similar between different species32 and is presented 
diagrammatically in Figure 1.1. The olfactory epithelium is located in the dorsal or 
dorsoposterior nasal passage and contains bipolar sensory neurons with an axon in the olfactory 
bulb and a dendrite in the epithelium capped with numerous cilia which extend into a surface 
mucous layer and can interact with dissolved odourant molecules. The axonal synapses of the 
olfactory neurons converge onto mitral or tufted cells in the glomeruli of the olfactory bulbs33, 
with stimulation of different classes of receptor neurons leading to the formation of a map of 
excited glomeruli34. Unlike all other sensory inputs which are primarily relayed through the 
thalamus, the olfactory bulbs first transmit signals along the myelinated lateral olfactory tract 
(LOT) to project diffusely into the largest region of the primary olfactory cortex called the 
piriform cortex, which is only two synapses removed from the external environment34. The 
piriform cortex is made up of three layers, a sparsely populated superficial layer, a main input 
layer containing densely packed somata of glutamate-releasing principal neurons and finally, a 
deep layer containing principal neurons at a lower density34. Gamma aminobutyric acid 
(GABA)-releasing interneurons are scattered across all layers and provide feedforward and 
feedback inhibition of principal cells34. From the primary olfactory cortex, information is 
projected widely to secondary olfactory areas such as the orbitofrontal cortex via the 
mediodorsal thalamic nucleus35.   
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Figure 1.1. Basic organisation of the olfactory system. Adapted from Nicola-Antoniu.36 
 
1.2.2.2 Epilepsy and the Olfactory System 
The olfactory system, in particular the piriform cortex, has been suggested to have an important 
role in epilepsy, as suggested by the historical and epidemiological links described above, 
which science has since illuminated. Olfactory impairment in some focal epilepsies, especially 
of the temporal lobe, has been shown by neuroimaging to be associated with changes in the 
piriform cortex that parallel the odour discrimination, memory and identification impairment 
reported30. Furthermore, atrophy and reduced olfactory bulb volume have been described37,38. 
Seizures that produce olfactory hallucinations typically show widespread orbitofrontal and 
anterior temporal lobe activity. Olfactory auras have been suggested to correspond to epileptic 
activity that causes an intense activation of the piriform cortex and amygdala, as is seen when 
an unpleasant odour is smelt in the environment, however it is worth noting that human seizures 
have been noted to arise from the piriform cortex without an olfactory aura30,39. Interestingly, a 
similar intense activation of the olfactory cortex is also a hypothesis behind the success of 
strong odours in prevention of some seizures by disrupting the synchronised progression of 
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epileptic discharges between regions40 30. Alternative explanations include a change in alertness 
due to a smell which may interrupt seizure progression or a pharmacological effect of the 
odourants30.  
The many neurological connections between the olfactory system and seizures have been 
reviewed in detail by Vaughan and Jackson30 and Vismer et al.41, with both attesting to the great 
therapeutic potential that may be achieved by targeting the piriform cortex. The links between 
the two systems are numerous, with implications of a role for the piriform cortex in seizure 
generation and distribution, epileptogenesis and pharmacoresistance30. As highlighted by 
Vismer et al41, the propagation of seizures through the brain is not a random process and they 
instead exploit existing circuits that normally support highly controlled recurrent activity. In 
this respect, the anatomical arrangement of neural networks in the piriform cortex make it 
inherently susceptible to seizure activity30. Each glomerulus in the olfactory bulb has over 1000 
broad projections (mainly mitral cells) across the piriform cortex to random pyramidal cells30. 
This is necessary to allow complex odour mixtures to be detected, but also forms a large, highly 
interconnected, excitatory network which needs to be carefully regulated by interneurons30. If 
local inhibitory circuits are modified or removed, it is extremely prone to forming hyper-
excitable local networks30. Furthermore, strong reciprocal connections of the piriform cortex to 
nearby structures (e.g. olfactory bulbs, amygdala, hippocampus) normally provide an additional 
means of modulating olfactory inputs, but run the risk of becoming circuits that could sustain 
seizure activity30,42.   
Vaughan and Jackson30 reviewed the roles of the piriform cortex in generation and distribution 
of seizures. In terms of generation, the most obvious connection can be found in the deep 
anterior piriform cortex which contains a well-known chemoconvulsant trigger zone called the 
‘area tempestas’41, which is crucial for seizure initiation within the limbic network. In addition 
to chemical stimulation, the piriform cortex can be electrically kindled to generate seizures 
which follow the same progression of motor features as kindling from other sites such as the 
amygdala30. With regards to the distribution of seizure activity, they noted a number of 
elements. Firstly, the role of the piriform cortex in the process of amygdala kindling42–44 (as 
well as the loss of GABA-ergic interneurons in it during this process45). Secondly, its role as a 
common target of discharge spread in frontal and temporal lobe epilepsies (indicated by the 
sites of lesions that can produce an olfactory aura46. Thirdly, the impact of these epilepsies on 
olfactory function47 and detection of piriform cortex activity by electroencephalogram-
informed functional magnetic resonance imaging (EEG-fMRI)48). Fourthly, its relationship to 
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clinical descriptions of aura progression, and finally, its broad outputs to cortical and subcortical 
regions. Both this distributive ability, combined with the potential for sustained hyper-
excitability, form the basis of hypotheses for a role of the piriform cortex in epileptogenesis 
(through recruitment as a secondary hyper-excitable node) and drug resistance (through 
alterations in neural networks)30. Though these processes fall outside the scope of this review 
and project, it is interesting to consider the effect piriform cortex-targeted therapeutics may 
have on them in light of these theories.  
1.2.3 Clinical and Social 
The clinical application of intranasal (i.n) treatments for seizures have been investigated for 
almost two decades. Despite the extensive aforementioned neurological links between the 
olfactory sensory network and seizures, the current clinical treatments have emerged to exploit 
an entirely different opportunity; the rich vascular bed present in the lower nasal passage49. This 
presents itself as an obvious candidate for rapid absorption of lipophilic therapeutics, namely 
the benzodiazepines, which have so far been used for this purpose. The administration method 
has proven a valuable asset in addressing the need for a practical, effective and socially 
acceptable treatment for seizure emergencies outside of hospital (including prolonged single 
seizures, acute repetitive seizures, and status epilepticus). Due to a lack of registered 
formulation development, this has been used as an off-license management strategy, but 
pharmaceutical companies have taken an interest in optimising nasal spray composition and 
devices21. Importantly, trials are being conducted in human subjects, supporting the potential 
clinical translatability of other such intranasal approaches that are being developed in basic 
science models. The subject has recently been reviewed by Kälviänen50 and Kapoor et al.21, to 
which the reader is referred for a detailed discussion, but the key information will be briefly 
discussed below.  
It has been shown that prompt initiation of medical treatment for seizure emergencies occurring 
outside of hospital can reduce the risks associated with progression to status epilepticus51. To 
make this possible, intranasal, rectal and buccal benzodiazepines have all been used given that 
they are able to be administered quickly and safely by non-clinical caregivers, who will most 
commonly be the first people available to act in such situations. While each achieves rapid 
access to the systemic circulation through blood vessel-rich areas, from a social perspective, 
the intranasal route has gained a lot of favour. Firstly, it avoids the social embarrassment and 
legal liability concerns associated with rectal administration52,53, and secondly, it avoids the risk 
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of aspiration of buccal doses, and inconsistent absorption due to ictal hypersalivation54,55.  
Furthermore, from a clinical perspective, the onset of action and effectiveness of intranasal 
benzodiazepines has been shown to be superior to rectal administration56. 
The most studied benzodiazepine for intranasal administration is midazolam, which was first 
reported to treat acute seizures in 199657 and was followed by a number of other studies 
testifying to its efficacy and safety58–62. It achieves 67-100% bioavailability and peaks within 
10 minutes, leading to seizure control within 2-5 minutes after administration50. It is classified 
as a “water soluble benzodiazepine” as good solubility can be achieved in aqueous solutions 
below a pH of 463, however this is likely responsible for the commonly reported burning or 
irritation sensation in the nose, and bitter taste lasting for 30-45 seconds, after 
administration64,65.  With increasing pH, midazolam reverts to a lipophilic form, affording it 
high systemic absorption and bioavailability. Notably, intranasal administration of midazolam 
up to doses of 10 mg has been repeatedly shown to be more effective than rectal diazepam, 
including in a home-administration setting66–69, supplementing the social benefits of this route 
described above. Furthermore, despite having a slightly slower onset than i.v. diazepam (2-5 
minutes vs 2-3 minutes50), it has been suggested to also have applications in an emergency room 
setting, in that the total time until seizure cessation after arriving at hospital is reduced by 
avoiding the delay associated with establishment of an i.v. line70–73.   
Diazepam, the i.v. benzodiazepine of choice (half-life around 50 hours) and the rectal 
alternative to i.n. midazolam, has also been tested by the i.n. route. Peak plasma concentrations 
are reached significantly later than with i.n. midazolam (45 minutes vs 10 minutes74), but time 
to onset of seizure cessation has not yet been reported, let alone in a head to head trial with 
midazolam. Nasopharyngeal adverse effects studied with one formulation were reported to 
resolve within 12 hours74, but would seem to be more extensive and long lasting, or perhaps 
just more meticulously reported, than those of midazolam. Side effects listed included 
headache, dysgeusia, nasal discomfort, lacrimation, nausea, rhinorrhea, somnolence, 
oropharyngeal pain, paranasal sinus hypersecretion, tongue injury, dizziness, nasal congestion, 
parosmia, cough, fatigue, myalgia and throat irritation74. Additionally, it is possible that the co-
solvents required to formulate the lipophilic diazepam may explain the apparent increase in 
adverse effects compared with low pH midazolam solution, which was likely buffered quickly 
in the nasal passage. Furthermore, different formulation compositions of diazepam may also 
influence i.n. bioavailability75.   
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Finally, lorazepam is reported to be four to six times less lipid soluble than midazolam and 
diazepam, and has been found to have a peak effect time of 30 minutes and half-life of 18.5 
hours after intranasal administration76,77. It has been evaluated in a study in children up to doses 
of 4 mg and found to be non-inferior to i.v. lorazepam with the same median onset time of 3 
minutes (range 1-25 minutes)78. Evaluation of adverse effects and pharmacokinetics after i.n. 
administration has also been performed in healthy volunteers in comparison to the i.v. route76, 
however, the formulation used was likely different. Thus, it is uncertain whether any benefit is 
obtained from lorazepam compared with the more extensively studied midazolam, other than 
perhaps an extended duration of action and being easier to formulate than diazepam.  
Overall, it would appear that intranasal administration of anti-seizure medication is a rapid, 
effective and socially acceptable practice with industry engagement in product development 
both in terms of formulation and administration devices. However, the scope is currently limited 
to benzodiazepines, which are really only an emergency treatment of severe prolonged or 
cluster seizures due to issues such as side effects, tolerance and dependence, as well as reliance 
on a systemic absorption mechanism. It should also be noted that because systemic absorption 
is the main proposed route of entry into the brain, high doses are still required, so it does not 
currently offer any benefit in terms of decreasing systemic exposure. The more exploratory 
pharmaceutical science field has been developing an increased interest in taking this further and 
exploring the potential of the nose as a route for addressing other challenges in the clinical 
treatment of seizures and epilepsy, primarily focusing on bypassing the systemic circulation 
and exploiting direct nose-to-brain transport pathways.  
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1.3 The Anatomy and Physiology of Intranasal Administration to 
the Brain 
1.3.1 The Nasal Passage and Epithelia 
The nasal septum divides the nasal cavity longitudinally into two passages, each having three 
key regions: the nasal vestibule (a slight dilatation just inside the nares and before the main 
chamber), the respiratory region and the olfactory region33,79. The latter two comprise the main 
chamber of the nasal passage and essentially consist of an epithelial layer covered by a 
continuous layer of mucous. Bony structures (turbinates) lined with mucosal tissue project into 
the lumen to increase the surface area of the nasal passage and facilitate filtering, humidification 
and warming of inspired air79. Four types of epithelia exist in the nasal passages and help 
distinguish the different regions. The nasal vestibule primarily contains a squamous epithelium, 
which becomes a non-ciliated, cuboidal/columnar (transitional) epithelium, then a ciliated, 
pseudostratified cuboidal/columnar (respiratory) epithelium in the anterior main chamber and 
finally the olfactory epithelium in the dorsal or dorsoposterior main chamber79. The respiratory 
and olfactory epithelia (Figure 1.2) will be the focus of the following discussion as they are 
considered to be the most relevant to therapeutic delivery to the brain33. For detailed reviews of 
nasal anatomy to supplement the following text, the reader is referred to more extensive 
reviews33,79–82.  
 
Figure 1.2. Basic anatomy of the olfactory (A) and respiratory (B) epithelia of the nasal passages. 
Figures adapted  from Uriah & Maronpot.83 
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1.3.2 Respiratory Epithelium 
The respiratory epithelium (Figure 1.2B and Figure 1.3A) consists of goblet cells, cuboidal 
cells, brush cells, basal cells and ciliated and non-ciliated columnar cells33,83. It also contains 
various glands for producing nasal secretions in addition to the mucous secreted by goblet 
cells33. The mucous layer consists of a low viscosity layer, which bathes the cilia, and a more 
viscous layer on top84. Deposited substances are generally subject to rapid mucociliary 
clearance by the motile cilia of the brush cells, which results in removal from this region in 
approximately 15-20 minutes81. The respiratory epithelium has a far richer supply of blood 
vessels and lymphatics in comparison to the olfactory epithelium82. Interestingly, it is 
innervated by branches of the trigeminal nerve, many fibres of which extend through the 
epithelium so that their free nerve endings lie just beneath tight junctions (i.e. very close to the 
surface)33. The trigeminal nerve has a predominantly sensory function whereby information, in 
the case of the nasal epithelium fibres, is relayed back to both the brainstem at the level of the 
pons and a small portion to the olfactory bulbs33,82 (Figure 1.4B). It should be noted that while 
most significant to the respiratory epithelium, the extension of free trigeminal nerve endings to 
near the surface is also a feature of the olfactory epithelium33.  
1.3.3 Olfactory Epithelium 
The key feature of the olfactory epithelium is the many dendrites of bipolar sensory (olfactory) 
neurons extending out from the central nervous system (CNS) to make direct contact with the 
external environment84 (Figure 1.2A and Figure 1.3B). Each dendritic process ends in a small 
swelling, known as the olfactory knob, which projects 10-23 cilia into the overlying mucous 
layer84. It is important to note that in contrast to the respiratory epithelium, these cilia are non-
motile, so dynamic mucociliary clearance does not occur in this area33,79,84. Rather, mucous 
slowly drains into the respiratory region when it is over-produced. The axons of each olfactory 
neuron are collected into nerve bundles surrounded by interlocking olfactory ensheathing cells 
(the fila olfactoria), which are subsequently collected into a bunch of nerve bundles and further 
enclosed by fibroblasts to form a peri-neural sheath80,82 (Figure 1.3C). These channels extend 
back through small gaps in the cribriform plate (separating the nose and the cranial cavity) to 
enter the cranial cavity, pass through the subarachnoid space containing cerebrospinal fluid 
(CSF), and synapse (along with around 1500 other olfactory neuron axons) with a single mitral 
of tufted cell in the olfactory bulb84. Other features of the olfactory epithelium include 
microvillus sustentacular cells (which act as adjacent supporting cells for the olfactory 
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neurons33), Bowman’s gland cells (which form ducts originating in the lamina propria and 
produce a serous fluid to aid dissolution of odourant molecules33) and horizontal basal cells 
which lie along the basal lamina and act as progenitors to olfactory neuron progenitor basal 
cells, sustentacular cells and cells of the Bowman’s gland and duct. As in the respiratory 
epithelium, blood and lymphatic vessels also exist in the lamina propria33, but to a lesser 
extent82.  
 
Figure 1.3. Possible transport pathways through the (A) respiratory and (B) olfactory epithelia of the 
nasal passage to the brain. (C) Cross-sectional diagram of the arrangement of olfactory nerve bundles 
into the fila olfactoria as they travel towards the brain. Figures adapted with permission from Lochhead 
& Thorne33 and Mistry et al.80 TJ = Tight junction; CSF = cerebrospinal fluid.  
 
1.4 Nasal Routes of Absorption for Therapeutics 
The features of the abovementioned epithelia provide a number of potential delivery routes to 
the CNS (Figure 1.3 and Figure 1.4), collectively divided into the olfactory and respiratory 
pathways. These have been reviewed in detail elsewhere33,82, but will be summarised below. As 
implied by Figure 1.4, the different pathways are most easily classified as systemic, intracellular 
or extracellular and a prerequisite for all pathways, other than intracellular transport via 
olfactory neurons, is an initial transport into the lamina propria. Depending on the properties of 
the molecule, macromolecule or particle concerned, it may achieve this via paracellular 
transport through tight junctions or alternatively, passive diffusion or transcytosis through 
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epithelial cells. Alternatively, it will be trapped in the nasal mucous and eventually cleared from 
the surface.    
 
Figure 1.4. (A) Pathways by which intranasally-administered therapeutics may be cleared or 
transported to the brain. (B) Diagram of rat brain highlighting the olfactory and trigeminal pathways 
to the brain. (C) Distribution of labelled insulin-like growth factor 30 minutes after intranasal 
administration to the respiratory and olfactory epithelia of an anaesthetised rat, showing transport to 
the olfactory bulbs and brainstem. Figure adapted from Thorne et al.85(with permission), Lochhead et 
al.86 and Lochhead & Thorne.33 (with permission). AICA = anterior inferior cerebellar artery; SCA = 
superior cerebellar artery; MCA = middle cerebral artery; OFA = olfactofrontal artery; CSF = 
cerebrospinal fluid.  
 
1.4.1 Systemic Transport 
As indicated in previous sections, the nasal mucosa is highly vascular, which may lead to 
extensive, and possibly undesired, systemic absorption of therapeutics, especially via the more 
endowed respiratory epithelium. Vasculature in this region has of a mixture of continuous and 
fenestrated endothelia, permitting transport of both small and large molecules into the systemic 
circulation82. A proposed advantage of systemic intranasal delivery into the bloodstream may 
be the potential for ‘counter-current transfer’ whereby drug may enter the venous blood supply 
in the nasal passages, but then be rapidly transferred to carotid arterial blood, thereby reaching 
the brain rapidly and in higher concentrations compared to if it underwent an initial distribution 
throughout the systemic circulation82. Alternatively, if substances are not absorbed into the 
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bloodstream, they may drain into the lymphatic vessels in the lamina propria and ultimately to 
the cervical lymph nodes33. 
1.4.2 Intracellular Transport 
The most desirable of the brain delivery pathways to exploit is the intracellular transport of 
therapeutic molecules directly through the olfactory neurons. Given that these neurons extend 
numerous cilia directly into the mucous covering the surface of the epithelium, providing a 
large surface area for odourant detection, the hope has been that they may also provide a large 
surface area for therapeutic absorption by passive diffusion, or in the case of larger 
macromolecules or nanoparticles, a receptor-mediated or adsorptive endocytosis. Therapeutics 
might then diffuse or be transported as cargo through these neurons directly to their axonal 
synapses within the CNS80. Studies have shown that large molecules such as horseradish 
peroxidase, wheat germ agglutinin-horseradish peroxidase and albumin, as well as some viruses 
may be transported intracellularly along the olfactory neuron axons towards the brain33,87. A 
similar route has been proposed for intracellular transport through trigeminal nerve fibres33, 
however, this would first require transport of the molecules into the lamina propria via other 
pathways, as discussed earlier. Given that the trigeminal nerve transmits information to both 
the brainstem and olfactory bulbs, albeit to varying degrees, it can be difficult to infer from 
experimental data the route(s) (trigeminal or olfactory) by which intranasally-administered 
molecules reach the olfactory bulbs if they appear in both regions82. Despite the apparent 
potential for intracellular delivery through these neurons, the current consensus seems to be that 
this pathway is too slow to be mediating the rapid direct uptake of the various molecules 
reported in literature, which is instead attributed to extracellular pathways33,81,82. It may 
therefore have limited relevance in acute nasal delivery applications.  
1.4.3 Extracellular Transport 
Extracellular pathways from the nose to the brain are presently believed to play the most 
significant role in rapid and direct transport of molecules into the CNS33. They primarily 
involve bulk flow by extracellular diffusion or convection in perineural or perivascular spaces 
associated with nerve bundles or blood vessels passing through the cribriform plate to the 
olfactory bulbs or the anterior lacerated foramen to the brainstem33. The perineural spaces 
surrounding the olfactory and trigeminal nerves appear to allow transport of some molecules 
into the subarachnoid space82,88. It has been suggested that this may be facilitated by the 
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propulsion of molecules by structural changes occurring during depolarisation and propagation 
of action potentials in adjacent axons in the fila olfactoria82,89. Similarly, between the outermost 
layer of blood vessels and the basement membrane of surrounding tissue exist perivascular 
spaces, through which bulk flow is thought to be facilitated by arterial pulsations. Interestingly, 
it has been suggested that if molecules can exploit such a pathway to travel into the CNS, 
movement deeper into the brain via a cerebral perivascular network or CSF flow pathways 
could result in rapid and widespread distribution33,86,90.  
Lochhead and Thorne33 proposed that in order to exploit bulk flow pathways, a molecule would 
need to reach the lamina propria (e.g. via paracellular transport) and escape absorption into 
blood vessels and drainage into lymphatic vessels. However, they also noted the interesting 
possibility that molecules might be able to move more easily into such bulk flow pathways on 
the basis that olfactory neurons are constantly regenerating (about every three to four weeks82) 
and olfactory ensheathing cells maintain continuous open spaces for the regrowth of new fibres 
during this process. It should be noted that the key role of perivascular and perineural channels 
is to drain neuronal waste from interstitial fluid, so net flow is believed to be away from the 
CNS82. However, it has been proposed that flow could be bidirectional depending on such 
factors as posture and local vessel architecture33,86 and the existing literature would seem to 
agree, given the data suggesting intranasally administered molecules are able to rapidly move 
into the CNS via this route.  
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1.5 Animal Models for Intranasal Delivery 
The rat is the most commonly used model for studying direct nose-to-brain delivery routes91. 
Rats have a similar nasal epithelium, submucosa and olfactory sensation network to 
humans34,79,92, and are a relatively cost-effective and easy-to-handle model92. They do, 
however, exhibit some important anatomical and physiological differences which must be kept 
in mind when considering the potential for extrapolation of experimental results to humans. 
These parameters have been reviewed by others82,84,92 and are presented in Table 1.1, but the 
two most significant, in this author’s opinion, will be briefly discussed below for the purposes 
of this review.  
Most commonly referenced is the relatively small proportion of the total nasal epithelium that 
constitutes the olfactory region in humans compared to rats. This may be expected to have a 
large impact on the percentage of drug transport via direct olfactory pathways (as opposed to 
respiratory epithelium-associated systemic pathways) between rats and humans. Selective 
deposition of drug on the olfactory epithelium may act as the first step towards addressing this 
issue, but the actual surface area available for absorption and the size of the olfactory bulbs that 
drug may be transported to must also be considered. On an absolute scale, the olfactory bulbs 
of humans are larger than those of rats93. Traditionally quoted values of olfactory epithelium 
surface area in humans (e.g. 5 cm2 vs 6.75 cm2 in rats)84,94 have therefore implied that a higher 
percentage of drug delivery might be required from a smaller olfactory surface area to achieve 
comparable olfactory bulb concentrations. More recent reviews, however, have suggested that 
the olfactory epithelium of humans constitutes a larger area (e.g. 12.5 cm2)21,33,94, which puts 
the absolute surface area at almost double that of rats and favours the theoretical translatability 
of drug delivery through this region, should it be convincingly demonstrated in a rat model.  
The second important factor to consider concerns cerebrospinal fluid (CSF). As indicated 
earlier, current literature suggests that the most rapid and significant direct route from the nose 
to the brain may be in the CSF through perineural or perivascular channels. Given that the 
volume of CSF in humans is much greater than that of rats84, a drug may undergo significant 
dilution if it is widely dispersed by this pathway in the brain, suggesting that brain 
concentrations detected in rat models may significantly overestimate those which would be 
expected in humans. In saying that, drug in the CSF would be expected to come into contact 
with the olfactory bulbs first, and preferential transport (e.g. diffusion) into the parenchyma 
here due to the high concentration gradient may still permit a sufficient targeted delivery. 
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Furthermore, CSF turnover rate of rats (hourly) is higher than in humans (5 hourly)84, 
suggesting that if drug reaches the brain via the CSF in humans, it would have a longer period 
to cross into the parenchyma than in the rat.  
Table 1.1. Comparison between key aspects of the rat and human nasal passages. Based on Kapoor et 
al.21, Lochhead & Thorne33 and Illum84,92  with reference to a 70 kg human and a 250 g rat. 
 Human Rat 
Nasal cavity volume 25 cm3 0.26-0.4 cm3 
Nasal cavity surface area 150-160 cm2 13.4-14 cm2 
Surface area per unit 
volume  
6.4 51.5 
Olfactory epithelium area 
(area, %) 
12.5 cm2 , 8% 6.75 cm2 , 50% 
CSF volume 160 mL 150 µL 
CSF volume replacement 
frequency 
5 hourly Hourly 
Shape of upper airways L-shaped Linear 
Type of breathing at rest Oronasal Obligate nose 
Connection between nasal 
cavity and oral cavity 
No (incisive canal is not 
patent) 
Yes (nasopalatine canal is 
patent) 
Vascular swell bodies in 
septum 
No Yes 
Turbinates (number and 
shape) 
3; comma shaped 3; t-shaped with elaborate 
scrolls  
Presence of ethmoid 
sinuses (air cells) and 
spheroid sinuses 
Yes No 
Maxillary sinuses Large; open Small; closed 
Nasal secretion movement Mostly posteriorly (to 
nasopharynx) 
Mostly anteriorly (towards 
nostril) 
Inspiratory airflow route Close to floor of nasal 
passage 
Upward and laterally 
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1.6 Animals as Seizure and Epilepsy Models for the Evaluation of 
Anti-Seizure Therapeutics 
1.6.1 Overview of Key Models 
In order to screen for antiseizure activity of a compound, simple, high throughput models are 
preferred to avoid investing extensive time and resources in inactive compounds6. Many models 
of seizures and epilepsy have been described (Figure 1.5A)14,95, however, the problem with 
most is that they haven’t been clinically validated95, i.e. shown the ability to correctly predict 
the effectiveness of a drug in humans. Traditionally, the Anticonvulsant Screening Programme 
(ASP), recently rebranded the Epilepsy Therapy Screening Programme (ETSP), has used the 
Maximal Electroshock Seizure (MES) test and the s.c. pentylenetetrazole (PTZ) test for this 
purpose, due to their simplicity and good predictive value for clinical efficacy in humans14 
(Figure 1.5B). Another simple test, the 6-Hz test, has made its way into the acute screening 
protocol in more recent times in an attempt to identify therapies that may be effective against 
“drug-resistant” seizures. Kindling has also been used as a validated chronic model to 
secondarily differentiate effectiveness in partial epilepsy.  
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Drug Anticonvulsant effect in rodent models Clinical efficacy (seizure suppression) 
MES 
(mice/rats) 
s.c. PTZ (mice/rats) Amygdala kindling 
(rats, focal seizures) 
Partial seizures Generalised seizures 
Convulsive Non-
convulsive 
Predominant Na
+
 (and Ca
2+
) channel activity       
Phenytoin + NE + + + NE 
Carbamazepine + NE + + + NE 
Oxcarbazepine + NE + + + NE 
Lamotrigine + ± + + + + 
Zonisamide + ± + + + + 
Predominant Ca
2+ 
channel activity       
Ethosuximide NE + NE NE NE + 
GABA systems       
Benzodiazepines   + + + + + + 
Vigabatrin  NE + + + + NE 
Tiagabine  NE + + + + NE 
Mixed       
Valproate + + + + + + 
Felbamate + + + + + + 
Topiramate + NE + + + + 
Phenobarbital + + + + + ± 
Novel targets       
Gabapentin ± ± + + + NE 
Pregabalin + NE + + + NE 
Levetiracetam NE NE + + + ± 
Lacosamide + NE +       
Retigabine + + +       
 
Figure 1.5. General classification of seizure models (A) and pharmacological profiles of clinically 
validated models (B). Figures adapted with permission from Löscher.14 MES = Maximal electroshock 
seizure test; s.c. PTZ = subcutaneous pentylenetetrazole test; NE = no effect; 6-Hz = 6-Hertz test; SE 
= Status epilepticus; BLA = basolateral amygdala; GAERS = genetic absence epilepsy rat from 
Strasbourg; GEPR = genetic epilepsy prone rat.  
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For any seizure experiment, it is essential to consider the hypothesis that is being tested when 
selecting a model95. In the context of this review, it is the hypothesis that intranasal delivery of 
anti-seizure therapeutics will elicit anti-seizure effects by way of one or more of the pathways 
discussed earlier. Therefore, as the most validated and commonly used models of primary ASD 
testing, the above-mentioned four models (as well as a variation of MES, the MEST) will be 
described below, followed by a discussion of their usefulness in the context of assessing 
intranasal therapies.  
1.6.1.1 Maximal Electroshock Seizure Test 
The Maximal Electroshock Seizure (MES) test was the first model to be used to systematically 
screen compounds for anti-seizure efficacy, leading to the discovery of phenytoin in 193796. 
The test is considered to be a measure of the effect of a drug to prevent seizure spread through 
neural tissue and thereby prevent generalised tonic-clonic seizures95. The classic procedure 
entails the application of a suprathreshold electrical stimulus to mice (50 mA) or rats (150 mA) 
using a constant current stimulator with a sinusoidal alternating current waveform for 0.2 
seconds at a frequency of 50-60 Hz95,97. The endpoint is usually tonic hind limb extension 
(HLE), the most severe seizure behaviour resulting from this type of stimulation (Figure 1.6). 
Naïve animals are pre-tested to ensure they exhibit this behaviour and failure to demonstrate 
tonic HLE on a subsequent stimulation after treatment implies anti-seizure drug action. The 
stimulus is most commonly applied through corneal electrodes, but auricular electrodes may 
also be used. While initially thought to be equivalent, studies have shown differences in the 
characteristics of seizures elicited by each of these mechanisms (Figure 1.7). For instance, 
transauricular seizures have been shown to more reliably produce tonic HLE at maximal 
currents, as well as to decrease latency to, and increase duration of, HLE98,99.  
 
Figure 1.6. Typical stages of MES seizures (adapted from unknown source).  
 
It is a simple procedure in that the outcome is binary and the suprathreshold nature of the 
stimulus reduces variability in response, but it does run the risk of failing to detect more subtle 
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anti-seizure effects, such as is the case for primidone and clonazepam, which are known to be 
clinically effective in humans, but which produce a negative result99. For this reason, we will 
also consider a slightly more technical, but more sensitive variation of this test, the Maximal 
Electroshock Seizure Threshold (MEST) test which, although not a conventional model used 
by the ETSP, will be discussed next due to its ability to detect effects on seizure threshold.   
 
 
Figure 1.7. Characteristics of brainstem and forebrain seizures. Figure reprinted with permission from 
Peterson & Albertson.97 
 
1.6.1.2 Maximal Electroshock Seizure Threshold Test 
In contrast to the MES test, the MEST test is considered to be a measure of the effect of a 
compound on anticonvulsant threshold, rather than spread and is therefore more sensitive to 
detect anti-seizure hits. For example, as mentioned above, primidone and clonazepam do not 
show anticonvulsant activity in MES, however a dose-dependent anticonvulsant effect is 
detected by MEST, which translates to humans99.  
The aim of this test is to determine the current that elicits tonic hind limb extension in 50% of 
a group of animals (i.e. CC50 - the convulsive current in 50% of rats)
99. This is most commonly 
determined using the “up and down” method of Kimball et al.15,99,100 which involves stimulation 
of a group of animals in series, where the current used for stimulation of a given animal depends 
on the response of the preceding animal. If the preceding animal displays tonic HLE after 
stimulation, the current for stimulation of the next animal is lowered, usually by 0.06 log units 
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in rats and 0.01 log units in mice99. If the preceding animal did not display HLE, the stimulation 
current is elevated by the same log interval. The current used for the first animal is determined 
by the researcher, but must approximate the CC50 of the group
100, which can pose some 
technical difficulty with the use of this model.  The complete data set of responses is used to 
calculate the CC50 for the group. One advantage of this model is that animals can be subjected 
to multiple stimulations as threshold does not significantly change provided at least 48 hours is 
left between sessions101. In this way, control and treated thresholds can be assessed in the same 
group of animals to lessen variability. In contrast to MES, this test will also yield information 
on proconvulsant effects if these are present101.  
The lower stimulation currents employed in this test result in a wider range of responses 
depending on the brain regions activated (Table 1.2). This is turn leads to more pronounced 
differences becoming evident between transcorneal and transauricular stimulation, the most 
obvious being the clonic phase. With corneal stimulation, facial (vibrissae, jaw and ears) and 
forelimb clonus can be observed, while with transauricular, a behaviour referred to as “running-
bouncing” clonus is seen102, which has parallels to the behaviour seen in audiogenic seizures 
induced in genetically-susceptible rats97,103 and involves a more symmetrical clonus in all four 
limbs interspersed with periods of running and possibly bouncing due to jerks of the hindlimbs. 
The mechanisms behind these behaviours can be linked to the pathways of seizure propagation 
in each (Table 1.2); simply, a seizure initiated in the forebrain through the corneas, compared 
to one initiated in the hindbrain by way of the ears. Ultimately, both types of seizure must 
engage the brainstem to elicit the tonic HLE component of maximal seizures, but the corneally-
induced seizure must spread further to get there and has been proposed to better represent 
seizure spread and better detect drugs which block this99.  In support of this, phenobarbital and 
primidone demonstrate lower potency in auricular compared to corneal MEST testing99. It has 
also been found, however, that seizure threshold determined by transauricular stimulation is 
lower and less variable than thresholds determined by transcorneal stimulation, consistent with 
the more severe seizures and more consistent induction of seizures performed in MES, which 
possibly supports increased reliability of the model using this stimulation route. 
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Table 1.2. Seizure behaviours observed in the MEST model with varying current intensity and relevant 
regions of brain activation. Table reprinted with permission from Peterson & Albertson.97 Note: The 
currents indicated are approximate only and may vary greatly between laboratories.  
Response to 
corneal 
electroshock 
Alternative 
names 
Stimulus current 
(mA) 
Quantified 
convulsion 
components 
Brain 
region 
activated 
Rats Mice 
Subconvulsive 
response 
Stun, rage <18 <5 No convulsive 
response 
No 
epileptiform 
activity 
Face and 
forelimb clonus 
Minimal 
clonic 
seizure, 
minimal 
electroshock 
18-20 5 Amygdala kindling 
scale, clonic spasm 
Forebrain, 
limbic 
seizures 
Running-
bouncing 
Wild running 20-21 10 Occurrence of running 
episode 
Minimal 
activation of 
brainstem 
Tonic flexion Flexion, 
opisthotonus 
20-21 10 Occurrence of tonic 
flexion 
Minimal 
activation of 
brainstem 
Threshold 
tonic-clonic 
Threshold 
tonic 
extension, 
threshold for 
maximal 
seizures 
(MEST) 
22-50 12-30 Occurrence of tonic 
hindlimb extension, 
duration of tonic 
extension, 
flexion/extension (F/E) 
ratio (maximal) 
Submaximal 
activation of 
brainstem 
Maximal tonic-
clonic 
Maximal 
electroshock 
(MES) 
150 50 Occurrence of tonic 
hindlimb extension, 
duration of tonic 
extension, F/E ratio 
(minimal) 
Maximal 
activation of 
brainstem 
 
Despite the potential usefulness of the MEST test in more sensitively screening for antiseizure 
(or proseizure) effects99, it has not been adapted by the ETSP. This is most likely due to a 
combination of reasons which make it more technically complex and variable and therefore 
decrease throughput and increase cost. Aside from these drawbacks, the other major limitation 
is that it gives no insight into the mechanism of action of the compound – i.e. whether it elevates 
threshold or prevents seizure spread or both104. Ethosuximide, phenytoin and valproic acid have 
been used as key drugs to illustrate this concept previously in that valproic acid (which increases 
seizure threshold and prevents spread) is active in MES (seizure spread measure), MEST 
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(maximal threshold measure) and PTZ (minimal threshold measure) tests, while phenytoin 
(prevents seizure spread) is active in MES and MEST and ethosuximide (increases minimal 
threshold) is only active against PTZ104. This supported the use of the MES and PTZ models 
for routine evaluation of potential ASDs, as they could distinguish potential usefulness against 
different types of seizures. It does not however, underscore the use of the MEST test in basic 
research which clearly still has value. It is worth noting in this respect that minimal threshold 
seizures may also be induced with electroshock, thereby overcoming some of the limitations 
that will be discussed next with the PTZ model, but the endpoint of the minimal electroshock 
seizure threshold test (min-EST) has been reported to be highly variable and therefore not 
suitable for routine evaluation of ASDs104.   
1.6.1.3 Pentylenetetrazole Test 
For years, the s.c. PTZ test has been used as a first line screening model by the ASP in order to 
detect drugs that block generalised non-convulsive seizures, such as absence and myoclonic 
seizures, which are not detected by the MES test (e.g. ethosuximide). It has recently been 
demoted to the end of the screening pipeline in the revitalised ETSP where a failure marks a 
drug with a cautionary red flag, but does not necessarily halt development6. This change is the 
result of its clinical predictive ability being questioned after failing to correctly predict the effect 
of lamotrigine and levetiracetam in suppression of absence seizures and giving false positive 
data for vigabatrin and tiagabine95. This is possibly a result of its predictive value being 
restricted to certain chemical categories of compounds – i.e. those acting on GABA pathways 
– as PTZ elicits its actions by antagonism of the GABAA receptor
105.  
The aim of this test has classically been to find the convulsive dose of subcutaneously injected 
PTZ inducing a clonic threshold seizure of at least five seconds duration in 97% of animals 
(CD97) by observing animals for a post-injection period of 30 minutes for such a “threshold” 
seizure, after which they are euthanased95. Part of the problem with the PTZ test has most likely 
been its dependence on pharmacological actions to produce acute seizure behaviours. This 
requires consideration of route, doses, metabolism, time of measurement and pharmacokinetics 
and pharmacodynamics of the test drug, as well as interspecies variation in all these things and 
has led to conflicting data for some drugs between labs, a subject which has been discussed in 
detail elsewhere105. Traditionally, it has been an s.c. injection, but i.v. administration has been 
suggested as an alternative to overcome some of the limitations associated with PTZ delivery 
by the s.c. (or even the i.p.) route. Key issues with the model include interspecies variation in 
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metabolism of PTZ and use of the model for the analysis of drugs with a short duration of action 
that peaks early in the 30 minute observation period and has necessitated the use of ‘time to 
seizure onset’ as the measure of effectiveness in a lot of studies105. Time to the first threshold 
seizure (after s.c. injection) or initial myoclonic twitch (during i.v. infusion) therefore appear 
to be the most reliable endpoints to differentiate ASDs105. Being a threshold test, seizure 
behaviour as a whole may also be assessed, in order to provide a more sensitive measure of 
anti-seizure effect and enrich the prediction of possible clinical potency against different seizure 
types105. Finally, U-shaped dose curves have been reported to contribute to variability with 
some drugs (e.g. phenytoin and carbamazepine) due to possible proconvulsant effects induced 
at high doses in rodents and humans, so testing at a single high dose is not recommended 
1.6.1.4 6-Hz “Psychomotor” Seizure Test 
The 6-Hz test was first developed in the 1950s, but at the time was largely disregarded due to a 
lack of response to phenytoin, which was interpreted as a poor utility to predict efficacy in 
humans106. More recent times have seen its resurrection107,108 and ultimately elevation to the 
ETSP testing pathway as an acute model of “drug-resistant” partial seizures6. This ascension 
has for the most part stemmed from two things; (1) the ineffectiveness and therefore 
“resistance” of this model to phenytoin and other commonly used ASDs107,109 (Table 1.3) and 
(2) the remarkable effectiveness of levetiracetam against the 6-Hz seizure, which correlates 
with clinical activity in human refractory partial epilepsies110, while it is ineffective in the 
traditional screening tests, MES and s.c. PTZ111,112.  
Table 1.3. Pharmacological characterisation of the 6-Hz seizure model in mice. Adapted with 
permission from Potschka.109 R = Resistant; S = Sensitive, efficacy demonstrated; ? = Unknown.   
ASD 6-Hz 
32 
mA 
44 
mA 
Carbamazepine R R 
Phenytoin R R 
Valproate S S 
Ethosuximide S R 
Lamotrigine R R 
Topiramate R R 
Felbamate S R 
Tiagabine S R 
Levetiracetam S S 
Lacosamide S ? 
Retigabine S S 
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The endpoint of the test, the 6-Hz seizure, is described as immobility or stun, awkward but 
upright posture, Straub (elevated) tail, facial automatisms (head nodding, jaw movement, 
twitching of the vibrissae) and forelimb clonus107,113,114.  It is induced by means of corneal 
electrodes, through which a rectangular pulse train with a frequency of 6 Hz and pulse width of 
0.2 ms is passed for 3 seconds107. Two currents are conventionally used, 32 mA and 44 mA, 
corresponding to the 1.5 x CC97 (current at which 97% of animals demonstrate the endpoint) 
and 2 x CC97 reported by Barton et al. in their characterisation of the model
107. At 44 mA, only 
two ASDs, levetiracetam and valproic acid, completely protected against the 6-Hz seizure, 
however, their efficacy was reduced compared to 32 mA stimulation107.  
The proposed partial nature of the seizures has been supported by immunohistochemistry of c-
fos expression as a marker of seizure-induced neuronal activation. Barton et al.107 showed an 
intense c-fos staining to be induced by the 32 mA stimulus, which was localised to the amygdala 
and piriform cortex. Increasing to 44 mA, resulted in additional intense staining of the dentate 
gyrus, the recruitment of which was a hypothesised cause for the decrease in potency of ASDs 
at 44 mA, leading them to suggest that levetiracetam may exert its major effects via the 
amygdala, supporting its effectiveness in the kindling model of partial epilepsy115. They 
proposed that a lack of recruitment of the hippocampus (specifically, the dentate gyrus) at 32 
mA suggests a different pattern of limbic seizure activation compared with MES and PTZ.  
As stated earlier, the most unique purported feature of the 6-Hz test was being the “only acute 
electrically-induced seizure model in which levetiracetam was effective”108, however this was 
not entirely true. Despite criticisms of the MES test for failing to respond to levetiracetam, it 
should be noted that levetiracetam has been reported to show similar effectiveness to valproic 
acid in the corneal MEST test111. Furthermore, it is also interesting to consider that behaviour 
in the minimal electroshock seizure threshold test  (min-EST) mentioned earlier presents 
similarly to the 6-Hz seizure and is also, per se, “resistant” to phenytoin and any other ASD 
that affects seizure spread, but not minimal threshold104. Nonetheless, the 6-Hz test clearly has 
some technical advantages over MEST (or min-EST) as an acute seizure screening test which 
have propagated its use; these being the suprathreshold, one fits all, nature of its stimulation 
currents and the relatively large difference in current required to elicit a simple stun versus a 
clonic or tonic seizure response, providing clearer and less variable outcomes114. Furthermore, 
the relatively very short pulse width and reduced frequency of the electrical stimulus may be 
expected to decrease the volume of directly stimulated neural tissue116 causing perhaps a much 
more focal discharge than min-EST or MEST, which is consistent with data reported above.    
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The 6-Hz model had previously only been characterised in mice107,108, however, its very recent 
pharmacological characterisation in rats113 stands to expand its potential scope as an acute 
screening model for activity in “drug resistant” seizures. Metcalf et al.113 concluded that the 6-
Hz test could be conducted in rats in a similar way to mice, but did find some differences 
between the two species. Interestingly, they found phenytoin to be effective in their CF-1 mice 
and suggested that either genetics or a different time point of testing after drug administration 
may have contributed to this finding. In contrast, they found rats to be resistant to phenytoin, 
as well as a number of other compounds, while response to levetiracetam was maintained. They 
speculated that different toxicity assessments between species (as efficacy is determined on the 
basis of the ratio between effective and toxic doses) or different pharmacological profiles of 
some compounds between species may at least partially explain their results. They also noted 
the possibility that 6-Hz may induce a different pattern of neuronal or brain-region activation 
in rats, which could explain the apparently more widespread lower sensitivity to drugs spanning 
different mechanisms (i.e. compounds acting on sodium channels, GABAA receptors or GABA 
uptake in comparison to the mouse 6-Hz model), possibly implying a greater usefulness in 
detecting compounds with novel mechanisms compared to the mouse. They noted that a 
significant limitation of the key studies that have pharmacologically characterised the 6-Hz 
model to date, including their one, is that they did not quantify blood or brain drug 
concentrations in their animals, so pharmacokinetic variability or inaccurate dosing was not 
accounted for. This factor was addressed by Leclercq and Kaminski117 in a study of phenytoin 
and levetiracetam with different mouse strains, from which they concluded that 
pharmacokinetics could not explain the differences in drug responses seen (e.g. Naval Medical 
Research Institute (NMRI) mice are not resistant to phenytoin and are more responsive to 
levetiracetam than other strains), so genetic differences were the most likely cause. It should be 
noted that they used ‘duration of immobility’ as their endpoint, which appears to differ from 
previous studies employing 6-Hz. It is also unclear whether their findings would also apply to 
rats, given that the use of a different species is a much bigger genetic leap.  
So while the 6-Hz test is a relatively simple model of great interest for the modern screening of 
compounds for activity in pharmacoresistant epilepsy, the model would seem to require further 
characterisation and possibly development to realise its full potential. It should be noted that 
demonstration of the efficacy of levetiracetam in the 6-Hz model was performed retrospectively  
and despite currently being used by the ETSP to differentiate compounds, it has also yet to 
demonstrate clinical translatability. For example, several investigational ASDs (brivaracetam, 
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carisbmate and retigabine) have potently suppressed 6-Hz seizures at 44 mA, but have not 
shown evidence of effectiveness in humans with drug-resistant partial seizures118.  
1.6.1.5 Kindling 
Kindling traditionally involves repeated excitatory electrical stimuli via a depth electrode 
surgically implanted into a region of the limbic system (for example, the amygdala, which will 
be discussed in this review given its relevance to temporal lobe epilepsy). This is used to induce 
partial, and later secondarily generalised, seizures that increase in length and severity with 
continued stimulations, ultimately creating an animal with a permanently increased 
susceptibility to seizures. Seizure severity is classified according to the Racine scale (Table 
1.4).  
Table 1.4. The Racine scale of the stages of seizure behaviour. Adapted from Töllner et al.119 and 
Racine.120   
Stage Behaviour 
1 Immobility, slight facial clonus (eye closure, 
twitching of vibrissae, sniffing) 
2 Head nodding associated with more severe facial 
clonus 
3 Clonus of one forelimb 
4 Rearing, often accompanied by bilateral forelimb 
clonus 
5 Tonic-clonic seizure accompanied by loss of balance 
and falling 
 
Initially, the threshold for inducing after discharges (the after-discharge threshold (ADT)) is 
determined by a stepwise procedure, then constant current stimulations are delivered once daily 
through the electrode until this induces reproducible (e.g. at least 10) fully kindled secondarily 
generalised seizures (i.e. Stage 5 on the Racine scale)119. The ADT is then determined again in 
the kindled animal on multiple occasions until this too is reproducible119. Recorded parameters 
include seizure severity, seizure duration, afterdischarge duration and generalised seizure 
threshold (where this differs from ADT), which are defined elsewhere119. The effect of 
treatments or other variables on kindling development can also be evaluated by comparing the 
number of days until the first stage 5 seizure, the number of days until the fully kindled state is 
reached, the cumulative seizure duration and the cumulative afterdischarge duration119.  
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In contrast to models of acute seizures, kindling is a model of chronic epilepsy and therefore is 
thought to represent the epileptic brain much better when testing antiseizure interventions95. 
The changes that occur in the brain as a result of limbic kindling have been linked to those 
which occur in human temporal lobe epilepsy121 and it is the only model that has successfully 
predicted (i.e. not retrospectively) the clinical usefulness of novel ASDs, such as levetiracetam, 
against partial seizures in humans with epilepsy14. Furthermore, models of  pharmacological 
resistance have been developed from it119,122,123, such as the phenytoin-resistant rat, which 
provide scope for assessing the ability of new treatments to overcome certain mechanisms of 
resistance (e.g. the multi-drug transporter (MDT) hypothesis)124. Despite its usefulness, limbic 
kindling is a very labour-intensive and time consuming process, making it unsuitable as an 
initial screening model. Potential replacements (e.g. corneal kindling), however, have so far 
been unsuccessful as their predictive ability is not clear14,95.  
1.6.2 Relevance to the Evaluation of Intranasal Delivery Pathways 
As discussed earlier, there are three main pathways that intranasal therapeutics are thought to 
be able to exploit in order to reach the brain; the direct olfactory, direct trigeminal and indirect 
systemic pathways. Based on previous reports and theoretical considerations, these may target 
drugs to the olfactory bulbs and piriform cortex, the brainstem, or the whole brain via blood 
vessels, respectively.  
Considering the olfactory pathway first, an ideal model would exhibit focal seizures generated 
or propagating through the piriform cortex or closely associated areas, such as the amygdala. 
The most obvious therefore would be the very well-characterised amygdala kindling model of 
epilepsy in which seizures secondarily generalise from this region. Though the nose-to-brain 
field is still, as Kozlovskaya91 puts it, immature, perhaps the most well thought out publications 
(in terms of marrying hypothesis to method selection) in the current intranasal ASD delivery 
literature21,22 have employed this technique somewhat successfully, as will be discussed in the 
next section. In contrast, a model described above which does not appear to have been used 
before, but reportedly represents acute focal seizures in the relevant regions107 is the 6-Hz 
seizure test. As discussed, while it appears to still be a model in need of more reproducible and 
thorough characterisation, its recent expansion to the rat arena makes it an intriguing potential 
platform for assessment of olfactory delivery, particularly in light of its technical simplicity 
relative to the kindling model.  
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In the MES model of generalised seizures, the olfactory targeting pathway would seem to have 
minimal relevance, given that it functions in the forebrain, whereas it has been shown, by way 
of precollicular lesions, that the tonic components of corneal MES seizures do not depend on 
the forebrain for their initiation or progression102. In further support of this, the “area tempestas” 
(part of the piriform cortex that is very sensitive to induction of seizures by GABA antagonists 
and is thought to function as a broadcasting system by triggering generalised seizures in 
response to stimulation of limbic circuits) cannot exert control over tonic seizures induced by 
corneal MES, again supporting that generation of these seizures does not depend on the 
forebrain125. Therefore, any selective forebrain delivery of drug to areas like the piriform cortex 
would be expected to be ineffective in stopping the spread of corneal MES seizures, however a 
potential effect on the clonic components, despite not being the endpoint of this test, cannot be 
ruled out. As MEST similarly uses tonic endpoints, it would also likely be of little use. Minimal 
electroshock threshold could be considered, but is not a preferred test for reasons discussed 
above.  Likewise, one might also consider the use of minimal seizures observed in the PTZ 
model, but given its systemic, pharmacological nature, it would be expected to have widespread 
effects throughout the brain, suggesting that it would lack the specificity required to assess 
intranasal delivery in targeting a focus and the spread of seizure activity. Transauricular MES 
(and MEST) seizures would seem to have even less involvement than transcorneal MES with 
the forebrain and given that lesions of the amygdala have no effect on transauricular 
electroshock seizures (or tonic audiogenic seizures for that matter)125, a drug effect targeted to 
this region is unlikely to be detected by this model. A clonic phase is reportedly not reliably 
seen after the tonic phase resulting from transauricular stimulation97, so may not be a suitable 
alternative for assessment. Despite the predicted failure of this test to model olfactory pathway 
delivery to the limbic regions, its role in detecting trigeminal pathway delivery to the brainstem 
would seem a lot more promising, as will be discussed shortly. 
In order to speculate about the possible effects of inhibitory drugs being focally delivered to 
olfactory networks, it is interesting to consider a study which reported the effects of olfactory 
bulb ablation in mice on response to seizure tests126. In corneal MES, olfactory bulb ablation 
was reported to decrease the duration of clonic convulsions and postictal coma, however, it did 
not affect the tonic component, which is consistent with the above discussion. In contrast to the 
predictions above, they found a marked increase in corneal electroshock seizure threshold after 
ablation of the olfactory bulbs. It should be noted that although the authors reported using a 
minimal electroshock threshold test (defined by Swinyard114 as clonic activity of the vibrissae, 
lower jaw, or forelimbs, without loss of posture), they seem to have classified a “minimal full 
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seizure” as including running movements, clonic convulsion, tonic flexion and tonic extension. 
This would suggest that their measure was closer to the definition of the threshold for a maximal 
electroshock seizure, although it was not specified whether the flexion and extension involved 
the hindlimbs. The CC50 reported for their controls, is similar to the maximal electroshock 
seizure threshold reported elsewhere for CF-1 mice (8.85 mA)104, which suggests this was the 
likely measure reported. Finally, in the s.c. PTZ test, total incidence of convulsion was not 
different from control, but in contrast to the MES model, clonus was more marked and long-
lasting in mice without olfactory bulbs, suggesting perhaps a decreased inhibition of seizures 
by the olfactory bulbs. Such a theory may be consistent with the ability of strong olfactory 
stimuli to interfere with kindled seizures40, but introduces uncertainty as to the effect inhibitory 
ASDs would be expected to have in the PTZ model. To add to the complexity, tonic convulsion 
incidence was decreased, indicating an apparently opposite effect of olfactory bulb ablation on 
this component. Overall, the effects of olfactory bulb ablation are most definitely a lot more 
complex and far-reaching than might be expected from acute drug administration, but offer 
insight into the role of the olfactory networks in these seizure models.  
The trigeminal pathway primarily offers a potential route from the respiratory mucosa through 
the rear of the brain via the brainstem and assessment of drug delivery by this route calls for a 
different approach from a model. As stated earlier, the MES and MEST tests present as the most 
obvious candidates, given their unquestionable relationship with the brainstem. Transauricular 
stimulation may possibly have advantages over transcorneal in that it would appear to generate 
seizures directly through the brainstem, rather than initially spreading through the frontal brain, 
providing a more specific assessment of focal drug delivery. Of note, it has been used in a few 
studies on this topic127–129 which will be discussed in the next section. In this author’s opinion, 
MEST presents itself as a more appropriate initial candidate for assessment of intranasal 
delivery to the brainstem in order to detect an effect on seizure threshold, rather than setting the 
benchmark as the ability to interfere with a superthreshold stimulus which runs the risk of 
masking more subtle information. Recalling the earlier discussion, the kindling and 6-Hz 
models would likely be of little use in assessing delivery by this pathway, while the PTZ model 
again may suffer from eliciting a pharmacological effect on the whole brain.  
Finally, for assessment of drug delivery by a systemic pathway (or an alternative widespread 
brain delivery pathway, such as a direct transport in the CSF), any model may feasibly detect 
an anti-seizure effect of intranasally delivered drug. This will, however, be largely dependent 
on the usual ability of the model to detect a specific compound after systemic administration 
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(e.g. phenytoin is reported to be effective in MES,  MEST and kindling, but generally not in the 
PTZ or 6-Hz models), as well as the dose of drug that is able to be delivered through the nose. 
In the context of the systemic circulation, this will be subject to the usual impeding factors (e.g. 
dilution, protein binding, metabolism, efflux transporters) and may mean that the relatively low 
doses attainable through the intranasal route could render them completely ineffective. 
Nonetheless, intranasal pharmaceutical studies with ASDs to date have generally reported a 
direct nose-to-brain delivery component co-existing with a significant systemic component, but 
still with some degree of anti-seizure efficacy where this was tested. The following section will 
discuss these studies and what can be learnt from them as a whole in order to move forward.  
 
1.7 Pharmaceutical Formulation of Anti-Seizure Therapeutics 
1.7.1 Role of Pharmaceutical Formulation 
The potential advances that could come from exploiting a direct nose-to-brain delivery route to 
deliver anti-seizure therapeutics, as well as the essential role of pharmaceutical formulation in 
achieving this have been introduced thus far. The clearest advantage of this direct delivery 
would be the avoidance of the systemic circulation, at least prior to initial contact with the brain. 
The doses of ASDs required to achieve therapeutic plasma concentrations are much larger than 
the quantities of drug that are actually required in the brain130,131, secondary to pharmacokinetic 
factors such as systemic metabolism, plasma protein-binding, clearance and widespread tissue 
distribution. A direct intranasal route may therefore allow the administration of much lower 
doses in order to increase tolerability, a modifiable contributor to the definition of drug-resistant 
epilepsy. Furthermore, while still speculative, a direct delivery by an olfactory pathway to 
seizure generating or propagating regions such as the piriform cortex, may also play a role in 
circumventing proposed mechanisms of resistance, such as inadequate drug levels reaching 
these regions due to overactive efflux transporters at the blood-brain barrier (BBB)132,133. Even 
in responsive epilepsy, such a pathway might conceivably be exploited as a means of 
controlling some types of focal epilepsy and not just reducing systemic exposure, but also 
exposure of unproblematic brain regions to the drug. To test all these exploratory visions, 
however, there are challenges to overcome, both in therapeutic formulation (reviewed 
elsewhere21,22) and the pre-clinical evaluation of the mechanisms by which direct nose-to-brain 
delivery may be an effective therapeutic tool. While research into the latter expands beyond 
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just anti-seizure treatment, the following section will be limited to discussing studies which 
explore this therapeutic use, in light of their relevance to this review and the PhD project it 
underlies. 
1.7.2 Studies of Pharmaceutical Formulation for Anti-Seizure Therapeutic Delivery 
Anti-seizure therapeutics have been formulated into a range of different pharmaceutical 
delivery systems to date in attempts to exploit a direct nose-to-brain delivery pathway (Table 
1.5). The components of these formulations are listed for the reader’s reference, given that 
administration vehicles can potentially confound the results of seizure tests134, but the specific 
formulation methodology, ingredient rationale, stability and release properties fall outside the 
scope of this review. Instead it will discuss methodological aspects of in vivo testing of such 
formulations and what can be learnt from the imperfect endeavours to do so thus far. The 
discussion should be taken in the context of a recent review of intranasal pharmaceutical 
formulations in general that suggested that compounds reach the brain most efficiently by direct 
routes in the order of particles > gels > solutions, but in terms of total brain delivery, the order 
was gels > particles > solutions, suggesting a higher systemic contribution from gels91. It should 
be noted that they did not differentiate whether particles referred to nanoparticles, 
microparticles or both however, which is important as these systems, reviews of which can be 
found elsewhere80,135,136, may act differently to deliver drugs.  
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Table 1.5. Summary of studies using pharmaceutical formulation to investigate a direct nose-to-brain 
pathway for ASDs.  
ASD/therapeutic Delivery system Materials Toxicity 
study 
PK 
study 
Efficacy 
study 
 
Carbamazepine Gel Carbopol 974P 
(mucoadhesive polymer, 
Hypromellose, pH 7.4 
X  X [137] 
Phenobarbital Gel Carbopol 974P 
(mucoadhesive polymer, 
Hypromellose, pH 9.5 
X   [138] 
Carbamazepine Mucoadhesive 
o/w nanoemulgel 
Oleic acid, Labrasol, 
xanthan gum (anionic 
mucoadhesive polymer) 
X X  [139] 
Carbamazepine Thermo-
reversible gel 
Carbopol 974P 
(mucoadhesive polymer), 
Pluronic F127 
X  X [140] 
Lamotrigine Thermo-
reversible gel 
Carbopol 974P 
(mucoadhesive polymer), 
Pluronic F127 
X  X [141] 
Carbamazepine Microemulsion Oleic acid, Tween 80, 
Propylene glycol 
 X  [129] 
Carbamazepine Microemulsion Oleoyl polyoylglycerides, 
Polyoxyl 40 hydrogenated 
castor oil, Diethylene 
glycol monoethyl ether, 
Polycarbopil 
(mucoadhesive) 
 
(earlier 
paper142) 
 X [143] 
Lamotrigine Microemulsion  Glyceryl monostearate, 
Oleic acid, Tween 80, 
Pluronic P188 
X   [127] 
Phenytoin Microemulsion Capmul MCM (glyceryl 
monocaprylate), Labrasol, 
PEG-8 caprylic/capric 
glycerides and Transcutol 
(diethylene glycol 
monoethyl ether) 
   [128] 
Diazepam Polymeric 
nanoparticles 
PLGA (Poly(D,L-lactide-
co-glycolide), Pluronic 
F127 
X  X [144] 
Thyrotropin 
releasing hormone 
Polymeric 
nanoparticles 
PLA (Polylactide) X X  [16,17] 
Valproic acid Lipid 
nanoparticles  
Cetyl palmitate, soy 
lecithin, octyldodecanol 
X   [145] 
Lamotrigine Microspheres  
(as suspension) 
Chitosan, glutaraldehyde            X       [146] 
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1.7.2.1 Administration Technique 
A number of techniques have been used for intranasal administration to rats over the years. 
Most studies have been carried out in anaesthetised rats in a supine position to facilitate 
deposition and retention on the olfactory epithelium, which comprises the upper third of the 
nasal cavity82. Most researchers position animals with their head horizontal to the bench to 
prevent drainage to the oesophagus and trachea when supine82. Historical techniques have 
involved cannulation of the trachea to aid breathing, then circulation of drug solution in the 
nasal cavity by a peristaltic pump under anaesthesia or alternatively, sealing the oesophagus 
with adhesive before administration (and possibly the nares after administration) of a small 
volume with a micropipette92. In contrast, more modern approaches involve administration of 
a small volume through the nares to the conscious or lightly sedated (e.g. halothane) rat92. This 
may be a single dose administered to one nostril via insertion of polyethylene (PE) tubing147, 
or smaller aliquots gradually sniffed in over a period of time after placement on the nares85. The 
former offers the advantage of being able to direct the dose to the posterior nasal cavity where 
the olfactory epithelium lies, in contrast to the latter which will have significant initial contact 
with the respiratory epithelium and consequently be subject to rapid mucociliary clearance and 
higher systemic absorption. Tubing-mediated delivery may also be used simply to ensure 
adequate coverage of the nasal mucosa via a deep delivery point. In line with these advantages, 
Table 1.6 (at end of Chapter on page 49) shows that the majority of studies investigating 
intranasal delivery of ASD formulations employed a similar tubing administration method. 
Interestingly, Czapp et al.138 reported alternating between delivery at the opening of the nares 
and tubing-mediated delivery into the deep nasal cavity, which may have had implications for 
their pharmacokinetic and efficacy results, which did not differentiate between the two 
administration techniques.  
The volume of an administered dose may affect deposition within the nasal cavity and is a key 
challenge to the intranasal delivery of lipophilic therapeutics, such as most ASDs, in general. 
There is a balance between adequately covering the epithelia through which absorption is 
intended (olfactory and/or respiratory) and avoiding so large a volume that it overflows out of 
the nasal passage, causing a lower dose to be delivered and running the risk of deposition in the 
nasopharynx and subsequent inhalation causing respiratory distress in an experimental 
animal82. Rats generally receive a volume of 40-100 µL if given as a series of drops applied to 
the nares, whereas with administration to the posterior nasal passage via tubing, lower volumes 
of 20-40 µL are used, as there is less surface area to cover82. Considering this, the rationale for 
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the volumes used in a number of the studies in Table 1.6 is unclear given that doses were 
administered mostly via tubing, suggesting a targeted delivery to the upper nasal passage was 
desired. Rats commonly received between 100-200 µL of fluid in their nasal passages, with a 
mouse also receiving a 100 µL dose, suggesting that the nasal passages would have been 
saturated with formulation and inhalation or swallowing would have been extremely likely. 
Others, usually purely pharmacokinetic studies utilising mice or rats, used total volumes of 14-
27 µL which are more in line with the above guidelines and may be more likely to detect direct 
olfactory delivery to the brain.  
While light sedation is necessary to perform most intranasal administration procedures on 
rodents82, it should be noted that anaesthesia (mainly long-acting anaesthesia) has been 
suggested to increase nasal absorption of therapeutics in rats, most likely due to impairment of 
mucociliary clearance and decreased losses due to drainage and mechanical removal (e.g. 
sneezing/snorting) in the conscious state147. For this reason, results may overestimate the true 
absorption that would be expected in a conscious animal. Nonetheless, such studies are still a 
valuable screening tool with which to assess nasal absorption of different therapeutics. Almost 
all of the studies in Table 1.6 utilised anaesthesia in the dose administration process. Two did 
not report either way, but considering the volumes administered, almost certainly would have 
required it, while another claimed to have administered a gel via tubing to conscious rats. In 
addition to the effect on anaesthesia on mucociliary clearance, efficacy studies of intranasal 
antiseizure therapeutics must also control for another potential confounder, the effect of 
anaesthetics on seizure threshold, which will return in the later discussion.  
1.7.2.2 Adverse Effects and Toxicity 
Intranasal delivery studies in general seem to give poor attention to adverse effects or toxicity 
of administered formulations to the nasal mucosa148. While this is an aspect that seems to be 
brushed over in preclinical trials, it is important to consider, especially in terms of exploiting a 
direct nose-to-brain pathway. Kozlovskaya et al91 suggested that the fractions of drug reported 
to have been delivered to the brain intranasally in a number of studies were so substantial that 
they implied a breach of physiological barriers by formulation constituents (e.g. permeation 
enhancers and co-solvents). Furthermore, they speculated about the toxicity that could 
potentially result from chronic exposure of olfactory or trigeminal neurons to drugs or particles 
transported via intracellular routes. To consider adverse effects as a whole, one must evaluate 
both behavioural and histological aspects. While the former receives a lot of attention in human 
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trials74, preclinical studies offer an excellent opportunity to screen histologically and optimise 
dosage and formulation, given the great similarities between rodent and human nasal epithelia79 
and the extensive guidelines on nasal tissue processing and evaluation79,83,149,150. Most of the 
studies reviewed in Table 1.5 did not report any data on either behavioural or histological 
adverse effects and those that did presented low quality images of sheep nasal mucosa exposed 
in vitro without any indication as to what type of epithelium or anatomical structures were 
shown128,129,142,146. Given that all studies performed in vivo experiments in rodents, be they 
pharmacokinetic, pharmacodynamic or both, there seems no reason why the nasal passages of 
those rats could not have been dissected after the experiment and histologically processed to 
provide a substantially more meaningful evaluation of epithelial integrity.   
Behavioural assessment is also important in rodents as, aside from ethical considerations and 
determining how much formulation an animal can feasibly tolerate in its nasal passage, it may 
draw attention to a highly irritant formulation. It also has implications for follow on studies, 
such as evaluation of antiseizure effects, given that susceptibility to these might be altered by 
stress or pain secondary to a nasal administration. Therefore, this appears to be an area which 
deserves more attention in intranasal studies.  
1.7.2.3 Quantification of Drug in Tissues 
The efficiency of intranasal delivery is most adequately assessed by calculation of two 
parameters (Equation 1.1 and Equation 1.2)91. The first is Drug Targeting Efficiency percentage 
(%DTE), which is the relative exposure of the brain to the drug following IN and systemic 
administration. The second is the Nose-to-brain Direct Transport Percentage (%DTP) - the 
percentage of the dose that is estimated to reach the brain via direct routes compared with the 
overall delivery to the brain. A %DTE > 100% indicates better overall brain delivery via the 
intranasal route compared the parenteral route, while a %DTP > 0% indicates an increased 
efficiency of brain delivery by direct routes (e.g. olfactory and trigeminal pathways)91.  
Equation 1.1. Calculation of Drug Targeting Efficiency (%DTE). AUCbrain = AUC (concentration vs 
time) for brain; AUCblood = AUC (concentration vs time) for blood. 
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Equation 1.2. Calculation of Direct Transport Percentage (%DTP).BIN = Brain AUC over time after 
i.n. administration; BIV = Brain AUC over time after i.v. administration; BX = Brain AUC fraction 
contributed by systemic circulation through blood-brain barrier after i.n. administration; Pin = Blood 
AUC over time following i.n. administration; Piv = Blood AUC over time following i.v. administration. 
 
Calculation of these parameters is based on the following assumptions91: 
 Drug pharmacokinetics are assumed to be linear (no saturation of individual absorption, 
distribution, metabolism or elimination processes).  
 AUCbrain and AUCblood are assumed to reflect pharmacologically relevant drug 
concentrations in the brain and blood despite (1) that drug can exist in several forms in 
these sites (e.g particle-based formulations may exist as free, protein-bound or 
encapsulated drug) and (2) differences in intra-brain disposition of the drug, as a result 
of reaching the brain via different routes. The latter, may obviously be remedied by 
microdissection of different brain regions and the former may possibly be addressed 
with analytical methods.  
Kozlovskaya et al.91 reviewed all nose-to-brain delivery studies available in February 2014 and 
found that only 3.1% contained the pharmacokinetic information required to calculate in vivo 
AUC of concentration vs time for both brain and systemic circulation after i.n. and parenteral 
routes respectively. They noted that drug was in most cases not completely eliminated at the 
last sampling point (8-24 hours), introducing error into drug exposure calculations derived from 
partial curves. With this is mind, we turn to the studies involving anti-seizure therapeutics that 
presented pharmacokinetic data, a number of which have been published since that time.  
There have been some remarkable claims made about the intranasal delivery of anti-seizure 
therapeutics in recent years, but unfortunately the designs of the studies (Table 1.7, at end of 
Chapter on page 51) and the non-standardised reporting of results make the pharmacokinetic 
data difficult to interpret. Eskandari et al.145 reported a brain:plasma ratio of around 8 for 
valproic acid delivered in intranasal lipid nanoparticles (4 mg/kg), compared to a ratio of less 
than one from an intraperitoneal control (150 mg/kg) at 60 minutes after administration. The 
different doses used, the single time point evaluation and the use of intraperitoneal 
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administration as a control impede assessment of contribution from the direct pathway that the 
authors claim was demonstrated in these results. Though it is likely that sustained release from 
the lipidic formulation and nasal absorption played a role in the differences seen, one may 
speculate that the control was disadvantaged at 60 minutes, considering that this time point 
equates to the lower limit of the half-life of valproic acid in rats151 (Table 1.8). Acharya et al.128 
assessed an intranasally administered microemulsion containing phenytoin. They reported 
higher levels of phenytoin in the brain after the i.n. microemulsion compared to i.p. phenytoin 
solution at 15 and 30 minutes following administration. Again, this study suffered from an i.p 
control and insufficient time points to calculate any pharmacokinetic parameters. There was 
also no data provided on plasma concentrations. Alam et al.127 also assessed a type of lipid 
nanoparticle, this time with lamotrigine. Once again, there was no i.v. (or even i.p) control and 
measurements were performed at only one time point, 24 hours after administration with the 
intent of demonstrating a sustained effect of drug delivered with the intranasal formulation. 
Plasma concentration was higher than brain concentration at this time. Two of these studies 
also employed intranasal solutions of their respective ASDs, which performed better than the 
systemic controls, suggesting that intranasal delivery of the free drug solution did occur, but 
that the formulations appeared to enhance drug delivery in some way, at least at the time point 
tested.  
Two further studies assessed intranasal particle delivery in more detail, however still with 
setbacks. Patel et al.143 studied an intranasal microemulsion containing carbamazepine both 
with and without a mucoadhesive agent to aid retention in the nasal passage. They studied time 
points from 30-480 minutes after administration and reported a carbamazepine %DTE of 241, 
188 and 110 for their mucoadhesive microemulsion, microemulsion and carbamazepine 
solution respectively. Similarly, %DTP values were reported as 59, 47 and 9. The catch here 
was that the i.v. control values from which these values were calculated was based on i.v. 
administration of the microemulsion, rather than free drug solution which likely had significant 
effects on the pharmacokinetic profile. Evidence of this is implied in their supporting gamma 
scintigraphy images which to this author, suggest both an extravasation in the tail vein where 
they were injected and an extensive accumulation of the emulsion particles in the liver. Sharma 
et al144 studied the delivery of diazepam with polymeric nanoparticles with reported 
mucoadhesive properties, also covering a time range of 30-480 minutes. They reported a %DTE 
of 258 for the i.n. nanoparticles and 125 for the i.n. drug solution, while %DTP values were 
61.3 and 1. The i.n. nanoparticles resulted in brain levels higher than i.v. and i.n solutions from 
30 minutes onwards. Despite this more encouraging indication of direct delivery, it should be 
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noted that both studies derived their “drug quantification” data indirectly from scintillation 
measurements of Technetium-99m in tissues, so the values do not unequivocally represent 
actual quantities of the drugs concerned.   
The most extensive studies in this area have been reported with intranasal gels comprising the 
mucoadhesive polymer Carbopol 974P. Barakat et al.137 began by testing such a gel loaded with 
carbamazepine over 5-120 minutes after administration. They reported a peak in i.n. 
concentrations in the brain at 5 minutes after administration (brain:plasma ratio of around 10), 
which significantly exceeded plasma concentrations for up to 20 minutes after administration. 
The i.v. control was administered at a 40 times higher dose (8 mg/kg vs 0.2 mg/kg), but brain 
levels did not peak until 20 minutes and maximum concentration (Cmax) was 4.5 fold lower than 
i.n. Despite these intriguing results, an i.v. comparison with an equivalent dose to that 
administered i.n. would have been useful for direct comparison, especially considering that 
higher doses of carbamazepine can lead to induction of its own metabolism152, which could 
have potential to alter the systemic pharmacokinetic profile. Czapp et al.138 followed with a 
study of a gel containing phenobarbital, recording two types of pharmacokinetic data. The first 
was microdialysis in the frontal cortex extracellular space from 15-240 minutes. The gel 
provided a higher drug concentration in the dialysate than i.n. or i.v. control solutions, which 
was significantly different from 30 minutes onwards, but the plasma:dialysate ratio was not 
significantly different after this. The second method was the classic brain homogenisation from 
2-240 minutes, although they microdissected and analysed different regions to provide more 
detailed information at 10 minutes. They found that whole brain concentrations rapidly 
increased during the first 10 minutes after gel administration, but so too did plasma 
concentrations. Ultimately, they found no difference in whole brain penetration rates between 
i.n. and i.v. administration. Upon microdissection at 10 minutes, however, they found the 
olfactory bulbs to have 3-fold higher concentration after i.n. gel administration. Concentrations 
in other brain regions, however, including those implicated in trigeminal nerve delivery routes 
(e.g. pons), remained similar or even decreased compared with i.v. Despite this, it is interesting 
to consider their finding of respiratory centre depression at high doses of the i.n. gel that was 
not seen after i.v. administration which might imply selective delivery to this area. However, 
brains of these animals were not analysed and they instead attributed this to increased toxic 
metabolites reaching the brain due to shorter systemic exposure.  
More recently, Serraheiro et al.140,141 investigated intranasal gels containing carbamazepine or 
lamotrigine administered to mice. They calculated the %DTE in both experiments to be 96% 
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and 98% respectively, which implied equivalent overall drug delivery to the brain by both i.n. 
and i.v. routes. Their concentration vs time plots for lamotrigine show the i.v. administration 
resulted in a shorter Tmax (5 minutes vs 45 minutes) and greater Cmax in the brain, however, 
upon microdissection into olfactory bulbs, frontal cortex and remaining brain, the i.n. profile 
revealed significant heterogeneity between the regions. In line with the observations of Czapp 
et al.138, they observed markedly elevated concentrations (25 to 67 fold) in the olfactory bulbs 
at 5 and 10 min relative to the other brain regions. Importantly, this remained elevated above 
plasma levels, suggesting an alternative source of penetration. Concentrations in the rest of the 
brain appeared to steadily increase over the time period, but did not reach the magnitude of that 
seen in the olfactory bulbs. Had other regions of the brain been dissected and analysed 
separately, it may have revealed further differences, although the results of Czapp et al. would 
suggest otherwise138. In the case of carbamazepine, the results were not so profound. They 
claimed to have shown higher values in the olfactory bulbs and frontal cortex up to 15 minutes 
after administration, but unlike lamotrigine, these were barely above plasma levels and very 
similar to concentrations seen after intravenous administration. Given that these two 
experiments were performed by the same lab, it would suggest different behaviour of the drug 
molecule, perhaps highlighting different absorption routes and brain distribution patterns. 
While the study of Barakat et al.137 discussed earlier would appear to contest this, the fact that 
it was performed in rats may suggest an interspecies difference. Alternatively, the differences 
may be an indication that, from a pharmaceutical perspective, one thermo-reversible gel does 
not fit all and the interactions of different therapeutics with a delivery system may significantly 
affect their in vivo performance. 
From the above-discussed data, it is evident that the pharmacokinetics of intranasal anti-seizure 
therapeutics has a foundation, but there are clearly improvements and further discoveries to be 
made. Firstly, it is interesting to note that the claims of superior brain delivery from the particle-
based studies are all based on the analysis of whole brains, rather than microdissected ones, 
which the gel studies insisted were required to identify significantly elevated concentrations 
compared to plasma. Whether this is because of the proposed benefit of particles over gels by 
Kozlovskaya et al.91 or simply the methodological shortcomings of the particle studies is 
unclear and further, more comprehensive and objective, studies with these systems are clearly 
needed to begin answering these questions. Furthermore, routine pharmacokinetic analysis of 
different brain regions, particularly those of relevance to olfactory and trigeminal pathways 
(e.g. olfactory bulbs and brainstem) will further elucidate the roles of different pathways in 
nose-to-brain transport and how they might be best utilised to treat neurological diseases such 
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as epilepsy. Another factor to consider is the therapeutic relevance of the concentrations 
reported to reach the brain. While not detailed in this review, ASDs have been studied for many 
decades and a deeper literature search will reveal what is considered as a therapeutic brain 
concentration in a given animal model. Intranasal delivery systems that hope to be translated 
for human use one day for the delivery of existing ASDs would do well to consider whether the 
doses they are delivering via direct pathways are relevant to the treatment of seizures when 
reporting their results. However, in the case of heterogeneous delivery this may be difficult, so 
will require efficacy studies and validated positive controls, which they will ultimately 
encounter on the pathway to translation anyway. Finally, putting the direct-pathway-only 
mentality aside, a realist may speculate that if you can successfully exploit a direct nose-to-
brain route through administration of a lower overall dose than is required systemically (i.e. 
achieve a %DTP above 0) and deliver sufficient therapeutic concentrations directly to key brain 
regions (e.g. olfactory bulbs), then perhaps it does not matter if some is absorbed systemically, 
provided that the systemic exposure is low enough that it will not have any significant adverse 
effects.  
1.7.2.4 Qualitative Distribution in Tissue 
To supplement (or replace in some cases) tissue quantification data, a few of the listed studies 
performed gamma scintigraphy using formulations labelled with Technetium-99m127,128,143,144, 
which was reportedly associated with the drug. Acharya et al128 provided images of rats after 
i.n phenytoin microemulsion and i.p phenytoin solution. They reported accumulation of i.v. 
phenytoin in the liver and spleen, while the i.n. microemulsion was associated with the brain 
and respiratory tract. Similarly, Patel et al143 presented images after administration of i.v. 
microemulsion, i.n. microemulsion,  i.n. mucodhesive microemulsion and i.n. carbamazepine 
solution. They claimed that brain distribution was higher with i.n. compared with i.v. 
administrations, particularly for the mucoadhesive formulation, but the image quality obscures 
the shape of the animal and possibly even exhibits different scales. Finally, Alam et al.127 
presented images of a rat at different time points after i.n. lipid nanoparticle administration 
describing an initial deposition in the nostrils which moves to the brain. They also noted a 
significant portion in the oesophagus and abdominal region. While this data complements their 
pharmacokinetic studies to an extent, it is very difficult to discern objectively where the drug is 
depositing, especially given that the brain sits directly above where the liquid formulation is 
initially deposited. In particular, this renders comparisons of relative i.v. and i.n. brain 
distribution rather useless.  
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Kubek et al.16, on the other hand, used fluorescent illumination (exact procedure not specified) 
to examine the brains of animals after administration of polymeric nanoparticles containing 
Nile Red. This was necessary as due to the endogenous nature of their therapeutic molecule, 
TRH, the exogenously administered peptide could not be directly quantified and distinguished 
from the endogenous peptide in the brain tissue. Based on the Nile Red fluorescence, they 
claimed widespread distribution and sustained presence of nanoparticles within the brain for up 
to 96 hours, however, the control presented was a rat exposed to larger-sized nanoparticles at 
24 hours, rather than Nile Red alone. Given that free Nile Red will emit a red wavelength on 
contact with polar membrane lipids153 such as the extensive array found in the brain, the claim 
that this represented the presence of nanoparticles would seem unconvincing. Furthermore, they 
developed an immunohistochemistry assay to detect their nanoparticle polymer in the brain, but 
only showed a validation of the assay after intra-amygdala injection of the nanoparticles, rather 
than their detection in the brain of an intranasally-treated animal.  
Thus, while qualitative data may provide a supplement to quantified drug distribution patterns, 
it would seem to be inadequate, at least in the ways it was used in the reviewed studies, to 
convincingly demonstrate the existence of a direct nose to brain pathway. The gamma-
scintigraphy studies did, however, provide an interesting insight into distribution of the 
formulation into other body regions after the intranasal administration (e.g. possible swallowing 
or inhalation) indicating that the administration and volume could be optimised further. In 
saying that, it should be noted that the animals were anaesthetised so that they could be imaged, 
which likely changed the distribution compared to when they were conscious, especially in 
terms of clearance from the nasal cavity which may explain partially why the label appears to 
remain in the head area. 
1.7.2.5 Efficacy 
The other important consideration in any drug delivery study is demonstrating 
pharmacodynamic efficacy in an animal model. As discussed in the previous section, a number 
of clinically-predictive seizure models have been designed to provide a platform for high 
throughput and cost effective screening of anti-seizure therapeutics. In Table 1.5, it can be seen 
that the intranasal formulation literature to date has largely focused on the recapitulation of 
well-characterised anti-seizure drugs and this provides an advantage as far as efficacy testing 
is concerned in that it can be predicted which seizure models will be most useful for testing 
whether these molecules are reaching the brain in sufficient concentrations to elicit an effect. 
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The discussion in the previous section also highlights how it might be predicted, based on the 
theory of direct nose-to-brain pathways, which models may be most useful for detecting these 
specific effects from direct nasal delivery routes and thereby fit a model to the question.  
Of the studies in Table 1.7, eight employed a seizure model. Most performed the Maximal 
Electroshock Seizure (MES) test or unvalidated variations thereof, while two performed a 
pentylenetetrazole (PTZ) test and two used an amygdala kindling model. Aside from the 
kindling studies, no rationale was provided for why a specific model or seizure endpoint was 
chosen. In most cases, the model chosen was at least relevant to the drug being tested, but in 
the case of carbamazepine and lamotrigine-based formulation testing in the PTZ model this is 
questionable14. While most reported anti-seizure effects, in a lot of cases this could not be 
reliably attributed to anything other than an enhancement of systemic absorption, especially in 
the cases where efficacy claims were not accompanied by pharmacokinetic data129,139,146. 
Furthermore, considering the lack of adverse effect and toxicity data provided, as discussed 
above, it is possible that damage to physiological barriers could have been a major contributor 
to any enhanced delivery. Nonetheless, like the pharmacokinetics data, and despite their 
limitations, they would seem to support the use of the nose as a rapid and sustained method of 
drug delivery.   
The end points used were fairly standard in most studies, except in the case of MES variations, 
which in this author’s opinion, were not justified. Assuming the reported values were not a 
typing error, Samia et al.139 employed extremely lengthy stimulations and used stimulations 
until death as an endpoint, which would seem to have no scientific basis. Eskandari et al.145 
used parameters of 110 mA, 100 Hz, 1 ms pulse width and 0.2 s shock duration, validating their 
method with a seemingly excessive dose of i.p. phenytoin (90 mg/kg), on the basis that more 
than 50% of rats displayed extension when untreated, but none did when treated.  Given that 
less than 100% of untreated rats displayed extension, it is unclear firstly how they used a 
decrease in extension:flexion ratio compared to control as an endpoint, secondly why they did 
not simply report it as flexion:extension ratio and furthermore, why the decrease in this 
parameter appeared to be almost as high as the drug-treated rats in those given blank 
nanoparticles. Although not commented on by the authors, this might suggest that the 
components of the formulation itself may have played a role in eliciting the apparent anti-
seizure effects, as has been reported elsewhere134. Alternatively, it is also possible this may 
have been related to the anaesthesia (reported as ‘light ether’) used during administration that 
the untreated controls may not have received.  
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In fact, most studies who reported using anaesthesia did not comment on whether this was also 
applied to untreated controls to which efficacy data was compared or normalised to account for 
a potential confounding effect on seizure threshold127,139,145,146. For short-acting inhaled 
anaesthesia, this was likely less influential, but certainly with systemically-administered longer-
acting anaesthetics, ketamine154,155 and propofol156, this may have been an important 
confounder in tests performed 60 minutes or less after administration. Czapp et al.138, was an 
exception, in that they specifically stated that the administration of propofol alone in 
preliminary experiments did not affect kindling parameters and also administered anaesthesia 
to all i.v. controls. They did, however, require increased doses of propofol to administer 
increased doses of nasal gel (containing more phenobarbital) and considering the synergistic 
interaction previously reported between propofol and phenobarbital157, it should be noted that 
this may have contributed somewhat to the significant anti-seizure effects noted at the higher, 
but not the lower, dose after i.n. administration. 
The most commonly used time point for testing, regardless of the ASD studied, was 60 minutes. 
Given that a key aim of intranasal delivery is to exploit direct and rapid routes to the brain, 
which the pharmacokinetic data discussed in the previous section suggest the existence of, the 
rationale for the popularity of this time point was unclear. In some cases, such as that of Czapp 
et al.138, where kindling parameters were measured 60 minutes after administration, it may have 
been related to the fact that substantial anaesthesia was used during the administration (in that 
case, i.v. propofol), necessitating a significant time delay to allow the animals to regain 
consciousness before stimulations. Alternatively, it may have been based on the time to peak 
effect of systemic phenobarbital99, but given that relatively high concentrations were found in 
the olfactory bulbs at 10 minutes after i.n. compared with i.v. administration, an earlier time 
point would have been interesting if it were possible. Only one study performed stimulations at 
a range of time points (15-120 minutes) to determine a time of peak effect145, which would have 
been useful in other studies given that nasal administration may change the pharmacokinetics 
of an ASD. The parenteral half-lives and times to peak effect of the ASDs used in the reviewed 
studies are included for the reader’s reference in Table 1.8.  
1.7.2.6 In the Pipeline 
Outside of the published literature, pharmaceutical formulation for the intranasal treatment of 
seizures is also gaining traction in the patent and pharmaceutical company scene, particularly 
in the arena of cannabinoids. The potential role of these molecules in the treatment of 
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pharmacoresistant epilepsy is an area of much current interest158, but their inherent lipophilicity 
and low bioavailability makes delivery an issue. It would appear that intranasal pharmaceuticals 
are being explored to address this challenge, albeit not specifically for seizures, but neurological 
conditions in general. One such recent example, which is aiming to exploit a direct nose-to-
brain pathway, or at least a rapid systemic absorption for cannabinoids, is a contract between a 
Canadian health company and the University of Queensland Pharmacy department to formulate 
sol gels for this purpose159.  Another example is found in a patent for the development of 
phospholipid nanoparticles containing cannabinoids, with intranasal delivery listed as a 
potential application160. Hence, while this area is still young, formulation is increasingly being 
recognised as a requirement to exploit intranasal delivery, and innovative therapeutics, to their 
fullest.   
1.7.2.7 Conclusions 
The above discussion highlights some important considerations that should be addressed in 
order to further the exploration of the field of intranasal treatment of seizures with the 
development of pharmaceutical formulations. All but one of the formulation publications 
discussed have come from the past decade, suggesting why this area still appears to be 
establishing a solid foundation. Gels would seem to be the most well-characterised 
pharmacokinetically for the delivery of ASDs, but a review of the wider intranasal formulation 
literature suggests that particulate delivery systems may be an important contributor once they 
are more rigourously studied91. A number of other attempts to formulate, with similar drugs 
(lamotrigine161,162, valproic acid163,164, carbamazepine165, midazolam166) and approaches 
(microspheres, microemulsions and gels) have been published, but without biological testing to 
follow up pharmacokinetic and pharmacodynamic efficacy at present. With all its 
shortcomings, the existing literature would suggest that there are quite likely advantages to 
delivering anti-seizure drugs through the nose, but which direct pathways (if any) are able to be 
exploited and whether this can be achieved without damaging the nasal mucosa, as well as 
whether it is a feasible chronic treatment, is yet to be determined. More attention to obtaining 
quality and hypothesis-driven pharmacokinetic and pharmacodynamic data with suitable 
controls, as well as more detailed and standardised reporting of methodology should contribute 
a lot towards answering these questions.   
With all this in mind, the following Chapters aim to establish and apply an intranasal screening 
model to the investigation of two types of particulate delivery systems for delivering ASDs 
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intranasally to the brain. Chapter Two begins by validating a screening model based on the 
MEST test to measure changes in seizure threshold using a known ASD, phenytoin. Chapter 
Three follows by evaluating the ability of the model to measure the effects of phenytoin 
delivered intranasally using a previously characterised microparticle formulation. Chapter 
Four then concludes by applying the model to the investigation of oleoylethanolamide, an 
endogenous molecule with hypothesised, but unknown anti-seizure activity, where delivery is 
mediated by a cubosome dispersion. All experimental Chapters aim to provide as holistic an 
assessment as possible, with histological and pharmacokinetic data to accompany the 
pharmacodynamic data as appropriate, exemplifying an improved standard for future studies of 
intranasal ASD delivery that follow on from those discussed in the above review.
Chapter One: Intranasal Treatments for Epilepsy 
 
49 
 
Table 1.6. Summary of intranasal doses and administration methods used in studies investigating intranasally-delivered ASDs. 
Drug/therapeutic Animal 
model 
Dose Volume Anaesthesia Method Reference 
Carbamazepine Mouse 12-16 µg 12-16 µL in one 
nostril 
Ketamine and 
xylazine (i.p) 
Tubing 
 
[140] 
Carbamazepine Mouse 0.625 mg 100 µL in one 
nostril 
Diethyl ether  
 
Cannula strengthened by jacketed non-
protruding needle 
[139] 
Carbamazepine Rat 35-40 µg 10 µL in each 
nostril 
Ketamine (i.m) 
 
Tubing 
 
[143] 
Carbamazepine Rat 50 µg 
(administered) 
40 µg 
(accepted) 
50 mg gel into one 
nostril.  Estimated 
that 80% was 
accepted.  
None Tubing  
 
[137] 
Carbamazepine  Rat 1.6-2 mg 55 µL in each 
nostril 
None mentioned Tubing 
 
[129] 
Lamotrigine Mouse 0.11-0.125 mg Not stated. Both 
nostrils.  
Ketamine and 
xylazine (route not 
stated) 
Tubing 
 
[146] 
Lamotrigine Mouse 120-160 µg 12-16 µL in one 
nostril 
Ketamine and 
xylazine (i.p) 
 
Tubing 
 
[141] 
Lamotrigine Rat 0.72-0.97 mg 100 µL in each 
nostril 
Ketamine (i.m) 
 
Not stated 
 
[127] 
Phenytoin Rat 3.52 mg 88 µL in each 
nostril 
None mentioned Tubing 
 
[128] 
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Phenobarbital Rat 1.1-1.2 mg 
2-2.2 mg 
6-6.6 mg 
7-40 µL in each 
nostril 
Propofol (i.v) 
 
Deposited at opening of nares or using 
tubing 
[138] 
Valproic acid Rat 0.72-0.84 mg 100 µL in each 
nostril over a few 
minutes 
Light ether 
 
Tubing 
 
[145] 
Diazepam Rat 40-50 µg 10 µL each nostril Ketamine (i.p) Tubing 
 
[144] 
Thyrotropin 
releasing hormone 
(TRH) 
Rat 20 µg 25 µL in each 
nostril (chronic 
administration) 
Isoflurane Surgically inserted cannulae [16,17] 
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Table 1.7. Summary of methodology used in studies analysing pharmacokinetics and anti-seizure efficacy of intranasally-delivered ASDs.  
ASD/molecule Tissues 
analysed 
Pharmacokinetic 
parameters 
reported 
Time points after 
administration 
Routes/formulations 
compared 
Test Endpoint Time of 
test 
Anaesthesi
a 
Referen
ce 
Diazepam Brain, plasma %DTE, Brain 
concentration, Plasma 
concentration, Cmax, 
Tmax, AUC 
30, 60, 120, 240, 
480 min 
i.n. (drug solution) 
i.n. (drug formulation) 
i.v. (drug solution) 
 
- 
 
- 
 
- 
Ketamine 
(i.p) 
[144] 
Lamotrigine Brain – 
olfactory 
bulbs, frontal 
cortex, 
remainder.  
Plasma.  
Liver.  
DTE, Brain 
concentration, Plasma 
concentration, Liver 
concentration, 
Brain:Plasma ratio, 
Tmax, Cmax,, AUC, kel 
(terminal elimination 
rate constant), k 
(tissue elimination 
rate constant), t1/2, 
Mean residence time 
(MRT), Absolute i.n. 
bioavailability (F), 
AUC ratio 
(liver:plasma) 
5, 10, 15, 30, 60, 
120, 240 min 
i.n (drug formulation) 
i.v. (drug formulation) 
 
- 
 
- 
 
- 
Ketamine 
and xylazine 
(i.p) 
 
[141] 
Carbamazepine Brain – 
olfactory 
bulbs, frontal 
cortex, 
remainder.  
Plasma.  
Liver. 
DTE, Brain 
concentration 
Plasma concentration, 
Brain:Plasma ratio, 
Liver concentration, 
Tmax, Cmax, AUC, kel, 
t1/2, MRT, F. 
5, 10, 15, 30, 60 
min 
i.n (drug formulation) 
i.v. (drug formulation) 
 
- 
 
- 
 
- 
Ketamine 
and xylazine 
(i.p) 
 
[140] 
Carbamazepine Brain 
Plasma  
Brain concentration, 
Plasma concentration, 
AUC, Tmax, Cmax, Kel, 
t1/2, %DTE, %DTP. 
30, 60, 120, 240, 
480 min 
i.n. (drug formulation x 
2) 
i.n (drug solution) 
i.v. (drug formulation) 
 
- 
 
- 
 
- 
Ketamine 
(i.m) 
 
[143] 
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Carbamazepine Brain 
Plasma 
Brain concentration, 
Plasma concentration, 
Brain:Plasma ratio, 
AUC, Cmax, Tmax, 
MRT, AUC ratio 
(brain:plasma). 
5, 10, 15, 20, 30, 
45, 60, 90, 120 min 
No treatment 
i.n. (drug solution) 
i.n. (drug formulation) 
p.o. (drug solution) 
 
- 
 
- 
 
- 
None [137] 
Lamotrigine Brain 
Plasma 
Brain concentration, 
Plasma concentration. 
 
24 hours  IN (solution) vs IN 
(formulation) vs PO 
MES 
(auricular) 
HLE incidence 
Latency to HLE 
Duration of HLE 
60 min  
24 hours 
Ketamine 
(i.m) 
[127] 
Phenobarbital Whole brain.  
OB, frontal 
cortex, 
piriform 
cortex, 
amygdala, 
hippocampus, 
parahippocam
pal cortex, 
caudal cortex, 
cerebellum, 
pons.  
Frontal cortex 
dialysate.  
Plasma. 
 
Dialysate:Plasma 
ratio (microdialysis in 
frontal cortex) 
Brain concentration 
(homogenate) 
Plasma concentration 
(homogenate) 
Brain:Plasma ratio 
(homogenate) 
 
10 min 
(microdissected 
regions) 
 
2, 5, 10, 20, 30, 60, 
200, 240 min 
(whole brain and 
plasma) 
 
15, 30, 60, 90, 120, 
180, 240 min 
(dialysate) 
i.n. (formulation without 
drug) 
i.n. (formulation with 
drug) 
i.v. (formulation without 
drug) 
i.v. (formulation with 
drug) 
Amygdala 
kindling 
ADT 
Seizure severity 
Seizure duration 
Afterdischarge 
duration 
GST 
60 min Propofol 
(i.v) 
[138] 
Valproic acid Brain 
Plasma 
Brain concentration, 
Plasma concentration, 
Brain:Plasma ratio. 
 
60 min i.n.  (formulation without 
drug) 
i.n. (formulation with 
drug) 
i.n. (drug solution) 
i.p.  (formulation without 
drug) 
i.p. (formulation with 
drug) 
i.p. (drug solution) 
MES 
variation 
(auricular) 
E:F ratio of 
hindlimbs 
15, 30, 60, 
90, 120  
Light ether [145] 
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Phenytoin Brain Brain concentration. 
 
15 and 30 min No treatment 
i.n. (drug formulation) 
p.o. (drug formulation) 
i.p. (drug solution) 
 
MES 
(auricular) 
Duration of HLE 60 min None 
mentioned 
[128] 
Carbamazepine  
- 
 
- 
 
- 
i.n. (solution)  
i.n. (formulation) 
p.o. (formulation) 
i.n. (solution) 
No treatment 
MES 
(auricular) 
Duration of HLE 60 min None 
mentioned 
[129] 
Carbamazepine  
- 
 
- 
 
- 
i.n. (drug formulation) 
i.n. (drug solution) 
No treatment 
MES 
variant 
(auricular) 
 
PTZ (i.p) 
MES variant: 
number of trials 
until death 
PTZ: onset to 
convulsion, time 
until death 
5 min  
(MES 
variant) 
15 min 
(PTZ) 
Diethyl ether [139] 
Lamotrigine  
- 
 
- 
 
- 
Saline (route not 
reported) 
i.n. (drug formulation) 
i.p. (drug formulation) 
PTZ (s.c.) Onset to clonic 
convulsion 
Protection against 
mortality 
30 min Ketamine 
and xylazine 
(route not 
reported) 
[146] 
Thyrotropin 
releasing 
hormone 
 
- 
 
- 
 
- 
i.n. (drug formulation) 
i.n. (formulation without 
drug) 
Amygdala 
kindling 
ADD 
Number of 
seizures until first 
stage 5 
Number of 
seizures until fully 
kindled 
Daily 
stimulations 
until fully 
kindled 
Doses 
administered 
at both 60 
and 30 min 
before 
stimulation.  
Isoflurane [16,17] 
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Table 1.8. Half-lives and times to peak effect of ASDs used in the reviewed formulation studies. 
ASD/therapeutic Plasma half-life (h) 141,151,167,168 
 
Time to peak effect after single 
parenteral dose 99,169 
Rats Mice Human  Rats Mice 
Carbamazepine 1.2-3.5 30-60 25-50 30 min 15 min 
Phenobarbital 9-20 7.5 70-100 60 min 30 min 
Lamotrigine 12-30 8* 21-50 60 min 120 min 
Phenytoin 1-8 16 15-20 30 min 120 min 
Valproic acid 1-5 0.8 8-15 15 min 5 min 
Diazepam 1.4 7.7 24-72 15 min 15 min 
*Estimated from plasma concentration graph in Serralheiro et al141
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     Chapter Two 
 
The Validation of a Seizure Model 
                                                       
2.1 Introduction 
The first step towards testing intranasal drug delivery systems in this thesis was to establish a 
suitable model with which to measure their effects on seizure threshold. The suitability and 
previously reported use of a range of models was discussed in Chapter One. Based on this 
discussion, it was decided that the Maximal Electroshock Seizure Threshold (MEST) test was 
most suited to perform these early investigations. The test has several key benefits, as touched 
on in Chapter One, including an increased sensitivity to detect anti-seizure effects (compared 
to an “all or nothing” suprathreshold effect as in the MES test), the ability to simultaneously 
test for pro-seizure effects that may be caused by previously un-investigated therapeutics or 
different doses of known anti-seizure drugs170, and the lack of assumption of a pharmacological 
mechanism of drug action (as opposed to chemically induced seizures)171.   
As discussed in Chapter One, the typical MEST test is based on the “up and down” method of 
Kimball et al99,100 and compares the threshold for hind-limb extension (HLE) with and without 
anti-seizure drug treatment by stimulating each rat on two occasions: once after control 
treatment administration, then again >48 hours later after drug treatment administration. The 
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mean current inducing HLE in 50% of rats (CC50) in each group is calculated and compared 
between the groups. An increase in CC50 (i.e. seizure threshold) after test drug treatment 
suggests an anti-seizure effect of the drug treatment in the animals.   
Despite its common use in the literature, this typical design has a few limitations which may 
have presented as obstacles for the proposed study of intranasal delivery in this thesis. Firstly, 
in the traditional MEST experiment, interday variability and the possibility of sequence effect 
are not accounted for. Generally, the control trial is performed first, followed by the drug trial 
on the assumption that the order of the treatments and the effect of multiple stimulations has no 
effect on the seizure threshold. Although it has been reported that the CC50 does not 
significantly vary for HLE or fore limb extension (FLE) provided 48 hours is left between 
stimulations101, a host of factors may influence seizure threshold99 and inter-lab (and even inter-
batch) variability can be considered a very real possibility. Secondly, the traditional MEST 
experiment analyses a batch of rats as a group on the basis of seizure threshold for a single 
parameter; usually HLE. This means that the responses of individual rats cannot be assessed at 
baseline and after treatment to reduce intra-subject variability as they are likely to be stimulated 
at different currents in each trial. Furthermore, only one response (e.g. HLE or FLE) can be 
assessed per round of the “up and down” method, limiting the information obtained from each 
stimulation and potentially missing more subtle variations in responses. Finally, the success of 
the “up and down” method is dependent on quickly reaching a value close to the true population 
CC50 in the serial stimulations
100. If this is not achieved by correctly estimating the starting 
current for a particular group of animals, which can be a particular issue after they have received 
drug treatment with an unknown effect, then the confidence interval will be large. This may be 
further complicated by the administration of potentially confounding anaesthetic prior to drug 
administration as was a requirement for intranasal delivery studies in the following Chapters.   
With the expectation that the effects of drugs delivered intranasally may be localised in the 
brain and could be more subtle than those seen after systemic administration, it was necessary 
to aim for the highest sensitivity and lowest variability possible while still maintaining a fairly 
simple screening procedure. This Chapter therefore establishes and validates a new study design 
based on the MEST procedure where baseline threshold for a group of animals is determined 
initially, then used to stimulate each group with and without drug treatment in a cross-over 
fashion. The anti-seizure drug chosen to validate this new study design was phenytoin. The 
rationale for its use over other drugs was primarily due to its use as a model drug for intranasal 
delivery in Chapter Three, the subsequent reasoning for which is discussed in that Chapter. 
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Also of critical importance was that phenytoin, unlike certain other drugs discussed in Chapter 
One, has been shown to be highly effective at increasing the threshold against MEST seizures 
in rodents172–174 and could therefore be administered as a positive control to validate the ability 
of the test to show statistically significant effects in our lab. To complement the 
pharmacodynamic experiments in this Chapter and the one that follows, a highly sensitive 
analytical liquid chromatography mass spectrometry (LC-MS) method was also validated and 
used to quantify the concentrations of phenytoin and its major hepatic metabolite 5-(4-
Hydroxyphenyl)-5-phenylhydantoin (4-HPPH) in the brain tissue and plasma of the tested 
animals in order to evaluate the pharmacokinetics of the drug in this study. Finally, the effect 
of the procedure on animal welfare is evaluated to justify the use of the model in future Chapters 
from an ethical standpoint.    
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2.2 Aims 
The overall aim of this Chapter was to validate a modified version of the MEST seizure model 
using a known anti-seizure drug, so that it could be applied to intranasal delivery studies in the 
succeeding Chapters. To achieve this, the following objectives were set:  
 Validate the ability of a modified MEST study design to detect the anti-seizure effect of 
phenytoin. 
 Develop and validate an LC-MS method to detect phenytoin and its major metabolite 
(4-HPPH) in rat plasma and brain tissue. 
 Evaluate phenytoin concentrations in brain and plasma after intravenous administration 
in the seizure-tested rats to correlate with pharmacodynamic effects. 
 Assess the impact of multiple stimulations of individual animals on their welfare during 
the course of the experiment.   
2.3 Hypotheses 
 The primary hypothesis on which this Chapter is based was that a therapeutic 
intravenous dose of the established anti-seizure drug phenytoin would show an anti-
seizure effect in the MEST test under the conditions used in our laboratory and with the 
crossover study design proposed.  
 It was also hypothesised that therapeutic brain and plasma levels would accompany the 
pharmacodynamic effects, thereby validating the ability of the model to detect anti-
seizure effects in the experiments constituting the subsequent Chapters. The hypothesis 
was based on the abundance of previous literature which documents the ability of 
phenytoin to increase the threshold for seizures elicited by the Maximal Electroshock 
Stimulation method.  
 Finally, it was also hypothesised that individual animals could receive three independent 
stimulations at 48 hour intervals without significant adverse effects on their wellbeing, 
an aspect which has not been specifically reported on in previous literature employing 
the MEST test.   
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2.4 Materials & Methods 
2.4.1 Materials 
Phenytoin (5,5-diphenylhydantoin) sodium injection (250 mg/5 mL) (DBL™ Phenytoin 
injection BP) was purchased from hameln pharmaceuticals GmbH (Germany). Isotonic (0.9 %) 
saline was purchased from Baxter (Australia). Isoflurane was provided by the Hercus-Taieri 
Resource Unit, University of Otago. Phenytoin sodium, 4-HPPH (5-(4-Hydroxyphenyl)-5-
phenylhydantoin), propylene glycol (PG), formic acid (for mass spectrometry, ~98%) and 
phosphate-buffered saline (PBS) sachets (pH 7.4) were purchased from Sigma Aldrich (New 
Zealand). Deuterated phenytoin (d10-phenytoin; (5,5-(diphenyl-d10) hydantoin)) was purchased 
from Toronto Research Chemicals (Canada). All water used in this study was ion exchanged, 
distilled and passed through a Milli-Q water purification system (Millipore, USA). Acetonitrile 
(ACN) (LiChrosolv®), Methanol (MeOH) (LiChrosolv®), tert-Butyl Methyl Ether (TBME) 
(LiChrosolv®) and Ethanol (EMSURE®) were purchased from Lab Supply (New Zealand). 
All of these solvents were liquid chromatography grade. Male Wistar rat plasma and brain tissue 
for LC-MS method validation and standard preparation was obtained in-house from control rats 
administered saline treatments. 
2.4.2 Animals 
All procedures involving animals were approved by the University of Otago Animal Ethics 
Committee pursuant to Animal Use Protocol 08/16. Male Wistar rats (260-320 g, 7-8 weeks 
old) sourced from the Hercus Taieri Resource Unit were used in this experiment. Specific 
weights and ages of animals over the course of the experiments can be found in the Results 
section of this Chapter and Appendix A and B, respectively. Animals were housed under 
laboratory conditions in the Hercus Taieri Resource Unit for the duration of the experiment.  
2.4.3 Drug Administration 
2.4.3.1 Isoflurane Anaesthesia 
Preliminary experiments determined that a short inhaled anaesthesia would be required in order 
to perform intranasal administration for MEST experiments in Chapters Three and Four. 
Therefore, in the interests of consistency, this anaesthesia was also administered in this 
validation experiment to ensure that the anti-seizure effect of phenytoin could be detected 
compared to control despite any potential contribution from the anaesthetic. Animals were 
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anaesthetised with 5 % isoflurane and an oxygen flow rate of 1 mL/minute for three and a half 
minutes immediately prior to drug administration, as described in Chapters Three and Four.  
2.4.3.2 Intravenous Administration of Phenytoin Solution and Saline 
While the animals were unconscious, phenytoin sodium solution (25 mg/kg ≈ 150-180 µL) or 
equivalent volume of saline (0.5 mL/kg) was administered via a lateral tail vein using a 0.3 mL 
Lo-dose U-100 insulin syringe with 29 G x 12.7 mm needle (BD Biosciences, New Zealand). 
The phenytoin dose used was reported elsewhere to achieve therapeutic and non-toxic plasma 
concentrations that persisted up to 60 minutes175–177 and previous studies indicated it would be 
sufficient to raise the threshold for hind-limb extension in the MEST test up to this time 
point99,172,174. Considering this and the initial planned time point for the intranasal MEST trial 
in Chapter Three, the treatment was administered 60 minutes before stimulation in this 
validation experiment.  
2.4.4 Maximal Electroshock Stimulation Threshold Test 
2.4.4.1 Auricular Electrode Habituation 
In order for the animals to feel more comfortable with the stimulation procedure and minimise 
technical errors due to uncooperative behaviour, rats were habituated to the application of 
auricular (ear clip) electrodes (Harvard Apparatus, USA) over a period of four days prior to the 
first stimulation, as well as between successive stimulation days. This was achieved through 
once daily application of the electrodes and placement into the custom-made transparent acrylic 
container (420 x 420 x 210 mm) in which the stimulations would occur, for up to 30 seconds. 
Following this, the electrodes were removed and the animal returned to their home cage.  
2.4.4.2 Electrical Stimulation 
Preliminary experiments with an Electoconvulsive therapy (ECT) unit (Ugo Basile, Italy) 
demonstrated the importance of using a sinusoidal rather than rectangular pulse current 
stimulator (as had been reported by some studies in the literature145,178,179) for this procedure in 
order to observe the necessary maximal seizure response. The constant current stimulator used 
in these experiments was therefore a Rodent Shocker Sine-Wave Shock Generator with Foot 
Switch (230 Volts of alternating current (VAC), 50 Hertz (Hz)) (Harvard Apparatus, USA). 
Auricular electrodes smeared with a conductive gel were applied to each animal’s ears 
immediately prior to stimulation. The animal was placed in the container described above and 
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a stimulus of 0.2 seconds duration was delivered through the electrodes to initiate a seizure. 
The current used for the stimulation varied, as described below. Each test was recorded on video 
for later reference and blinded evaluation of the seizure response observed. 
2.4.4.3 Cross-Over Study Design 
To account for variability in seizure thresholds and observed seizure behaviours in our animals, 
we modified the typical design of the MEST test as discussed in the introduction to this Chapter. 
This involved using a cross-over method, as outlined in Figure 2.1, where a total of three 
stimulations were delivered to each rat, no less than 48 hours apart.  
 
Figure 2.1. Crossover method design of the MEST test used in this study. 
 
For the first stimulation, the “up and down” method was used to estimate the convulsive current 
inducing the maximal seizure endpoint of hind-limb extension in 50% of animals (CC50) in the 
group (Figure 2.2). Isoflurane anaesthesia was performed 60 minutes before each stimulation 
so as to determine the CC50 under the influence of any potential confounding effects from the 
anaesthesia and to therefore determine a reasonable estimate of it for the subsequent treatment 
trials that would also need to employ it. The initial current of stimulation was 50 mA, based on 
the CC50 threshold of male Wistar rats reported in the literature
15,101,172. Each animal was 
stimulated in series, altering the current of stimulation by 0.06 log units down or up, depending 
on whether the previous animal did or did not display the endpoint, respectively. The CC50 
calculated for the group of rats (using the method of Kimball et al.100) was used as the 
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stimulation current for all of the animals in the subsequent two stimulations. All stimulations 
for a given rat were performed at least 48 hours apart. Exact relative timings of all the 
stimulations are presented in Appendix A.  
 
Figure 2.2. Principles of the “up and down” method to determine the threshold for tonic hindlimb 
extension by serial stimulation of a group of rats.  
 
Prior to the second stimulation, rats were randomly divided into two groups. All were briefly 
sedated with isoflurane anaesthesia as outlined above, then intravenously administered 
phenytoin sodium solution (25 mg/kg) or an equivalent volume of isotonic saline (0.5 mL/kg). 
After 60 minutes, they were stimulated at the CC50 and their response recorded. The third 
stimulation followed the same protocol, except that the treatments were switched so that the 
response of each rat was measured after both saline and phenytoin treatment. Outcomes were 
compared statistically with Prescott’s test180, with p < 0.05 considered statistically significant.  
2.4.5 Tissue collection for pharmacokinetic analysis 
Tissues were collected and processed in order to study brain concentrations of phenytoin and 
4-HPPH in rats that had participated in the pharmacodynamic MEST experiments. Rats were 
euthanased by guillotine decapitation within 10 minutes of the third and final MEST 
stimulation. Trunk blood was collected in a 6 mL tube coated with sodium heparin (BD 
Biosciences, New Zealand) at the time of euthanasia and centrifuged at the conclusion of the 
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experiment (2000 G for 10 minutes at ambient temperature (Heraeus Multifuge X3FR, Thermo 
Fisher Scientific, New Zealand). The brain was also dissected and kept on ice until the 
conclusion of the experiment, after which they were frozen and kept at -80 ºC until required for 
LC-MS analysis.  
 
2.4.6 LC-MS Method for Analysis of Phenytoin in Plasma and Brain Tissue 
2.4.6.1 Extraction and Sample Preparation 
Thawed brains were homogenised after adding 2 mL/g (based on wet weight determined after 
rinsing in PBS at time of dissection and blotting with filter paper after thawing) of Milli Q water 
prior to homogenisation on ice with a tip sonicator for periods of up to 5 seconds at a time until 
sufficiently homogenous (UP50H Ultrasonic Processor, hielscher Ultrasound Technology, 
Germany) (1 cycle, 100% amplitude). The homogenate was aliquoted into 1.7 mL ultra clear 
microtubes (Axygen, USA) in aliquots of 100 µL. Plasma was able to be thawed and extracted 
without dilution with water as it could be accurately pipetted due to low viscosity. A pilot run 
was conducted before the main study to estimate phenytoin concentrations in the tissues and 
where appropriate, samples for the main study were diluted with blank plasma or brain 
homogenate in order to be quantifiable within the standard range.  
Each 100 µL sample aliquot had 5 µL internal standard (d10-phenytoin) and 5 µL methanol 
(standard solvent) added (in the case of standards, the latter contained a standard concentration 
of phenytoin and 4-HPPH). This was vortexed, then 200 µL chilled ACN was added. This 
mixture was sonicated briefly in a water bath (Elmasonic S 60 (H), Elma Ultrasonics, New 
Zealand), then 800 µL chilled TBME was added and it was sonicated briefly again, then 
vortexed briefly. It was then centrifuged at 17,200 G for 20 minutes at 4 °C (Prism™ R 
Microcentrifuge, Labnet International, Inc., USA).  
The samples were taken into a precooled tray, then 800 µL of the supernatant was taken and 
transferred to a new tube. These tubes containing the supernatant were then evaporated to 
dryness in a centrifugal evaporator (Thermo Savant Speed Vac®, Thermo Fisher Scientific, 
New Zealand) until dry (8-12 hours). A 200 µL volume of methanol was then added to each 
tube and it was briefly sonicated and vortexed to reconstitute. A brief centrifugation (10,000 
rpm for 1 second) followed to ensure all liquid was moved to the bottom of each tube. Samples 
were then pipetted into the top of a 1 mL syringe (BD Biosciences, New Zealand) and filtered 
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through a 13 mm Nylon 0.22 µm syringe filter (Microanalytix, New Zealand) into a 250 µL 
insert (PP BM insert with bottom spring case (Phenomenex, USA)) in a 2 mL clear glass vial 
(Thermo Fisher Scientific, New Zealand). Samples were stored at ambient temperature until 
analysis.   
2.4.6.2 Standard Preparation 
Stock solutions for standard preparation were produced by dissolving analyte powders 
(phenytoin sodium, 4-HPPH and d10-phenytoin) in methanol at a concentration of 1 mg/mL. 
Serial dilution of these solutions in methanol was performed to achieve the desired standard 
concentrations. To prepare standard samples for analysis, aliquots of standard solutions (5 µL) 
were mixed with blank plasma or brain homogenate aliquots (100 µL) in place of the 5 µL of 
blank methanol added to the unknown samples, as described above. The extraction procedure 
was the same from that point forward. Standards covered a range of 7.81 to 250 ng/mL for 
plasma and 23.4 to 750 ng/g for brain tissue. Quality control (QC) samples were prepared 
alongside standards at concentrations within the relevant ranges.  
2.4.6.3 LC-MS Analysis 
Samples were analysed using an Agilent 1290 High Performance Liquid Chromatography 
(HPLC) system (G4226A autosampler, LC binary SL pump, TCC SL (Agilent, USA)) 
connected to an AB Sciex QTRAP 5500 mass spectrometer with Turbo Spray ion source (Sciex, 
USA). Parameters were optimised to detect the analytes of interest as shown in Table 2.1.   
Table 2.1. Optimised parameters for phenytoin and 4-HPPH analysis. 
Entrance potential (V) 10.0 
Curtain gas (psi) 15.0 
Collision gas Medium 
Ionspray voltage (V) 5500.0 
Temperature (ºC) 600.0 
Ion source gas 1 (psi) 40.0 
Ion source gas 2 (psi) 40.0 
 
Figure 2.3 shows the molecular structures and molecular masses of the compounds analysed 
(A-C) as well as the predicted fragmentation in positive ion mode (arrows).  
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Figure 2.3. Molecular structures of (A) Phenytoin (Mw = 252.3 g/mol), (B) 4-HPPH (Mw = 268.3 
g/mol) and (C) d10-phenytoin (Mw = 262.3 g/mol). The expected fragmentation point which produces 
the predominant daughter ion of each ([M+H]+) is shown with a yellow arrow. 
 
As predicted from the fragmentation shown in Figure 2.3 and previous literature181, the 
precursor/product ion pairs found to produce the highest intensity in positive ion mode were 
253.011/182.100 for phenytoin, 263.152/192.088 for d10-phenytoin and 269.051/198.100 for 4-
HPPH. These were monitored in multiple reaction monitoring (MRM) mode (positive 
ionisation) using the optimised parameters shown in Table 2.2.  
 
Table 2.2. MRM optimised parameters for ions monitored.    
Q1 Q3 
Time 
(msec) 
ID 
DP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
253.011 182.100 150.0 Phenytoin 71 27 10 
263.152 192.088 150.0 d10-Phenytoin 31 37 12 
269.051 198.100 150.0 4-HPPH 71 25 6 
 
Mobile phase A consisted of 0.1% formic acid in Milli Q water. Mobile phase B was 0.1% 
formic acid in 2:1 Acetonitrile:Methanol. Analysis was performed at a flow rate of 0.25 mL/min 
by injecting 5 µL of sample into a Kinetex EVO 5 µ 100 Å C18 (150 x 2.1 mm) column (fitted 
with a 4 x 2.0 Gemini-NX C18 SecurityGuard Cartridge) (Phenomenex, USA) maintained at 
40 °C. Starting pressure was approximately 1700 psi. The gradient was started at 80% A, 20% 
B, where it was held for 30 seconds before shifting to 5% A, 95% B over 7 minutes to elute the 
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analytes. It was then held at this ratio for 5 minutes to clean out matrix components, then 
returned to 80% A, 20% B over 30 seconds and allowed to re-equilibrate for 6 minutes, giving 
a total run time of 19 minutes. Eluent was allowed to flow to the MS detector for the first 6.9 
minutes for compound elution, then was diverted to waste until 13.0 minutes, then allowed to 
flow to the detector again until 19.0 minutes to re-equilibrate. A mixture of 90% methanol in 
Milli Q water was used for needle cleaning between samples (10 seconds). Draw speed and 
eject speed were 200 µL/min. 4-HPPH eluted first at 4.06 minutes, followed by d10-phenytoin 
at 5.12 minutes and phenytoin at 5.16 minutes. The auto-sampler was maintained at a 
temperature of 20 °C during analysis.  
2.4.6.4 Data analysis 
Data was collected in Analyst® software (Sciex, USA) and analyte/internal standard ratio was 
used to construct calibration curves and analyse the data in Microsoft Excel (Microsoft, USA). 
The assays were validated using triplicate samples on three separate days. The lower and upper 
limits of quantification of each of the assays was determined experimentally by analysis of 
accuracy and precision, with limits of ±15% considered acceptable. Intra- and inter-day 
variability was assessed using quality control samples for which accuracy and precision limits 
of ±15% were considered acceptable. Accuracy was calculated by taking the values of the 
standards as quantified by the assay and presenting them as percentages of the nominal standard 
concentrations that were expected. Precision was calculated as the ratio of the standard 
deviation to the mean of a set of measurements and is presented as the coefficient of variation 
as a percentage (CV%), also known as the relative standard deviation (RSD).  Standard curves 
were plotted in GraphPad Prism® (GraphPad, USA) for presentation in this thesis. Tissue 
concentration data was compared statistically with two-sided t-tests (unpaired or ratio paired) 
as appropriate, with p < 0.05 considered statistically significant.   
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2.5 Results 
2.5.1 Pharmacodynamic Validation of the MEST Seizure Model with Intravenous 
Phenytoin 
2.5.1.1 Pharmacodynamics I: Determination of the CC50 of the Group and Baseline 
Response 
The CC50 of the group of rats that participated in this study was estimated using the up and 
down method in order to determine a suitable stimulation current for the subsequent 
experiments. The primary endpoint used to determine the CC50 was tonic hind limb extension 
(HLE). All rats displayed tonic-clonic seizures during this first stage of the experiment, either 
with or without hind limb extension (Figure 2.4). 
 
Figure 2.4. (A) Tonic-clonic seizure with hind limb extension (HLE) and (B) Tonic-clonic seizure with 
fore limb extension (FLE) only.    
 
Figure 2.5 shows the course of the serial stimulations during the experiment and the data from 
which the CC50 of the population was calculated to be 40 mA (95% CI: 35-45 mA) (Panel A). 
Also shown is the subsequent experimental data of rats stimulated at this batch-specific CC50 
of 40 mA after being administered intravenous saline (Panel B) to represent the baseline control 
response, from which it can be seen that 57% showed HLE.  
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Figure 2.5. Determination of the CC50 (A) and baseline response to stimulation at the CC50 (B) in the 
batch of rats that participated in the study of intravenous phenytoin at 60 minutes. (A) Shows the 
experimental data from the up and down method which was used to estimate the CC50, where “X” 
represents HLE and “O” represents no HLE. (B) Shows the baseline responses of the rats when 
stimulated at the calculated CC50 60 minutes after intravenous saline administration and serves as an 
indication of the accuracy of the statistically estimated CC50 and the resolution for detecting anti-seizure 
drug effects. The black bar represents the percentage of rats which exhibited HLE at the calculated CC50 
and the grey bar represents those which exhibited FLE (with or without HLE).  
 
2.5.1.2 Pharmacodynamics II: Determination of the Response to Intravenous Phenytoin at 
the CC50 
As can be seen in Figure 2.6, 100% of HLE was prevented by intravenous phenytoin and 93 % 
of FLE. In addition, no pro-seizure effect (i.e. HLE occurring in rats which previously did not 
show HLE) was observed. The anti-seizure effect of phenytoin was statistically significant for 
HLE (p = 0.0035) and FLE (p = 0.0006) according to Prescott’s test and is presented as the 
percentage change in the response – i.e. the percentage of rats which displayed the response 
after saline treatment, but not after phenytoin treatment (anti-seizure effect) and vice versa (pro-
seizure effect).  
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Figure 2.6. Effect of intravenous phenytoin solution (25 mg/kg) on HLE (black; n=8) and FLE (grey; 
n=14) at the group CC50 current (40 mA) 60 minutes after treatment administration. Data is presented 
as percent change in response with respect to intravenous saline treatment in the same rats. Animal 
numbers and the method used to calculate the percentage difference are shown in Appendix C. Note that 
two rats were excluded due to a technical error rendering their results invalid.  
 
Rats that did not display FLE (i.e. all but one which was given phenytoin in this study) did not 
have a tonic phase as part of their seizure. All of these non-tonic responses began with a clonus 
of all four limbs and ended with a mild post-ictal period. In most cases, the clonus was 
characteristic of that seen in rats which are genetically-prone to audiogenic (sound-induced) 
seizures which originate at a similar location, as described in Chapter One. This highlights the 
lower threshold seizure activity that was being expressed phenotypically as the seizure 
struggled to spread and induce a tonic convulsion as it did in saline-treated rats. In the cases 
where the drug was most effective, this initial clonus was only short (one to three seconds), 
while in others it was longer (up to ten seconds). Between the initial clonus and post-ictal 
period, other behaviours indicating activation of low-threshold seizure circuits in regions of the 
forebrain were observed in a number of rats, manifestations of which included rearing, forelimb 
clonus, facial clonus, myoclonic jerks and vocalisation. 
2.5.2 Validation of LC-MS Method for Measuring Tissue Phenytoin and 4-HPPH 
Concentrations 
2.5.2.1 Specificity 
The optimised method parameters allowed resolution of three clear peaks representing the two 
analytes and internal standard in rat plasma and brain tissue (Figure 2.7). Phenytoin eluted 
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consistently at 5.16 minutes, 4-HPPH at 4.06 minutes and the internal standard d10-phenytoin 
at 5.12 minutes in samples from both matrices. Blank samples, containing neither of the 
analytes, confirmed the specificity of the signal (Appendix D).  A small peak was noted in the 
blanks around the phenytoin elution time, but further experiments determined this was not 
attributable to phenytoin and the signal was well below the limit of quantification (<20% of the 
lower limit of quantification (LLOQ)) making it insignificant.  
  
Figure 2.7. Representative chromatograms of phenytoin (blue), d10-phenytoin (red) and 4-HPPH 
(green) extracted from rat plasma (A) and rat brain homogenate (B). Note that original data has been 
plotted using GraphPad Prism® to enhance clarity. The phenytoin and 4-HPPH concentrations of the 
analytes in the samples used to produce these chromatograms were 125 ng/mL in plasma and 375 ng/g 
in brain tissue (equivalent to 125 ng/mL in brain homogenate). The internal standard (d10-phenytoin) 
concentration was equivalent to 90 ng/mL in plasma and 270 ng/g in brain tissue (equivalent to 90 
ng/mL in the diluted brain homogenate).  
 
2.5.2.2 Sensitivity 
To determine the sensitivity of the assay, standard curves were produced by plotting mean 
analyte/internal standard ratio values against concentration and fitting to second order 
polynomial (quadratic) equations. The standard curve was validated in triplicate on three 
separate days (Figure 2.8). Accuracy and precision for all concentration values was within an 
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acceptable range of ± 15% and the fit of the curve maintained a coefficient of variation (R2) 
value of greater than 0.99 (Appendix E).  
 
 
Figure 2.8. Standard curves of phenytoin (blue) and 4-HPPH (green) in plasma (A) and rat brain 
homogenate (B). Data shown are the mean values (± standard deviation) of the standards prepared and 
measured in triplicate on three different days. The relationship between analyte concentration and 
analyte/internal standard ratio was best modelled by fitting second order polynomial (quadratic) curves 
to the data as shown in the Figure. R2 values are provided in Appendix E. 
 
2.5.2.3 Accuracy and Precision  
The inter-day and intra-day accuracy and precision of the assays, based on quality control 
samples, are shown in Table 2.3 and Table 2.4, respectively. Variability was within an 
acceptable range of ± 15% for all assays.  
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Table 2.3. Inter-day accuracy and precision of phenytoin and 4-HPPH quantification in rat brain 
homogenate and plasma based on quality control samples. 
  Plasma 
Analyte 
Nominal 
conc 
(ng/mL) 
Inter-day (n=3) 
Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
Phenytoin 
15.6 15.3 98.1 4.0 
62.5 62.2 99.6 3.1 
250 255.2 102.1 4.5 
4-HPPH 
15.6 16.8 107.6 4.3 
62.5 65.0 104.0 3.2 
250 272.2 108.9 3.6 
  Brain 
Analyte 
Nominal 
conc 
(ng/g) 
Inter-day (n=3) 
Mean 
(ng/g) 
Accuracy 
(%) 
Precision 
(CV%) 
Phenytoin 
46.9 49.8 106. 2.8 
187.5 192.4 102.6 2.4 
750 768.8 102.5 1.6 
4-HPPH 
46.9 49.1 104.7 3.5 
187.5 185.9 99.2 2.1 
750 750.5 100.1 1.7 
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Table 2.4. Intra-day accuracy and precision of phenytoin and 4-HPPH quantification in rat plasma and brain homogenate based on quality control samples.  
Plasma 
Analyte 
Nominal 
conc 
(ng/mL) 
Intraday 1 (n=3)  Intraday 2 (n=3)   Intraday 3 (n=3) 
Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
 Mean  
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
 Mean      
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
Phenytoin 
15.6 15.8 92.6 5.1  14.5 92.6 5.1  15.75 100.8 3.0 
62.5 59.6 102.7 5.9  64.2 102.7 5.9  62.9 100.7 1.2 
250 243.8 100.4 2.9  250.9 100.4 2.9  270.9 108.4 1.1 
4-HPPH 
15.6 17.1 109.1 1.9  17.5 112.3 5.5  15.8 101.4 4.0 
62.5 65.2 104.4 4.5  67.4 107.8 7.3  62.3 99.7 3.5 
250 266.9 106.8 4.8  285.8 114.3 2.7  263.9 105.6 1.4 
Brain 
Analyte 
Nominal 
conc 
(ng/g) 
Intraday 1 (n=3)  Intraday 2 (n=3)   Intraday 3 (n=3) 
Mean 
(ng/g) 
Accuracy 
(%) 
Precision 
(%CV) 
 Mean   
(ng/g) 
Accuracy 
(%) 
Precision 
(%CV) 
 Mean     
(ng/g) 
Accuracy 
(%) 
Precision 
(%CV) 
Phenytoin 
46.9 51.7 110.2 5.0  49.3 105.2 3.6  48.4 103.2 4.6 
187.5 193.1 103.0 4.5  197.8 105.5 2.0  186.3 99.4 4.9 
750 777.8 103.7 3.8  777.6 103.7 4.5  751.1 100.1 1.4 
4-HPPH 
46.9 48.9 104.4 4.9  47.0 100.3 6.1  51.2 109.2 6.3 
187.5 180.9 96.5 4.0  186.7 99.6 5.7  190.2 101.5 1.8 
750 733.3 97.8 4.4  755.8 100.8 2.5  762.5 101.7 1.8 
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2.5.3 Validation of Pharmacodynamic Responses with Tissue Drug Concentrations 
2.5.3.1 Pharmacokinetics  
 
Figure 2.9. Plasma concentrations (A), brain concentrations (B) and brain/plasma ratio (C) of 
phenytoin (blue) and 4-HPPH (green) in rats stimulated at 60 minutes after intravenous phenytoin 
administration (25 mg/kg). Unfilled symbols represent data that was below the lower limit of 
quntification of the assay (or partially derived from such data in the case of the brain/plasma ratio). 
Note that the data is more accurately representative of tissue concentrations around 70 minutes due to 
the delay between seizure cessation and euthanasia, but is presented as 60 minutes for ease of 
comparison with the pharmacodynamic data.   
 
The plasma and brain concentrations of phenytoin are presented in Figure 2.9. The mean plasma 
concentration (Figure 2.9A) was found to be 6.96 µg/mL (± 1.07 µg/mL), which is just below 
the lower limit of the textbook therapeutic range of 10-20 µg/mL151. One rat exhibited a lower 
plasma concentration than the rest which was attributed to an administration error resulting in 
a lower dose being given. This rat also exhibited FLE in the pharmacodynamic study 
(Appendix F). The mean concentration of 4-HPPH in plasma (Figure 2.9A) was found to be 
3.45 µg/mL (± 0.28 µg/mL), which was to be expected given that 60 minutes has passed in 
which phenytoin would have begun to be metabolised. Plasma was also analysed for the rats 
which received intravenous saline for the final stimulation in order to confirm the successful 
washout of phenytoin after three days. Neither phenytoin nor 4-HPPH was detected within the 
quantifiable range in the plasma of these rats and was therefore considered to be absent.  
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The mean brain concentration of phenytoin (Figure 2.9B) was found to be 7.57 µg/g (± 1.09 
µg/g), but this was not statistically different to the plasma concentration (p = 0.3064). On the 
contrary, the concentration of 4-HPPH (Figure 2.9B) was 0.21 µg/g (±0.03 µg/g) which was 
significantly lower than that found in plasma (p < 0.0001). The analysis of brain tissue of the 
saline-treated rats was not considered necessary given the absence in plasma, as stated above. 
The brain/plasma ratio is also presented in Figure 2.9C, as this represents the average ratio of 
phenytoin and 4-HPPH in these compartments in individual rats which is not evident from the 
graphs of brain and plasma concentrations of the group.  The Figure suggests a predominance 
of phenytoin in the brain compared to plasma (average ratio = 1.10 ± 0.12), which is consistent 
with the expected distribution of the drug and the pharmacodynamic effects observed, but this 
did not reach statistical significance (p = 0.071). Also shown is the marked lack of 4-HPPH in 
the brain compared with that in plasma (average ratio = 0.06 ± 0.01, which is consistent with 
the increased polarity and water solubility of the metabolite and was highly significant (p < 
0.0001).   
2.5.4 Validation of Animal Welfare 
Based on the author’s experience in researching the MEST procedure to establish this model, 
animal welfare considerations are an important element that is usually omitted from scientific 
literature. This study was a crossover trial involving multiple stimulations of the same animals, 
so it was scientifically, as well as ethically important to assess animal welfare over the course 
of the experiment to minimise confounding variables such as stress, which can impact seizure 
threshold182,183. The final results of this Chapter will therefore be a brief description of the 
animal experience during this introductory study as a reference for future users and to present 
the final validating evidence for its continued use in the following Chapters.  
During the seizures, two adverse effects were noted in some rats within the group. Firstly, 
porphyrin discharge from the eyes and secondly tongue-biting, both of which were attributable 
to the intense muscle contractions that occur during a generalised seizure. After each 
stimulation, discharge was wiped from around the eyes if appropriate and a finger was wiped 
under the animal’s mouth to sample the saliva for blood. In cases where tongue-biting was 
suspected, animals were given special attention during post-stimulation monitoring and none 
were noted to display signs of pain or have difficulty eating. All rats began behaving normally 
again within 30 minutes of a stimulation, but were less active than usual. Phenytoin-treated rats 
displayed less severe seizure behaviours and subsequently recovered much more quickly on the 
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day of the stimulation. By the following day, behaviour of all animals had returned to normal 
and they showed no evidence of residual effects.  
Ear clips were reapplied without stimulation prior to the second and third stimulations to check 
for aversive responses that could suggest a fearful memory of the previous stimulation. No 
evidence was apparent to suggest that the animals remembered the previous stimulations. All 
rats behaved normally when the clips were reapplied and they were placed into the container, 
supporting the fact that they were unconscious throughout the seizures and the stimulation 
procedure had no noticeable impact on their psychological wellbeing. This was particularly 
important to consider for the phenytoin-treated rats which exhibited less severe and shorted 
duration seizure behaviours after stimulation, but were still unconscious during them and did 
not appear to have any negative memory of the procedure.    
Finally, weight was monitored at least once daily over the duration of the experiment (Figure 
2.10). A small decrease in weight appeared to occur in the 24 hours following each stimulation, 
but weight began increasing again within 36 hours (in all but one rat, whose weight continued 
to decrease very slightly until 48 hours post-stimulation) and all rats were gaining weight again 
by the time of the subsequent stimulation.  
 
Figure 2.10. Weight progression of the rats over the course of the experiment. Days of the three 
stimulations are indicated by red arrows. 
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2.6 Discussion 
This Chapter aimed to use intravenous phenytoin as a positive control to validate a suitable 
seizure model for testing the efficacy of intranasal drug delivery systems in the subsequent 
Chapters this thesis. While the proposed model was more complex compared with MES or 
traditional MEST experiments, the increased sensitivity and reduction in sources of variability 
was proposed to maximise its ability to detect anti-seizure effects after intranasal 
administration. Even at a glance, it was clear the model was successfully validated in this 
Chapter in that the intravenous dose of phenytoin prevented HLE in 100% of rats and FLE in 
93 %, the latter incomplete protection being attributable to an incomplete dose delivered to one 
rat. While this result was expected based on the previous literature99,172,174, it served as a 
demonstration of technical competency to perform the seizure induction procedure and the 
validity of the original crossover study design to detect it.  
In order to statistically compare the pharmacodynamic data, Prescott’s test was chosen180. This 
method presents an advantage over other tests of paired binomial data sets such as McNemar’s 
test and the Mainland-Gart test in that it acknowledges both the possibility of a sequence effect 
(i.e. order that treatments were given in the crossover study) and the “no preference” group in 
the study which showed the same response regardless of treatment. Obviously in the present 
experiment the latter group was non-existent given the dose of the drug, but for intranasal 
experiments, where effects were expected to be more subtle, this was considered important to 
minimise error due to chance.  As indicated above, Prescott’s test confirmed the significance of 
the anti-seizure effect observed in this validation trial with p values of 0.003 and 0.0006 for 
HLE and FLE respectively.  
As discussed earlier, the “up and down” method of Kimball et al.100 is usually used to estimate 
the CC50 with 95% confidence limits with and without drug treatment in order to compare 
between the two99,101. Usually, the drug vehicle is used as a control treatment, but saline was 
used in the present study as the altered design of the present study presented a unique 
opportunity to actually test the accuracy of the estimated CC50 experimentally by examining 
the results from the saline treated rats, and therefore determine the resolution for detecting drug 
effects in the individual experiment. As shown in Figure 2.5, the CC50 was calculated to be 40 
mA with a narrow confidence interval of 35-45 mA which ultimately translated to an 
appropriate 57% of rats displaying HLE experimentally upon stimulation at 40 mA. The 
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stimulation current was therefore shown to be an accurate estimation of the CC50 for HLE and 
supported the credibility of the “up and down” method to determine it in the subsequent studies.  
As discussed in Chapter One, the need to administer an anaesthetic prior to intranasal dose 
delivery in the succeeding Chapters was an anticipated challenge given the potential for 
anaesthetics to affect seizure threshold and confound the effect of the test drug157,184. The 
anaesthetic chosen for use in this study was isoflurane given its short duration of action and 
rapid recovery profile (return of righting reflex within 7.5 ± 5.7 minutes and successful rotarod 
test within around 11.6 ± 4.7 minutes after half an hour of anaesthesia)185 and recommendation 
for use by Impel Neuropharma (the manufacturers of the Rat Intranasal Catheter Device (RICD) 
used in Chapter Three and Four). It was administered prior to intravenous dosing in this 
Chapter in order to evaluate its influence, if any, on the experiment and the implications this 
might have for the intranasal experiments. The design of this study was proposed as a strategy 
to mitigate any effect of the anaesthetic by estimating the initial CC50 in rats after exposure to 
isoflurane without drug treatment and then stimulating treated rats at this CC50. If the seizure 
threshold were altered by the isoflurane in any way, this should have been reflected in the CC50 
and therefore still result in 50% of saline-treated rats showing HLE when stimulated at it, 
provided the threshold was not so high that the CC50 could not be calculated, in which case drug 
effects would most likely be concealed by the isoflurane anyway.   
The results of the experiment in this Chapter were interesting in that the estimated CC50 at 60 
minutes after isoflurane administration was actually lower than the estimate of 50 mA provided 
for untreated male Wistar rats in the literature101. This was considered to represent one of two 
things; either isoflurane unexpectedly had a pro-seizure rather than anti-seizure effect as 
suggested by one study184 or it did not significantly affect seizure threshold at 60 minutes after 
administration. Previous studies have suggested that transauricular MEST stimulation, as used 
in this study, requires lower stimulus currents than transcorneal stimulation to achieve the same 
response98. Given that the 50 mA estimate in the literature was based on transcorneal 
stimulation, it is quite possible this, along with general variability in animal genetics within the 
Wistar species, resulted in the lower than expected CC50 rather than confounding from 
isoflurane. It was therefore considered most likely that after 60 minutes, the effect of isoflurane 
on seizure threshold was insignificant which supported the likelihood of the model being able 
to detect anti-seizure effects after intranasal administration, at least at studies proposed for this 
time point and beyond, in Chapters Three and Four. Regardless of any isoflurane contribution 
in any direction, the effects of phenytoin were clearly observed compared to the saline-treated 
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trial of each rat in this study. The subsequent question posed in Chapter Three would be 
whether the dose of phenytoin delivered in those intranasal experiments could achieve the same.  
The above pharmacodynamic evidence all supported proceeding to studies of intranasal 
delivery using this model. As an additional means of validation, concentrations of phenytoin 
were quantified in plasma and brain tissue to support the attribution of the pharmacodynamic 
effect seen to phenytoin and the credibility of the tissue quantification method. Due to the 
obvious impracticalities associated with measuring brain concentrations in human patients, the 
therapeutic range of phenytoin is defined in humans and rodents by plasma concentrations. The 
dose of phenytoin chosen for this validation study was therefore based on other studies where 
a single dose of phenytoin was administered and reported to achieve therapeutic plasma 
concentrations in rodents (10-20 µg/mL total phenytoin151) that persisted for up to 60 
minutes175–177, as estimated from the provided figures and summarised in Table 2.5. Some 
studies also provided information on brain concentrations. The most closely relevant to this 
study is the data of Ogiso et al.175 who provided phenytoin concentrations in brain and CSF, 
although it should be noted that they administered an in-house solution consisting of saline and 
propylene glycol (20:80 v/v) rather than the commercial formulation which might have 
influenced drug behaviour134. Walton et al.186 also provided data on brain concentrations, but 
only up to 30 minutes. Nonetheless, the concentrations during this time frame appeared more 
or less consistent with the former study suggesting extrapolation would have supported the 
above data at 60 minutes. Wang and Patsalos176 provided CSF concentrations only, but given 
that these were consistent with those reported by Ogiso et al.175 at 60 minutes, it is likely that 
brain concentrations would have been too.  
Table 2.5. Plasma, brain and CSF concentrations reported at 60 minutes after intravenous phenytoin 
administration to male rats at comparable doses to those used in the present study.  
 
Study 
 
Rat gender 
and strain 
 
Phenytoin 
dose 
Average concentration 
after 60 minutes 
Plasma 
(µg/mL) 
Brain 
(µg/g) 
CSF 
(µg/mL) 
Ogiso et al.175 Male Wistar 20 mg/kg 10 12 1.5 
Gerber et al.177 Male Sprague-Dawley 25 mg/kg 12 - - 
Wang & 
Patsalos176 
Male Sprague-Dawley 30 mg/kg 10 - 2 
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The average plasma concentration in the present study (6.96 ± 1.07 µg/mL) appeared to be 
similar, but lower than that reported elsewhere. The same was noted for the average brain 
concentration (7.57 ± 1.09 µg/g) compared with Ogiso et al.175.  The difference may have been 
due to variations in the methodology of the studies described above (e.g. differences in dose, 
administration site, rat strain, rat age/weight or analytical method sensitivity) but to some extent 
may also have reflected the delay between stimulation and euthanasia of each rat which in a 
number of cases was up to ten minutes. However, additional studies by Kim et al.187 and Kim 
et al.188, found retrospectively, in which male Sprague-Dawley rats were given a 25 mg/kg 
intravenous dose of phenytoin reported average plasma concentrations of ~7.5 µg/mL, which 
support that the concentration found in the present study was reasonable at 60 minutes after 
administration.  
Despite plasma concentration being slightly below the lower limit of the textbook therapeutic 
range of 10-20 µg/mL at 60 minutes in this study, the plasma concentration was still clearly 
adequate to elicit a significant anti-seizure effect at this time point. This might be seen as a 
reflection of the sensitivity of the model used due to stimulation at the CC50 threshold. As an 
illustration of this, Loscher et al.174 reported a significant anti-seizure effect (~35 mA increase 
in seizure threshold) of phenytoin in the MEST test at 60 minutes after a 15 mg/kg dose, while 
after a supramaximal stimulus in the MES test by Loscher et al.99 after the same dose and at the 
same time point, the anti-seizure effect was poor (~10% protection from HLE). No phenytoin 
could be quantified in the plasma of saline-treated rats in the present study which confirmed 
adequate washout of phenytoin from the previous experiment and that the pharmacodynamic 
results in these rats reflected responses to stimulation in the absence of phenytoin. It is not 
possible to comment on whether the average brain concentration found in phenytoin rats in this 
study was technically inside or outside the brain therapeutic range, as this is not defined in the 
literature and is a complex concept given the potential for regional distribution, however clearly 
it was also adequate to elicit the anti-seizure effect despite being lower than might have been 
expected from the data of Ogiso et al.175.  
In addition to presenting the average brain and plasma concentrations of phenytoin, the present 
study also calculated the brain to plasma ratio of phenytoin for individual rats. As shown in 
Figure 2.9, this yields a more accurate result than just comparing the averages of brain and 
plasma concentrations as was done in the other mentioned studies. As can be seen in the Figure 
(Panel C), the average brain/plasma ratio was 1.10 ± 0.12 suggesting an accumulation of 
phenytoin in the brain compared to plasma which is consistent with the other reports described 
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above175,186. Walton et al.186 noted a retention of phenytoin in the brain while average plasma 
concentration started to decrease which they attributed to phenytoin binding to sites in the brain 
parenchyma and therefore delaying its diffusion back out into the plasma. As noted earlier, they 
only measured up to 30 minutes, but the same elevation of average brain concentration above 
plasma is reflected in the data of Ogiso et al.175 up to 60 minutes as is evident in the data from 
the present study. This weighting towards the brain appeared to subsequently disappear between 
60 minutes and the next time point they measured at 120 minutes suggesting a shift towards 
elimination of phenytoin from the brain after 60 minutes at this dose. Interestingly, the results 
of Kim et al.188 disagreed with this pattern, reporting a brain to plasma ratio of around 0.45 at 
their measured time point of 30 minutes after administration, but given the anomalous nature 
of this finding it is suspected that this may have been a result of the analytical method used for 
brain tissue for which few details were disclosed regarding the validation of analyte detection.  
The major metabolite of phenytoin, 4-HPPH, is less commonly measured in the literature, but 
was measured in conjunction with phenytoin in the present study in order to more accurately 
evaluate its pharmacokinetics. The most comparable study found in the literature was that of 
Kim et al.187 who, as mentioned earlier, injected a commercial solution of phenytoin 
intravenously into male Sprague-Dawley rats at a dose of 25 mg/kg and found both phenytoin 
and 4-HPPH plasma concentrations very similar to those in the present study. No data was 
provided on 4-HPPH brain concentrations in this study, but the omission of brain tissue data 
from the figure presenting 4-HPPH tissue to plasma ratios at 30 minutes while this was shown 
in an equivalent figure for phenytoin suggests that it was not detectable in the brain. This is 
consistent with the very low brain to plasma ratio of 4-HPPH shown in Figure 2.9B of the 
present study, showing the poor penetration of the metabolite into the brain from plasma. The 
fact that some was able to be detected in the brain could be a combination of the increased 
sensitivity of the analytical method used here and the later time point (60 minutes vs 30 minutes) 
at which the sample was collected. Further support of the low brain permeability of 4-HPPH is 
provided by DeVane et al.189 who were unable to detect any brain 4-HPPH, in this case in the 
maternal rat brain, over 16 hours after a 30 mg/kg intraperitoneal dose of phenytoin. The peak 
4-HPPH plasma concentration was relatively low (~1 µg/mL) in this study, possibly due to 
slower metabolism in female rats99, especially in pregnancy190.  
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2.7 Conclusions 
The results of this Chapter demonstrated the validity of a new study design based on the MEST 
test for assessing the effects of drug therapy on seizure threshold with increased sensitivity and 
reduced variability. It was demonstrated experimentally that the CC50 could be accurately 
estimated using the “up and down” method in a group of rats, that the known anti-seizure effect 
of phenytoin could be clearly detected and that isoflurane administration 60 minutes prior to 
stimulation did not appear to influence the ability for the effects of phenytoin on seizure 
threshold to be detected. Phenytoin and its major metabolite 4-HPPH behaved as expected in 
terms of pharmacokinetics, not only supporting the pharmacodynamic data, but also the validity 
of the quantification method developed to measure them. These findings combined with the 
ability to perform this procedure with minimal impact on animal welfare provided a solid 
foundation on which to proceed to the next Chapter which aimed to evaluate an intranasal drug 
delivery system and test the capabilities of the model in detecting anti-seizure effects following 
the intranasal delivery of phenytoin.  
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Chapter Three 
 
On the Intranasal Delivery of Phenytoin 
                                                                                             
3.1 Introduction 
Phenytoin was the first non-sedating anti-seizure drug to be discovered, emerging in the early 
1900s near the dawn of the pharmacological ASD age following the serendipitous discovery of 
the anti-seizure effects of phenobarbital191. It is thought to act by modifying ion transport to 
reduce post-tetanic potentiation in seizure foci and pathways and by selectively decreasing high 
frequency action potentials while having few CNS side effects at therapeutic doses192,193. Its 
primary mode of action is to prevent or reduce propagation of a seizure from its area of origin192. 
It is a powerful, fast-acting, long-acting and useful anti-seizure drug for generalised and partial 
seizures that is widely used, but has fallen out of favour in some circles over time due to a 
perception of an increased likelihood and severity of adverse effects compared to newer 
ASDs194,195. While conclusive evidence appears to be lacking to support this perception, as well 
as whether it is any more or less effective at controlling seizures than its alternative first line 
counterparts such as sodium valproate194,196,197,  its relative  pharmacokinetic complexity after 
systemic administration cannot be denied and lends to the clinical attractiveness of its 
successors.   
Phenytoin is a poorly water soluble drug, available in oral and intravenous formulations as a 
sodium salt. Upon systemic administration it is highly bound by plasma proteins (90%) 
necessitating elevated doses to maintain free plasma concentrations within its narrow 
therapeutic range and allow sufficient phenytoin to cross into the brain. It undergoes hepatic 
metabolism primarily by the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19 to 
produce the pharmacologically inactive and slightly water soluble major metabolite 5-(4-
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hydroxyphenyl)-5-phenylhydantoin (4-HPPH), which is subsequently metabolised to the very 
water soluble 4-HPPH-O-glucuronide and excreted in the urine198. Complexity arises because 
the conversion to 4-HPPH is saturable within the narrow therapeutic range, imparting a non-
linear and dose-dependent pharmacokinetic elimination profile to the drug which also exhibits 
significant interpatient variability198,199. The consequences of this are illustrated in Figure 3.1.  
 
Figure 3.1. Illustration of the effect of non-linear pharmacokinetics on phenytoin dosing in five different 
human patients. Figure adapted with permission from Richens & Dunlop199. The grey shaded area 
indicates the therapeutic range of phenytoin.  
 
The final contributor to the unpopularity of phenytoin has been that it is a substrate for the 
multi-drug transporter P-glycoprotein (P-gp)200. P-gp is highly expressed in brain capillary 
endothelial cells and functions as a protective efflux transporter, ejecting molecules back out 
into the blood plasma rather than permitting them passage into the brain parenchyma (Figure 
3.2)9. It is this transporter that links phenytoin to the multi-drug transporter (MDT) hypothesis 
of drug-resistant epilepsy. The hypothesis proposes that the high rates of ASD treatment failure 
discussed in Chapter One may be, at least in part, due to an upregulation of P-gp (and other 
efflux transporters) in the epileptic focus of the brain and subsequent reduction in drug levels 
to sub-therapeutic concentrations9,201,202. It has been the subject of extensive study over the past 
few decades and has spawned new animal models; of particular interest, the phenytoin-resistant 
kindled rat122,174,203, which supported the idea that humans with epilepsy could also develop 
resistance to phenytoin and other ASD substrates as a result of transporter upregulation9,133.  
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Figure 3.2. Efflux of phenytoin at the blood brain barrier by P-glycoprotein (P-gp). Efflux transporters 
are indicated by the number 1. Figure reprinted with permission from Kwan et al.9. Copyright 
Massachusetts Medical Society. The other numbers indicate alternative proposed resistance 
mechanisms, namely, altered expression or function of voltage-gated ion channels (2) and mechanisms 
not currently targeted by marketed ASDs such as mitochondrial dysfunction, autoantibodies to 
neurotransmitter receptors and gap junctions (3).  
The systemic challenges of phenytoin clearly leave a lot to be desired. The concept of delivering 
it via a direct intranasal route to the brain, without the need to navigate the systemic circulation, 
is therefore an enticing possibility. Such a delivery route could theoretically reduce dosage 
requirements and variability by bypassing pre-CNS plasma protein binding, metabolism and P-
gp efflux while also providing improved targeting of phenytoin to key regions involved in 
seizure spread, as discussed in Chapter One, where it is likely to exert its greatest effect. Also 
based on the discussions in that Chapter, the poor aqueous solubility of phenytoin dictates that 
formulation into a suitable drug delivery vehicle is a necessary prerequisite to successful 
administration via an intranasal route.  
The idea has been lightly explored in the literature outside the present author’s lab group. 
Firstly, the reader may recall the intranasal phenytoin microemulsion study of Acharya et al.128 
referenced in Chapter One, but if so, also the associated discussion of its shortcomings. 
Secondly, Kapoor et al.21 recently reported formulation of a supersaturated phenytoin solution, 
but abandoned the idea of further testing in favour of an intranasal benzodiazepine, on their 
presumption that phenytoin would not be sufficiently potent for intranasal administration 
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because it requires grams as an intravenous loading dose for seizure emergencies. This logic 
would seem to overlook the complex pharmacokinetics discussed above which contribute to 
this requirement for large systemic doses and their potential to be bypassed by exploiting a 
direct nasal route.  
By far, the most extensive study of a phenytoin intranasal delivery system is that performed 
within this author’s lab group by Yarragudi et al.204 who developed spray-dried muco-adhesive 
tamarind seed polysaccharide (TSP)-based phenytoin microparticles (MPs), tailored to a 10 µm 
size to maximise deposition in the olfactory region of the nasal passage (Figure 3.3). The 
formulation of phenytoin with the polymer was optimised so that it existed in an amorphous 
(i.e. non-crystalline) state in order to facilitate solubility and release and encapsulated the drug 
with an efficiency of 96%.  
 
Figure 3.3. Scanning electron micrographs of phenytoin-containing TSP microparticles, as presented 
by Yarragudi et al.204  
 
While two other studies have pitched the concept of phenytoin microparticles (formulated with 
alginate-chitosan and Poly(ɛ-Caprolactone respectively), their experiments did not go further 
than fundamental physical characterisation205,206. Yarragudi et al.204 performed physical, in 
vitro and ex vivo characterisation, as well as preliminary investigations on histopathology and 
in vivo pharmacokinetics which suggested a sustained release and direct nose-to-brain delivery 
of phenytoin (Figure 3.4), as well as decreased systemic exposure with regards to other major 
organs. 
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Figure 3.4. Intranasal pharmacokinetics of phenytoin (PHT) after in vivo administration of phenytoin 
microparticles, as presented by Yarragudi et al.204 Phenytoin concentrations in the brain (A), olfactory 
bulbs (B) and plasma (C) are shown, along with the brain to plasma ratio (D). Intravenous solution 
(square/white bars), intranasal solution (circles/black bars), intranasal microparticles (diamonds/grey 
bars).  
 
The results of that study set the premise for this Chapter which explores whether the previously 
reported pharmacokinetics translate to any biological effect in the seizure model established in 
Chapter Two and offers further insight into histological effects on the nasal epithelium and 
regional brain distribution (in this case, after an actual seizure).  
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3.2 Aims 
The overarching aim of this Chapter was to apply the MEST model established in Chapter 
Two to the study of an intranasal delivery system, namely, phenytoin microparticles. To 
evaluate this application and therefore the ability of the model to detect an intranasally-
mediated effect, the following objectives were set: 
 Determine the anti-seizure effect of phenytoin microparticles compared to a phenytoin 
control solution after intranasal administration. 
 Determine the plasma and brain tissue levels of phenytoin and its major metabolite (4-
HPPH) after intranasal administration of phenytoin in microparticles and control 
solution in the seizure-tested rats. 
 Determine the effects of phenytoin microparticles and control solution on the integrity 
of the nasal epithelium of the seizure-tested rats over the course of the study. 
 Determine the anti-seizure effect of blank microparticles without phenytoin at the 
determined time of peak effect of phenytoin microparticles to exclude a vehicle 
contribution.  
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3.3 Hypotheses 
The hypotheses for this Chapter were founded on the in vivo studies of Yarragudi et al.204 with 
phenytoin microparticles as outlined in Figure 3.4. It was hypothesised that:  
 The MEST model established in Chapter Two will be able to detect anti-seizure effects 
after intranasal administration.  
 Intranasal microparticles will facilitate a direct nose-to-brain delivery of the anti-seizure 
drug phenytoin to a sufficient level to demonstrate an anti-seizure effect in the seizure 
model.   
 The anti-seizure effect of intranasal phenytoin microparticles will be greater than that 
observed after administration of intranasal phenytoin control solution.  
 Tissue levels of phenytoin and its major metabolite, 4-HPPH, will complement the anti-
seizure effects observed.  
 Increased levels of phenytoin will be found in the olfactory bulbs and/or brainstem 
compared to the rest of the brain due to the drug reaching the CNS via a direct route 
associated with neuronal pathways that exist in the nasal mucosa.  
 Phenytoin microparticles will not disrupt the integrity of the olfactory mucosa to 
achieve their drug delivery while phenytoin control solution will cause some disruption 
due to the solvents required to solubilise the drug.  
 Blank microparticles which do not contain phenytoin will not have any effect in the 
seizure model after intranasal administration.  
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3.4 Materials & Methods 
3.4.1 Materials 
Tamarind gum powder was purchased from Xi’an Jiatian Biotechnology (China). Phenytoin 
(5,5-diphenylhydantoin) sodium injection (250 mg/5 mL) (DBL™ Phenytoin injection BP) was 
purchased from hameln pharmaceuticals GmbH (Germany). Isotonic (0.9 %) saline was 
purchased from Baxter (Australia). Isoflurane was provided by the Hercus-Taieri Resource 
Unit, University of Otago. Phenytoin sodium, 4-HPPH (5-(4-Hydroxyphenyl)-5-
phenylhydantoin), propylene glycol (PG), formic acid (for mass spectrometry, ~98%) and 
phosphate-buffered saline sachets (pH 7.4) were purchased from Sigma Aldrich (New Zealand). 
Deuterated phenytoin (d10-phenytoin; (5,5-(diphenyl-d10) hydantoin)) was purchased from 
Toronto Research Chemicals (Canada). All water used in this study was ion exchanged, distilled 
and passed through a Milli-Q water purification system (Millipore, USA). Acetonitrile (ACN) 
(LiChrosolv®), Methanol (MeOH) (LiChrosolv®), tert-Butyl Methyl Ether (TBME) 
(LiChrosolv®) and Ethanol (EMSURE®) were purchased from Lab Supply (New Zealand). 
All of these solvents were liquid chromatography grade. Male Wistar rat plasma and brain tissue 
for LC-MS method validation and standard preparation was obtained in-house from control rats 
administered saline treatments. 
3.4.2 Animals 
All procedures involving animals were approved by the University of Otago Animal Ethics 
Committee pursuant to Animal Use Protocol 72/16. Male Wistar rats sourced from the Hercus 
Taieri Resource Unit were used in all experiments. Specific weights and ages of animals over 
the course of the experiments can be found in Appendix A and B. Animals were housed under 
laboratory conditions in the Hercus Taieri Resource Unit for the duration of the experiment.  
3.4.3 Isolation of TSP and Preparation of Microparticles 
Tamarind seed polysaccharide was isolated from tamarind gum powder as described by 
Yarragudi et al.207 A 20 g quantity of tamarind gum powder was dispersed in 1 L of Milli Q 
water and brought to a boil for 20 minutes under constant stirring (800 rpm). Following this, 
the dispersion was left overnight at ambient temperature to allow protein and fibre 
sedimentation to occur. The following day, it was centrifuged at 4700 G for 25 minutes 
(Heraeus Multifuge X3FR, Thermo Fisher Scientific, New Zealand) before the supernatant was 
separated and mixed with twice the volume of absolute ethanol to form a TSP precipitate. The 
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precipitate was separated and washed with Milli Q water before being placed in a 60 ºC oven 
for 12 hours. The dried film of purified TSP was then crushed into flakes and stored in a 
dessicator until required.    
Microparticles were prepared using a Mini Spray Dyer (Büchi B-290, Büchi Labortechnik AG, 
Switzerland) as described by Yarragudi et al.204,207. The feed solution for blank microparticles 
was prepared by adding 4 g of purified TSP to 200 mL of Milli Q water which was constant 
stirred for at least 2 hours at a temperature of 60 ºC before cooling to ambient temperature. The 
feed solution for phenytoin microparticles was prepared by the same method, except that 50 
mL of Milli Q water was replaced by 50 mL of a phenytoin dispersion. The latter was prepared 
by dispersing 1 g of phenytoin sodium in 2 mL of propylene glycol by sonication then adding 
48 mL of Milli Q water and constantly stirring at 60 ºC for one hour before addition to the TSP 
dispersion (3 g of TSP and 150 mL of Milli Q water) which was then stirred for at least a further 
two hours at 60 ºC before allowing to cool to ambient temperature. Feed solutions were spray-
dried using a standard nozzle cap with an orifice diameter of 0.7 mm. Spray drying parameters 
were as described by Yarragudi et al.204: feed solution flow rate = 2 mL/min, inlet temperature 
= 120 ºC, outlet temperature = 75 ºC, atomising airflow = 574 L/h and aspiration = 55%. Dried 
microparticles were collected and stored in a desiccator until required.   
3.4.4 Preparation of Phenytoin Control Solution 
The phenytoin control solution was based on that used by Yarragudi et al.204 and was prepared 
by dissolving phenytoin sodium in a mixture of ethanol (50%), propylene glycol (10%) and 
water (40%) with a brief sonication. The solution was kept at 37 ºC immediately prior to 
administration in order to maintain a solution of phenytoin with no visible precipitate.   
3.4.5 Drug Administration  
3.4.5.1 Isoflurane Anaesthesia 
Preliminary experiments determined that it was necessary to anaesthetise the animals briefly in 
order to successfully administer the intranasal dose to the olfactory region and avoid causing 
stress and reflexive sneezing. Animals were therefore anaesthetised by placing in a chamber 
with 5 % isoflurane and an oxygen flow rate of 1 mL/minute for three and a half minutes. The 
duration was determined in preliminary experiments to be sufficient to prevent the sneeze reflex 
in most animals for around one minute after removal from the chamber in order to permit 
intranasal administration.  
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3.4.5.2 Intranasal Microparticle Administration using an Intranasal Insufflator 
Microparticles were loaded into the needle chamber and weighed before attachment to the rest 
of the insufflator apparatus. Each rat was anaesthetised with isoflurane for three and a half 
minutes as described above. The unconscious rat was then removed from the chamber and laid 
on the bench in a supine position. The blunt needle at the tip of the insufflator was promptly 
and gently positioned inside one nostril so it was directed downwards towards the olfactory 
region (Figure 3.5). Rotation of the stopcock handle of the insufflator enabled the syringe to be 
filled with compressed air by applying pressure to the plunger. The stopcock was then opened 
to spray the powder out through the needle tip. After administration, the needle was carefully 
withdrawn and removed so that it could be weighed again to enable estimation of the dose 
delivered. Average weights of phenytoin microparticles administered are given in Appendix 
G. The rat was moved to a recovery cage and returned to an upright position while regaining 
consciousness. Where animals received two intranasal doses over the course of the experiment, 
the alternate nostril was used in the second experiment (i.e. each nostril was only used once).  
 
Figure 3.5. Intranasal microparticle insufflator (constructed in-house, based on the design of the 
PenncenturyTM dry powder insufflator) used for microparticle administration in this study (A). It 
consisted of a 10 mL Luer Lock syringe, three way stopcock a 21 G needle bent at a 45 º angle 1 cm 
from the tip to direct the dose to the olfactory region. Intranasal microparticle administration technique 
(B). Figure adapted from Yarragudi et al.204.  
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3.4.5.3 Intranasal Phenytoin Solution Administration using a Rat Intranasal Catheter 
Device (RICD) 
 
Figure 3.6. Apparatus used for the intranasal administration technique. (A) PE tubing attached to a 
syringe and threaded through the rat intranasal catheter device (RICD), ready for administration (B) 
Markings on the tubing to guide insertion distance (C) Demonstration of how the RICD targets the 
olfactory region in a sagittally-dissected rat nasal passage. 
 
A 15 cm long piece of PE 10 tubing (Fort Richard Laboratories, New Zealand) was threaded 
onto the 29 G needle of a 0.3 mL BD® Ultrafine Lo-dose insulin syringe (BD Biosciences, 
New Zealand). Drug solution was drawn into the syringe through the tubing and adjusted to a 
volume of 20 µL. The tubing was then threaded into a Rat Intranasal Catheter Device (RICD) 
(Impel Neuropharma, USA) in preparation for administration (Figure 3.6). Each rat was 
anaesthetised with isoflurane for three and a half minutes as described above. The unconscious 
rat was then removed from the chamber and laid on the bench in a supine position. The tip of 
the RICD was promptly and gently positioned inside one nostril and the tubing gently guided 
in until 1 cm had entered the nasal cavity. At this point, the syringe was gently depressed to 
administer the dose. The apparatus was held in position for 5 seconds following administration, 
then was gently pulled out of the nasal cavity. The rat was then moved to a recovery cage and 
returned to an upright position before regaining consciousness. As described above, where 
animals received two intranasal doses over the course of the experiment, the alternate nostril 
was used in the second experiment (i.e. each nostril was only used once).  
3.4.6 Maximal Electroshock Stimulation Threshold Test 
The MEST experiments were performed in accordance with the stimulation procedure and 
cross-over study design outlined in Chapter Two.  
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3.4.7 Tissue Collection and Histological Processing  
Tissues were collected and processed in order to quantify brain concentrations of phenytoin and 
4-HPPH (as in Chapter Two) and to study the effects of phenytoin microparticles and solution 
on the olfactory epithelium in rats that had participated in the pharmacodynamic MEST 
experiments. Rats were euthanised by guillotine decapitation within 10 minutes of the final 
MEST stimulation. Trunk blood was collected in a 6 mL blood tube coated with sodium heparin 
(BD Biosciences, New Zealand) at the time of euthanasia and centrifuged at the conclusion of 
the experiment (2000 G for 10 minutes at ambient temperature (Heraeus Multifuge X3FR, 
Thermo Fisher Scientific, New Zealand). The brain, brainstem and olfactory bulbs were also 
dissected and kept on ice until the conclusion of the experiment, after which they were frozen 
and kept at -80 ºC until required for LC-MS analysis.  
In the 60 minute phenytoin microparticles and phenytoin solution MEST studies, the nasal 
cavity was dissected and preserved for histological analysis at the conclusion of the experiment 
as outlined in Figure 3.7. The eyes, lower jaw and excess skin and tissue around the nasal 
passage were removed from the skull after dissection of the brain. A blunt needle was inserted 
0.5 cm into the posterior nasopharyngeal duct and used to flush the nasal passage with 10 mL 
of 10% neutral buffered formalin (NBF). Subsequently, the nasal passage was fixed in 50 mL 
of NBF for 48-72 hours. The fixed nasal passage was then decalcified in 10% 
ethylenediaminetetraacetic acid (EDTA) (pH 7.2) for two to three weeks, sliced coronally into 
blocks, as per published methods83,150 and embedded in paraffin wax. A microtome (Leica Jung 
RM 2025, Leica Biosystems, Australia) was used to cut 5 µm sections from region III which 
were subsequently deparaffinised, stained with haemotoxylin and eosin, and cover-slipped with 
dibutylphthalate polystyrene xylene (DPX) mounting medium. Sections were imaged on an 
Aperio ScanScope (Leica Biosystems, Australia). Images were analysed using Aperio 
ImageScope v12.2.2.5015 software (Leica Biosystems, Australia). 
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Figure 3.7. Histological processing method for nasal tissue. (A) Demonstration of the procedure for 
flushing the nasal cavity with 10% NBF. Image reprinted with permission from Everitt & Gross.208 (B) 
Dissected rat skull undergoing fixation in 10% NBF. (C) Recommended sectioning sites for assessment 
of toxicity to different regions of the nasal passage. Sections from the faces of Regions I, II, III and IV 
are shown below the main diagram. The green box indicates the region that is used in this study. Figure 
adapted with permission from Young.150 
 
3.4.8 LC-MS Method for Analysis of Phenytoin and 4-HPPH in Plasma and Brain 
Tissue 
LC-MS quantification of phenytoin and 4-HPPH concentrations in plasma and brain tissue of 
rats from all MEST studies was performed and analysed in accordance with the validated 
method outlined in Chapter Two. The brain was dissected into three regions (olfactory bulbs, 
brainstem and main brain) for these studies in order to compare relative levels and their possible 
relationship to hypothesised routes of intranasal delivery. Standard curves were prepared using 
homogenates from each of these brain regions and compared to assess for any variation which 
could affect the relative quantification.  
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3.5 Results 
3.5.1 Pharmacodynamic Evaluation at 60 Minutes After Intranasal Treatment  
The first trial to detect an anti-seizure effect was performed at 60 minutes after treatment, based 
on the pharmacokinetic study of Yarragudi et al.204 (Figure 3.4) which reported the highest 
phenytoin concentrations after intranasal phenytoin microparticles at this time point. Phenytoin 
control solution, as used by Yarragudi et al.204, was also tested at this time point for comparison 
as levels in the brain were expected to be low compared to those after phenytoin microparticle 
administration by this stage.  
The CC50 and control responses to stimulation for these studies are shown in Figure 3.8. The 
rats in the phenytoin microparticles group had a calculated CC50 of 63 mA (95% CI: 47-83 mA) 
(Figure 3.8A), which translated to 55 % of rats exhibiting HLE after intranasal saline 
administration in the experimental control data (Figure 3.8B). In the phenytoin control solution 
group, the calculated CC50 for the group was 47 mA (95% CI: 41-54 mA) (Figure 3.8C) and 
61% of saline-treated rats subsequently exhibited HLE (Figure 3.8D). All saline-treated rats in 
both groups displayed FLE.  
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Figure 3.8. Determination of the CC50 and baseline response to stimulation at the CC50 in the batches 
of rats that participated in the study of intranasal phenytoin microparticles (A and B) and phenytoin 
control solution (C and D) at 60 minutes. The panels on the left (A and C) show the experimental data 
from the up and down method which was used to estimate the CC50, where “X” represents HLE and 
“O” represents no HLE. The panels on the right (B and D) show the baseline responses of the rats when 
stimulated at the calculated CC50 60 minutes after intranasal saline administration and serve as an 
indication of the accuracy of the estimated CC50 and the resolution for detecting anti-seizure drug 
effects. The black bar represents the percentage of rats which exhibited HLE at the calculated CC50 and 
the grey bar represents those which exhibited FLE (with or without HLE).  
 
Figure 3.9 shows the effect of phenytoin microparticles and phenytoin control solution at 60 
minutes after intranasal administration. No statistically significant decrease in HLE was 
associated with phenytoin microparticles at 60 minutes, despite the incidence of HLE being 
calculated to be 17% lower in the phenytoin microparticles group (p = 0.8) and they had no 
effect on FLE. Unexpectedly (recalling the data of Yarragudi et al.204 in Figure 3.4), phenytoin 
solution at this time point was more effective, decreasing HLE by 64% (p = 0.0136).  The 
incidence of FLE after phenytoin solution was still not statistically different however, 
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calculated as 6% less due to the response of a single rat (p = 1). To investigate this result further, 
pharmacokinetic and histological studies were performed.  
 
Figure 3.9. Effect of intranasal phenytoin microparticles and phenytoin control solution on HLE (black; 
n=6 for MPs; n=11 for solution) and FLE (grey; n=10 for MPs; n=18 for solution) at the group CC50 
currents 60 minutes after treatment administration. Data is presented as percent change in response 
with respect to intranasal saline treatment in the same rats. Animal numbers and the method used to 
calculate the percentage difference are shown in Appendix C. 
 
3.5.2 Pharmacokinetic Analysis of Tested Animals’ Brains and Plasma at 60 Minutes 
3.5.2.1 Pharmacokinetics of Phenytoin in Tested Animals at 60 Minutes 
To address the immediate question that emerged from the pharmacodynamic data above, 
concentrations of phenytoin in plasma and the main brain (cerebrum and cerebellum) were 
analysed and are presented in Figure 3.10. Mean plasma (Figure 3.10A) and brain (Figure 
3.10B) concentrations, as well as mean brain/plasma ratios (Figure 3.10C) all trended towards 
being higher in the phenytoin control solution group, which supported the pharmacodynamic 
results. While this was not statistically significant when comparing average brain (134 ng/g 
(microparticles), 307 ng/g (solution), p = 0.0567) and plasma (131 ng/mL (microparticles), 203 
ng/mL (solution), p = 0.2833) concentrations, it became significant when comparing the 
brain/plasma ratios (p = 0.0147), the ratio for control solution being significantly greater than 
1.0 (p < 0.0001) while the ratio for microparticles was not (p = 0.9541). The one particularly 
high concentration that can be seen in the phenytoin control solution data for plasma and brain 
was matched to the rat in which FLE was prevented in the MEST test.  
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Figure 3.10. Phenytoin plasma concentrations (A), brain concentrations (B) and brain/plasma ratio (C) 
of rats stimulated at 60 minutes after intranasal administration of phenytoin microparticles (circles) or 
phenytoin control solution (squares).   
 
3.5.3 Histological Evaluation of Tested Animals’ Nasal Epithelium 
To further speculate on the intranasal pathway each formulation used to get phenytoin to the 
brain, histology of the olfactory epithelium was examined in the tested rats (Figure 3.11) with 
reference to Renne et al.149. A clear destruction of the nasal epithelium was seen 60 minutes 
after administration of phenytoin control solution (Panel B) in which the olfactory epithelium 
appeared to have degenerated, fragmented and detached from the lamina propria. Three days 
later, the impact of this insult was still evident in the atrophic epithelium that remained, with 
obvious thinning and loss of the usual cellular architecture (Panel F). The olfactory epithelium 
of rats given phenytoin microparticles (Panel D and H), on the other hand, appeared no different 
to that after saline (Panel C and G) at either time point, maintaining an intact network of 
olfactory neurons and supporting cells atop a wholesome lamina propria.   
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Figure 3.11. Representative histological images of the olfactory epithelium of rats which participated 
in the 60 minute MEST studies with phenytoin microparticles and phenytoin control solution. Images 
show short-term effects of the formulations on the olfactory epithelium in rats stimulated at 60 minutes 
after administration of saline (A and C), phenytoin control solution (B) and phenytoin microparticles 
(D) and longer-term effects at three days after administration of saline (E and G), phenytoin control 
solution (F) and phenytoin microparticles (H). Scale bars = 50 µm. 
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3.5.4 Pharmacodynamic Evaluation at 120 and 180 Minutes 
Due to the lack of a statistically significant anti-seizure effect seen at 60 minutes with intranasal 
phenytoin microparticles, trials were conducted at time points later than 60 minutes with 
microparticles to find the time of peak effect which was suggested by Yarragudi et al.204 to 
occur later than 60 minutes. The CC50 and control responses to stimulation for these studies are 
shown in Figure 3.12. The rats in the 120 minutes group had a calculated CC50 of 62 mA (95% 
CI: 45-85 mA) (Figure 3.12A), which translated to 28 % of rats exhibiting HLE after intranasal 
saline administration in the experimental control data (Figure 3.12B). In the 180 minutes group, 
the calculated CC50 for the group was 54 mA (95% CI: 34-84 mA) (Figure 3.12C) and 33 % of 
saline-treated rats subsequently exhibited HLE (Figure 3.12D). All saline-treated rats in both 
groups displayed FLE.   
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Figure 3.12. Determination of the CC50 and baseline response to stimulation at the CC50 in the batches 
of rats that participated in the study of intranasal phenytoin microparticles at 120 minutes (A and B) 
and 180 minutes (C and D). The panels on the left (A and C) show the experimental data from the up 
and down method which was used to estimate the CC50, where “X” represents HLE and “O” represents 
no HLE. The panels on the right (B and D) show the baseline responses of the rats when stimulated at 
the calculated CC50 60 minutes after intranasal saline administration and serve as an indication of the 
accuracy of the estimated CC50 and the resolution for detecting anti-seizure drug effects. The black bar 
represents the percentage of rats which exhibited HLE at the calculated CC50 and the grey bar 
represents those which exhibited FLE (with or without HLE). 
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3.5.5 Pharmacodynamic Evaluation: The Big Picture 
Figure 3.13 shows the effect of intranasal phenytoin microparticles on seizure responses at 60, 
120 and 180 minutes. No statistically significant differences were evident, despite the consistent 
trend of a reduction in incidence of HLE after phenytoin microparticles by 17% (p = 0.8), 80% 
(p = 0.3647) and 67% (p = 0.1412) respectively. No reduction in FLE was observed. A single 
rat in the 120 minutes group demonstrated HLE after phenytoin microparticles, but not after 
saline and is presented as a 7 % increase in the incidence of HLE, however this was deemed to 
be an anomaly as the overall effect was heavily weighted towards an anti-seizure effect, further 
supported by the exclusively anti-seizure effect at the other time points. When data from all 
three experiments was pooled before analysis the anti-seizure result was, however, significant 
(p = 0.016), showing the microparticles in fact did have an effect. In the case of the 120 and 
180 minute groups, the lack of statistical difference according to Prescott’s test was likely due 
to the decreased resolution for detection of an anti-seizure effect due to the lower than expected 
percentage or HLE seen in the control group at the statistically estimated CC50. The trend in the 
data therefore suggested the time of peak anti-seizure effect of intranasal phenytoin 
microparticles to be 120 minutes after administration.  
 
Figure 3.13. Effect of intranasal phenytoin microparticles on HLE (black) and FLE (grey) at the group 
CC50 currents 60 minutes (n=6 and n=10 respectively), 120 minutes (n=6 and n=18 respectively) and 
180 minutes (n=6 and n=16 respectively) after treatment administration. Data is presented as percent 
change in response with respect to intranasal saline treatment in the same rats. Animal numbers and 
the method used to calculate the percentage difference are shown in Appendix C. Note that FLE is not 
visible in the above Figure as no change was found in this experiment. 
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3.5.6 Pharmacokinetic Evaluation: The Big Picture 
To substantiate the pharmacodynamic findings, plasma and brain tissue levels of phenytoin and 
its major metabolite (4-HPPH) were measured in the seizure-tested rats.  
3.5.6.1 Standard Curve Validation of Brainstem and Olfactory Bulb Homogenates 
Standard curves were constructed in brainstem and olfactory bulb homogenates so that these 
brain regions could be analysed separately from the remainder of the brain (henceforth referred 
to as the main brain) to provide more insight into intranasal pathways of phenytoin delivery 
(Figure 3.14). The mean values were found to be within the precision and accuracy limits 
(±15%) stated for the validated brain method in Chapter Two (Appendix H), indicating that 
the standard curve of the analytes did not differ significantly between the different types of 
brain tissue and samples could be compared directly.  
 
 
Figure 3.14. Comparison between phenytoin (A) and 4-HPPH (B) standard curves prepared with 
olfactory bulbs (blue; n=3; R2 = 0.9999 (Phenytoin); R2 = 1 (4-HPPH)), brainstem (red; n=3; R2 = 1 
(Phenytoin); R2 = 0.9998 (4-HPPH)) and remainder of brain tissue (grey; n=9; R2 = 1 (Phenytoin); R2 
= 1 (4-HPPH)). Variability between different regions was not significant and was within limits of the 
assay as validated in Chapter Two.  
The intra-day accuracy and precision of the assays, based on quality control samples, are shown 
in Table 3.1. Variability was within the acceptable range of ±15% for both brainstem and 
olfactory bulb assays.   
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Table 3.1. Intra-day accuracy and precision of phenytoin and 4-HPPH quantification in rat brainstem 
and olfactory bulb homogenates based on quality control samples. 
             Brainstem  
Analyte Nominal 
Conc.  
(ng/g) 
Intraday (n=3) 
Mean 
(ng/g) 
Accuracy 
(%) 
Precision 
(CV%) 
Phenytoin 46.9 48.9 104.3 6.0 
187.5 197.8 105.5 5.8 
750 739.5 98.6 1.6 
4-HPPH 46.9 50.2 107.0 4.2 
 187.5 200.8 107.1 4.6 
 750 744.4 99.3 4.1 
         Olfactory bulbs  
Analyte Nominal 
Conc.  
(ng/mL) 
Intraday (n=3) 
Mean 
(ng/g) 
Accuracy 
(%) 
Precision 
(CV%) 
Phenytoin 46.9 48.7 104.0 2.0 
187.5 187.7 100.1 3.1 
1000 758.4 101.1 0.4 
4-HPPH 46.9 48.0 102.4 1.8 
 187.5 187.8 100.1 2.1 
 750 759.8 101.3       2.7 
 
3.5.6.2 Pharmacokinetic Analysis of Phenytoin and 4-HPPH in Tested Animals 
The concentrations of phenytoin and 4-HPPH in the plasma and various brain regions after 
intranasal administration of phenytoin microparticles and phenytoin control solution are 
presented in Figure 3.15. Phenytoin plasma concentrations (Figure 3.15A) were found to 
decrease significantly between 60 (131 ng/mL) and 180 minutes (44 ng/mL) after microparticle 
administration. In comparison to the phenytoin control solution group at 60 minutes (203 
ng/mL), the only significant difference was with phenytoin concentrations 180 minutes (44 
ng/mL) after microparticles. The only statistically significant difference in average brain 
phenytoin concentrations between the time points after microparticles was the decrease in 
olfactory bulb concentrations between 120 and 180 minutes. In agreement with the 
pharmacodynamic findings, however, brain concentrations in all regions (i.e. olfactory bulbs, 
main brain and brainstem) (Figure 3.15B) after microparticles consistently trended towards 
increasing between 60 minutes (134 ng/g) and 120 minutes (142 ng/g) then towards decreasing 
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by 180 minutes (68 ng/g), suggesting a scientific relevance to the data, despite not being 
statistically significant.  
The plasma concentration of 4-HPPH (Figure 3.15C) was found to remain similar between 60 
(230 ng/mL) and 180 (192 ng/mL) minutes after phenytoin microparticles and was not 
significantly different to that after control solution at 60 minutes (p = 0.0556). Brain 
concentrations (Figure 3.15D) generally followed the same trends described for phenytoin 
concentrations, although the 4-HPPH concentrations after phenytoin control solution were 
notably lower than expected, being on par with concentrations 120 to 180 minutes after 
microparticles instead of being higher. Consequently, no significant differences were found 
within or between groups for 4-HPPH concentrations in the brain. Due to this unexpected result, 
the plasma concentrations of phenytoin and 4-HPPH after phenytoin control solution were 
statistically compared to concentrations in all brain regions using ANOVA. No significant 
difference was found between plasma and brain concentrations of phenytoin, but the 
concentration of 4-HPPH was significantly lower in all brain regions compared to plasma (424 
ng/mL) (ANOVA: p < 0.0001; Tukey’s post-hoc: main brain (38 ng/g, p = 0.0003), brainstem 
(40 ng/g, p = 0.0004), olfactory bulbs (29 ng/g, p = 0.0018)).  
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Figure 3.15. Phenytoin (A and B) and 4-HPPH (C and D) concentrations in plasma (purple), main brain 
(blue), brainstem (green) and olfactory bulbs (red) of rats administered phenytoin microparticles (60, 
120 and 180 minutes) and phenytoin control solution (60 minutes). Concentrations are plotted on a log 
scale for clarity. Unfilled symbols indicated values that were below the LLOQ of the assay or calculated 
from at least one such value. P-values are shown for comparison between different brain regions at a 
given time point and between each brain region in different experiments using one-way ANOVA. With 
respect to the latter, the coloured bars (matched to the symbol colours) represent statistically significant 
differences determined by post-hoc analysis (Tukey’s) of inter-study differences. Labels on the x axis 
reflect the time point at which stimulation occurred and it should be noted that tissue collection occurred 
up to ten minutes after this.  
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The brain region/plasma ratios of phenytoin and 4-HPPH calculated for individual rats are 
shown in Figure 3.16. For phenytoin (Figure 3.16A), the brain region/plasma ratios at 60 
minutes after microparticles were not found to differ from 1.0, while in all other groups, the 
ratios were found to be significantly greater than 1.0 according to ratio paired t-tests and 
significantly greater than their 60 minute microparticle counterparts (noting that olfactory bulbs 
could not be compared to the 60 minute microparticle group due to limited data). All ratios in 
these latter groups showed a similar trend with olfactory bulbs being the lowest, main brain 
higher and brainstem the highest. The difference between olfactory bulbs and brainstem was 
statistically significant at 180 minutes after microparticles and 60 minutes after control solution. 
Interestingly, the ratios within each brain region in these groups (e.g. brainstem data at 120 and 
180 minutes after microparticles and 60 minutes after control solution) were all of a similar 
magnitude, despite the different magnitudes of the concentrations described above.  For 4-
HPPH (Figure 3.16B), all brain region/plasma ratios were well below 1.0. As with the brain 
concentration data, no significant differences were found between brain regions within groups, 
but between groups, there were significant differences in that the brain/plasma ratio was 
consistently higher at 120 and 180 minutes after microparticles in all three brain regions 
compared to 60 minutes after microparticles (with the exception of the olfactory bulbs for which 
not enough data was available to test) as well as control solution.   
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Figure 3.16. Phenytoin (A) and 4-HPPH (B) brain region/plasma ratios. The ratios of main brain (blue), 
brainstem (green) and olfactory bulbs (red) to plasma are shown for rats administered phenytoin 
microparticles (60, 120 and 180 minutes) and phenytoin control solution (60 minutes). Unfilled symbols 
indicated ratios that were derived from at least one concentration below the LLOQ of the assay. P-
values are shown for comparison between different brain regions at a given time point and between 
each brain region in different experiments using one-way ANOVA. With respect to the latter, the 
coloured bars (matched to the symbol colours) represent statistically significant differences determined 
by post-hoc analysis (Tukey’s) of inter-study differences. The post-hoc significant differences between 
OBs and brainstem after phenytoin microparticle administration at 180 minutes and after phenytoin 
control solution are each represented by a grey bar. Asterisks represent mean values that were 
significantly different to 1.0 according to a ratio-paired t-test. Labels on the x axis reflect the time point 
at which stimulation occurred and it should be noted that tissue collection occurred up to ten minutes 
after this. 
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Figure 3.17 presents the ratio of phenytoin and 4-HPPH in the brainstem and olfactory bulbs to 
that in the main brain. For phenytoin (Figure 3.17A), no significant differences were found 
within the brainstem or olfactory bulb groups at different time points and compared with the 
control solution. However, significant differences were found between the olfactory bulb and 
brainstem ratios at 180 minutes after microparticles (p = 0.0233) and 60 minutes after phenytoin 
control solution (p = 0.0022) which is consistent with those described above for the brain 
region/plasma ratios. Ratio-paired t-tests on these groups determined that the brainstem/main 
brain ratio was significantly higher than 1.0 at 180 minutes after microparticles and that the 
olfactory bulb/main brain ratio was significantly lower than 1.0 at 60 minutes after control 
solution. For 4-HPPH (Figure 3.17B), no significant differences were found within or between 
brain regions.  
 
 
Figure 3.17. Ratios of Phenytoin (A) and 4-HPPH (B) in the brainstem (green) and olfactory bulbs (red) 
compared to the main brain. P-values are shown for comparison between different brain regions at a 
given time point using unpaired two-tailed t-tests and between each brain region in different experiments 
using one-way ANOVA. Asterisks represent mean values that were significantly different to 1.0 
according to a ratio-paired t-test. Labels on the x axis reflect the time point at which stimulation 
occurred and it should be noted that tissue collection occurred up to 10 minutes after this. 
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3.5.7 Pharmacodynamic Evaluation of Microparticles Without Phenytoin 
To exclude a contribution of the vehicle (i.e. the TSP polymer which formed the scaffold of the 
microparticles) to the results seen, blank microparticles without phenytoin were tested at the 
time of peak anti-seizure effect of phenytoin microparticles (120 minutes). The CC50 and 
control responses to stimulation for these studies are shown in Figure 3.18. The rats had a 
calculated CC50 of 56 mA (39-82 mA) (Figure 3.18A), which translated to 28 % of rats 
exhibiting HLE after intranasal saline administration in the experimental control data (Figure 
3.18B).  
 
Figure 3.18. Determination of the CC50 and baseline response to stimulation at the CC50 in the batch of 
rats that participated in the study of intranasal drug-free microparticles at 120 minutes (n=18). (A) 
shows the experimental data from the up and down method which was used to estimate the CC50, where 
“X” represents HLE and “O” represents no HLE. (B) shows the baseline responses of the rats when 
stimulated at the calculated CC50 120 minutes after intranasal saline administration and serves as an 
indication of the accuracy of the estimated CC50 and the resolution for detecting anti-seizure drug 
effects. The black bar represents the percentage of rats which exhibited HLE at the calculated CC50 and 
the grey bar represents those which exhibited FLE (with or without HLE). 
 
Figure 3.19 shows the effect of blank microparticles at 120 minutes after intranasal 
administration. No statistically significant effect on the incidence of HLE was seen (p = 1), 
however, a surprising amount of variability in responses in both directions were observed. The 
incidence of FLE was unchanged after blank microparticle administration.   
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Figure 3.19. Effect of intranasal drug-free microparticles (n=5) on HLE (black; n=5) and FLE (grey; 
n=18) at the group CC50 current 120 minutes after treatment administration (i.e. the time of peak effect 
of phenytoin microparticles). Data is presented as percent change in response with respect to intranasal 
saline treatment in the same rats. Animal numbers and the method used to calculate the percentage 
difference are shown in Appendix C. Note that FLE is not visible in the above Figure as no change was 
found in this experiment.  
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3.6 Discussion 
This Chapter applied the MEST model established in Chapter Two to the study of intranasal 
phenytoin microparticles, designed by Yarragudi et al.204. The pharmacokinetics of phenytoin 
release from the microparticles after intranasal delivery to rats was studied up to 60 minutes by 
that author (Figure 3.4) and found to be highest at this terminal time point, which therefore 
made it the starting point for the study of seizure prevention conducted in this Chapter. The 
results were surprising. The reduction in incidence of HLE was found to be significant with 
phenytoin solution, but not microparticles at 60 minutes. As shown in Figure 3.4, Yarragudi et 
al.204 had found that while phenytoin from microparticles was highest in the brain at 60 minutes 
after administration, phenytoin from control solution peaked at 30 minutes after administration 
and dropped off to become significantly lower than that from microparticles by 60 minutes. 
This suggested a lesser anti-seizure effect would be observed with the latter, but this was not 
the case.  
It was initially thought that this may be due to a confounding contribution from the ethanol in 
the control solution, which has been shown to decrease seizure threshold in the MES test after 
systemic administration209. A vehicle control was not run in this study (in order to allow for 
experimental evaluation of the statistically determined CC50 after saline, as discussed in 
Chapter Two), so a contribution cannot be excluded, but tissue phenytoin concentrations were 
measured to verify the discrepancy and were found to support the pharmacodynamic outcome 
(Figure 3.10). These therefore contrasted with the data of Yarragudi et al.204 in that brain 
concentrations of phenytoin after delivery in control solution were significantly higher than 
after microparticles. Relative plasma concentrations were, however, similar to those of 
Yarragudi et al.204 in that phenytoin from control solution appeared slightly higher than that 
from microparticles, but did not reach statistical significance. The reason for the relative brain 
concentration discrepancy between the two studies is unclear, but possible contributing factors 
are herein discussed in the context of formulation, animal and analytical method related factors.   
The first difference to note between the studies is that the dose and composition of the phenytoin 
control solution varied slightly in this study compared to that which was reported by Yarragudi 
et al.204. Firstly, the dose of phenytoin solution administered by Yarragudi et al.204 was 15 µL 
(equivalent to 1.5 mg of phenytoin) based on the average dose of phenytoin delivered in 
microparticles, as calculated by needle weight before and after administration. The average 
dose of phenytoin administered in microparticles at 60 minutes in the present study was 
calculated to be slightly higher at 1.7 ± 0.37 mg of phenytoin (Appendix G), so a control 
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solution volume of 20 µL (2 mg of phenytoin) was administered so as not to bias the experiment 
in favour of the microparticles. It was expected that this minor dose difference would not 
significantly affect the outcome given that Yarragudi et al. 204 had reported approximately three 
times lower brain concentrations after phenytoin control solution at 60 minutes compared with 
microparticles, but given the unanticipated result it warrants consideration, especially given the 
non-linear nature of the pharmacokinetics of phenytoin and the unreported characteristics of its 
potential metabolism by the nasal epithelium. In light of the remarkably different brain to 
plasma ratio compared to Yarragudi et al.’s study, the small dose increase seems unlikely to be 
the cause of the discrepancy as it would be reasonable to expect a corresponding relative 
increase in plasma concentration. Furthermore, the histological insult by the solution (Figure 
3.11B) means metabolism by the nasal epithelium probably did not play a role due to the 
destruction of enzyme-bearing cells.  
Secondly, the propylene glycol content of the phenytoin control solution was reported to be 1% 
by Yarragudi et al.204, but it is uncertain if this was the actual concentration used or a reporting 
error as a 10% PG concentration was found to be necessary to keep the phenytoin in solution 
in the present study. If the concentrations were indeed different, it is thought unlikely that this 
could have had such a dramatic effect on the brain concentration given that the histological 
insult to the olfactory epithelium (Figure 3.11B) is the most likely cause for the success of the 
control solution and supplementary data investigating the effect of a dispersion containing 
12.5% PG (Appendix I) showed no such insult. Furthermore, it was considered that if a 1% 
concentration was used and phenytoin was not dissolved fully, this may have led to a reduced 
brain concentration, but this would not explain the peak seen by Yarragudi et al.204 at 30 minutes 
and the plasma concentrations which were on par with those of microparticles in both studies. 
As a final note regarding dose, it could be considered that the dose of microparticle powder 
might have been different between the studies, however Yarragudi et al.204 reported an average 
weight of delivered powder of 1.5 mg (albeit with no standard deviation), which was very 
similar to the 1.7 mg average in the present study (Appendix G), so this is not likely to have 
caused the difference.  
The next consideration to note is with regards to the animals which participated. The rats in the 
present study had undergone three generalised seizures, one immediately prior to the 
measurement of their brain concentrations, as opposed to the naïve rats used by Yarragudi et 
al.204 Previous studies in rats and humans have suggested that seizures may affect the brain 
concentrations of ASDs due to changes in BBB function (i.e. transient leakiness and changes 
in multi-drug transporter expression) and cerebral blood perfusion200,210–214, however, the 
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direction in which this effect occurs is still a matter of debate. Most studies having examined 
permeability on the basis of hydrophilic proteins, dyes or contrast media rather than lipophilic 
ASDs such as phenytoin, the former suggesting that increased ASD concentrations would be 
expected after seizures while the latter suggest a decrease or net lack of difference, at least at 
the epileptic focus200,212,213,215. The present study analysed whole brain concentrations of 
phenytoin and is therefore not directly comparable with any of the above, but the principle that 
seizures could have altered concentrations compared to naïve rats applies. How this might 
explain the opposite brain concentrations after each of the formulations compared with 
Yarragudi et al. is more perplexing. Seizures would have been expected to affect the distribution 
of phenytoin in the same way, if at all, as it was still delivered by an intranasal route in each 
case and showed similar regional distribution, at least in the regions analysed (Figure 3.15). It 
is therefore considered unlikely that this was the cause.   
Next it should be considered that different analytical methods were used to analyse the results 
of each of the studies; i.e. HPLC by Yarragudi et al.204 and LC-MS in the present study. While 
the accuracy and precision of each was validated, the procedures involved a less than simple 
series of dilutions, concentrations and calculations. The data above has so far been discussed in 
terms of relative concentrations for comparison to Yarragudi et al.204 due to a final interesting 
discrepancy in that concentrations in the latter study, where comparable data was available, 
were generally about five times greater than those calculated in this Chapter. Given the 
acceptable limits of accuracy and precision reported, the most likely reason for this is deemed 
to be a calculation anomaly. The details of the calculation procedure used by Yarragudi et al.204 
were not available, but that used in the present study is provided in Appendix J for the reader’s 
reference. The author is confident that this procedure provides accurate quantitative values of 
plasma and brain concentrations, an assertion which is verifiable by comparing the values 
quantified in Chapter Two with those in the literature 60 minutes after a similar single 
intravenous dose (20-30 mg/kg) of phenytoin as discussed in the previous Chapter175–177,188. In 
the absence of this evidence, one may have suspected that a difference in extraction efficiency 
of the phenytoin between the studies might have contributed to the different values quantified. 
However, this suspicion is countered by the fact that both studies quantified phenytoin using 
the analyte/internal standard ratio and standards prepared in the same matrix and with the same 
extraction procedure as the samples which would have rendered any such differences 
ineffectual. Considering all this, the low phenytoin brain concentration from control solution 
compared with microparticles reported by Yarragudi et al.204 would seem to be somewhat of an 
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anomaly rather than a wide-ranging difference due to an inherent flaw in the method which 
would have been expected to equally affect all of the data including plasma concentrations. 
In this respect, it is worth briefly commenting on the HPLC method used by Yarragudi et al.. 
The recommended concentration of a low quality control to assess intra-day and inter-day 
variability is within three times the concentration of the lower limit of quantification (LLOQ)216 
in order to assure accuracy and precision at low concentrations. The LLOQs for phenytoin in 
plasma and brain were reported to be 48 ng/mL and 84 ng/g respectively, however the low 
quality control standard concentration was 1000 ng/mL (or ng/g) in both cases, making it 
approximately twenty times the LLOQ of phenytoin in plasma and ten times that in the brain 
tissue. The concentrations reported from the plasma samples were close to the low QC 
concentration and therefore can generally be considered accurate, however, the same cannot be 
guaranteed for all the brain samples (in particular the anomalous 60 minutes control solution 
sample) which was outside the limits of the low QC and may therefore have been subject to a 
degree of unquantified intra-assay error.  
Despite the unexplained differences in quantitative concentrations, the brain to plasma ratio 
offers a normalised comparison between the studies, with values above 1.0 indicating an 
accumulation of phenytoin in the brain above that in plasma. Due to the elevated brain 
concentration relative to plasma found in the present study, the average brain/plasma ratio was 
tipped in favour of the control solution (Figure 3.10C) in contrast to the study of Yarragudi et 
al.204 at 60 minutes (Figure 3.4). The discrepancy in brain to plasma ratio is an interesting 
finding as phenytoin plasma levels continued to increase over time while brain levels decreased, 
whereas literature175,186 and the trend in Figure 3.16 (discussed later) suggest that phenytoin 
accumulates in the brain due to its hydrophobic nature and concentrations only begin to reduce 
after plasma concentrations start to decline and shift the equilibrium. One might speculate on 
the possibility of extensive direct brain delivery leading to a peak, followed by equilibration 
and redistribution into plasma contributing to the steadily increasing plasma levels. 
Alternatively, extensive metabolism in the brain contributing to the rapid reduction in phenytoin 
concentration is possible, but the data available is inadequate to provide evidence for either of 
these suggestions.  
Whatever the case, histology provided the illuminating data to explain how the control solution 
was likely so much more effective than the microparticles in the present study. The high brain 
to plasma ratio (reflecting increased brain concentrations with only marginally increased 
plasma concentrations compared with microparticles), suggested that phenytoin from the 
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control solution was exploiting a direct route to the brain, however, histology showed that this 
was not without massive insult to the olfactory epithelial barrier (Figure 3.11B), which is 
clinically unacceptable, especially in light of the lasting damage when examined three days 
later. For this reason and the suspected confounding of pharmacodynamic studies that could 
have been attributable to ethanol, no further control studies were conducted in this Chapter. 
Yarragudi et al.204 did not provide any histology data for rats given intranasal control solution, 
but given that the same proportion of ethanol was used and the dose volume differed by only 
five microliters, it can be inferred that the effect would have been the same. Why this did not 
result in the elevated brain concentrations at 60 minutes that were observed here is unclear. 
While information is not freely available in the literature to evaluate commercially sensitive 
nasal formulations currently under development for seizure treatment, the data presented here 
raises questions about the long-term effects of those that contain irritating components such as 
ethanol in order to achieve dissolution.74,217 It also highlights the importance of more study into 
physiologically friendly drug delivery systems such as TSP microparticles which may act in 
their place, delivering directly to the brain by mechanisms other than total obliteration.  
After addressing the above comparisons with the data of Yarragudi et al.204 at 60 minutes after 
administration, this discussion now proceeds to the extended data that was obtained in this 
Chapter to determine the time of peak effect of the phenytoin from MPs and offer further insight 
into the intranasal delivery pathway by examining pharmacokinetics. It is important to highlight 
before proceeding that the maximum intranasal anti-seizure effect of phenytoin in these 
experiments did not push the seizure threshold any higher than that necessary to prevent HLE, 
so all rats, except the one in the phenytoin control solution trial mentioned above, still exhibited 
FLE despite a reduction in HLE. As may have been expected, this contrasts with the much 
higher dose of intravenous phenytoin in Chapter Two which increased the threshold 
sufficiently to prevent HLE and FLE, eliminating the tonic component of the seizures 
altogether, except for one rat who likely received a lower dose due to administration difficulty 
as indicated by tissue phenytoin concentrations.  This distinction is not commonly made in the 
literature, with studies reporting prevention of HLE, but not the relative magnitude of the effect, 
which in the above case would have led to phenytoin microparticles appearing to have a similar 
effect to the intravenous 25 mg/kg dose.  The data of Bankstahl et al.101 gives an indication of 
the change in threshold that might be expected to correspond to each of the cases with 
prevention of FLE requiring an approximately 20-30 mA increase in threshold above the 
increase required to prevent HLE.  
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The MEST experiments as a whole indicated 120 minutes to be the time of peak anti-seizure 
effect of the phenytoin microparticles (Figure 3.13). Importantly for the credibility of the 
seizure model for testing intranasal delivery systems, this finding was supported by the 
pharmacokinetic analysis which showed peak phenytoin levels in the main brain coinciding 
with this time point, despite the reducing concentrations of phenytoin in plasma after 60 minutes 
(Figure 3.15A).  Furthermore, the average brain to plasma ratio also followed this trend with a 
peak at 120 minutes (Figure 3.16A). This data is in agreement with the predictions of Yarragudi 
et al.204 who speculated, based on ex vivo release studies using porcine nasal mucosa, that brain 
levels of phenytoin from microparticles would continue to increase after 60 minutes, albeit not 
for the 4 hours that the ex vivo study predicted. With regards to the pharmacokinetics, it should 
be noted that the peak phenytoin concentration achieved in the brain at 120 minutes was still 
significantly lower than the concentration after phenytoin control solution at 60 minutes (Figure 
3.15A and B).  However, considering the confounding reasons discussed earlier (i.e. damage to 
the epithelial barrier by the control solution, along with a slight dose advantage) this is 
unimportant other than to suggest that if microparticles had been able to achieve this slightly 
higher concentration, a more significant (including statistically so) anti-seizure effect would 
likely have been observed, as was the case for the solution. Had control studies been performed 
at 120 and 180 minutes as well, it would have been interesting to see the trend in phenytoin 
levels compared with microparticles, but as discussed earlier, such trials were unjustifiable for 
the purposes of this study.   
Phenytoin concentrations in the olfactory bulbs and brainstem were also analysed for 
comparison to the main brain results in order to speculate on which intranasal pathway 
phenytoin was using to reach the brain. It should be noted before proceeding that olfactory bulb 
sample numbers were limited in some cases due to technical difficulties in dissecting the tissue, 
so may not represent the entire group of rats studied. Nonetheless, within each brain region the 
same trend described above for the main brain was seen, with peak levels being reached at 120 
minutes. Yarragudi et al.204 reported concentrations in the olfactory bulbs to be elevated above 
control solution levels at 60 minutes after microparticle administration (Figure 3.4B), which in 
the same manner as the main brain concentration data discussed extensively above, is in 
disagreement with the present study which found the opposite. The two studies did agree, 
however, that olfactory bulb concentrations did not exceed those in the main brain at this time 
point (after microparticles or control solution) which is in contrast to studies such as that of 
Czapp et al.138 and Serralheiro et al.140,141 who reported higher concentrations of their respective 
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model anti-seizure drugs phenobarbital, lamotrigine and carbamazepine in the olfactory bulbs 
relative to the brain to suggest a direct delivery via them/targeted delivery to them.  
This could be seen to support the review of direct intranasal pathway evidence in Chapter One 
by suggesting that accumulation in the olfactory bulbs may not be the case, contrary to what 
the aforementioned studies have suggested for other ASDs employing alternative delivery 
systems. Bulk transport pathways which lead to direct but widespread brain delivery seem more 
likely rather than a localised concentration that might be expected if intracellular pathways were 
being used. In saying that, Figure 3.17A (complemented by the brain region/plasma ratio data 
in Figure 3.16A) also reveals a trend towards elevation of brainstem concentrations of 
phenytoin relative to main brain after microparticles and the phenytoin control solution study 
at 60 minutes. While this was not statistically significant other than the brainstem/brain ratio at 
180 minutes after microparticles (Figure 3.17A), is interesting in that it could suggest direct 
movement of phenytoin to the brain predominantly via a brainstem-related pathway (e.g. bulk 
flow peripheral to trigeminal neurons) rather than the olfactory bulbs. Also interesting, is that 
the brain region/plasma ratios at 120 and 180 minutes after microparticles and 60 minutes after 
control solution (Figure 3.16A) all had a similar magnitude, despite variations in concentration, 
which may suggest that phenytoin from microparticles and solution was following a common 
pathway to the brain. The difference seen in the 60 minute microparticle data, in this respect, 
might have reflected a delay in uptake compared with control solution due to the existence of 
an intact epithelium to traverse in the former, but not the latter.  
To supplement the discussion of intranasal phenytoin delivery pathways, 4-HPPH (the inactive, 
major metabolite of phenytoin) was also quantified in plasma and brain regions of the tested 
rats (Figure 3.15C and D). The first important thing that can be taken from looking at the 4-
HPPH concentrations is confirmation that phenytoin found in the brain was clearly not the result 
of tissue contamination by blood, which is a common criticism of studies such as this where 
complete tissue perfusion (with saline for example) is not possible before analysis. Yarragudi 
et al.204 rebutted this criticism by pointing out that the volume of blood vessels in the rat brain 
amounts to approximately 48 µL of blood which represents an insignificant amount of drug 
compared to the total brain concentrations found218, however, the rebuttal would have been 
stronger had 4-HPPH concentrations been presented. Despite not being a classical low-
permeability reference compound, such as radiolabelled sucrose (1-2%219) which can be used 
as a co-administered marker of blood vessel volume in the brain220, penetration was expected 
to be very low after systemic delivery, based on the results presented in Chapter Two which 
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suggested very limited brain penetration from the systemic circulation (~5%). This finding is 
consistent with other reports discussed in Chapter Two189,221.   
It is therefore interesting that in the intranasal studies performed in this Chapter, the 4-HPPH 
levels in the brain appeared to be higher than expected, suggesting that perhaps this molecule 
was also following a direct pathway to the brain. In order for this to be true, however, some of 
the phenytoin would have to have been metabolised in the nasal passage prior to reaching the 
brain. It is important to acknowledge that CYP enzymes are expressed in the nasal 
epithelium222,223 and it could therefore be a site of metabolism of phenytoin to 4-HPPH other 
than the liver. Interestingly though, CYP2C9 and CYP2C19, the two enzymes reported to be 
responsible for metabolism to 4-HPPH224, have not to this author’s knowledge been reported to 
exist in the nasal epithelium222,223. Furthermore, Antunes-Viegas et al.225 studied metabolism of 
phenytoin in an ex vivo nasal tissue model but found no metabolism to 4-HPPH occurred in the 
tissue. While one could look critically upon the reliability of the ex vivo methodology, the 
different species the tissue was derived from, and the LLOQ of 200 ng/mL of their detection 
method, the available literature would seem to refute the possibility that phenytoin could be 
metabolised to 4-HPPH in the nasal epithelium. In contrast, the data of the present study, as 
discussed below, supports the possibility. The truth may lie in a couple of manuscripts that 
describe extensive capacity of other enzymes in the CYP2C family, namely CYP2C6 and 
CYP2C18, to metabolise phenytoin to 4-HPPH, the latter exceeding the turnover of CYP2C9 
and CYP2C19 by at least four times226,227. While hepatic expression is poor compared with 
CYP2C9 and CYP2C19228, CYP2C18 also happens to be the only 2C isoform that is highly 
expressed in the rat nasal mucosa223 which both explains the scarcity of pharmacokinetic 
documentation for the enzyme with respect to phenytoin and supports the existence of a 
metabolic pathway for local phenytoin hydroxylation in the nose. While seemingly 
counterproductive to the idea that intranasal phenytoin delivery completely bypasses the 
pharmacokinetic hurdles of the systemic circulation, the notion does support the direct delivery 
of molecules to the brain through the nose which is, in the broader picture, a core theme of this 
thesis which aims to be a stimulus for expansion of quality research in the area.   
As with phenytoin, concentrations of 4-HPPH in the brain following microparticle 
administration trended towards increasing between 60 and 120 minutes (Figure 3.15D). Unlike 
phenytoin concentrations, however, they did not show any evidence of reducing at 180 minutes, 
instead remaining at a similar level at 180 minutes and maintaining a similar distribution 
between the brain regions. As discussed earlier, plasma concentrations of phenytoin trended 
towards reducing after 60 minutes (Figure 3.15A), but for 4-HPPH they remained essentially 
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the same at all three time points after microparticle administration suggesting that production 
rate from phenytoin metabolism was essentially balanced by 4-HPPH clearance. This meant 
that the brain to plasma ratios (Figure 3.16B) reflected the brain concentration trend with an 
elevation at 120 minutes that persisted to 180 minutes. The main brain to plasma ratio of 4-
HPPH at 60 minutes after microparticles was already twice that seen after the aforementioned 
25 mg/kg intravenous dose in Chapter Two (Figure 2.9C) (0.12 ± 0.02 vs 0.06 ± 0.01) and 
while that intravenous ratio would be expected to decrease over time with phenytoin and 4-
HPPH plasma levels (recall Chapter Two discussion), the ratio at 120 and 180 minutes after 
microparticles was even higher, supporting a direct intranasal delivery of 4-HPPH to the brain 
after nasal metabolism. 
A further interesting consideration which could be relevant to the above is that 4-HPPH has 
been reported to exert a long-lasting inhibition of the hydroxylation of phenytoin in rats that 
produced it, meaning that during repeated administration, reduced elimination of subsequent 
doses is observed229. Considering the sustained release of phenytoin from microparticles, it is 
possible that in the context of an intranasal metabolism to 4-HPPH, phenytoin metabolism in 
the nose could be inhibited over time, leading to higher local concentrations of phenytoin which 
could be delivered directly to the brain and may have contributed to the high brain to plasma 
ratio at 120 minutes. What is usually a challenge to systemic delivery due to the potential for 
overshooting the therapeutic window and causing toxicity might therefore be an aid to optimal 
intranasal delivery. It should be noted though that limited evidence suggests the inhibition of 
phenytoin metabolism by 4-HPPH may not be significant in humans after systemic 
administration230, so the translatability of this potential advantage is unknown.   
The brain concentrations of 4-HPPH after the phenytoin control solution (Figure 3.15D) were 
interesting in comparison to those after microparticles, as unlike phenytoin levels, 4-HPPH did 
not appear to be elevated above the peak levels of the molecule measured after microparticles 
in the study. This contrasted with the plasma level (Figure 3.15C) which trended towards being 
elevated above those after microparticles at all time points. While the raised plasma 4-HPPH 
levels could expectedly be a product of the raised phenytoin levels in plasma which would be 
proportionately metabolised by the liver, this finding was not replicated in the brain 
concentrations. Consequently, the 4-HPPH brain to plasma ratios for the phenytoin control 
solution (Figure 3.16B) at 60 minutes were similar to those after microparticles at the same 
point and significantly less than those after microparticles at 120 and 180 minutes. A possible 
explanation for this can be constructed by again considering the histological confounding 
discussed earlier. If phenytoin were metabolised in the nasal epithelium, the nasal epithelium 
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would be required to be intact in order for this to occur. If the cells were damaged and could 
not metabolise the phenytoin, 4-HPPH would not be produced in the nasal cavity and therefore 
would not travel directly to the brain in quantities proportional to the phenytoin dose, as was 
postulated in the case of microparticles. Instead, phenytoin might be expected to be absorbed 
more easily into the systemic circulation through the damaged epithelium and exposed blood 
vessels and metabolised in the liver to 4-HPPH, thereby appearing elevated in the plasma, but 
not the brain due to its poor permeability when delivered systemically.   
As implied earlier, no data on 4-HPPH was presented by Yarragudi et al.204, despite validating 
the method to detect it. The reason for this is not stated, but it prevents what otherwise would 
have been an interesting comparison between the studies and perhaps could have shed some 
light on the discrepancies by allowing metabolite concentrations and trends to be followed to 
support the phenytoin concentrations reported. One possibility is that concentrations of 4-HPPH 
were not quantifiable with the method used. The LLOQ reported for 4-HPPH in the brain was 
441 ng/g, which is high compared with the 23.4 ng/g in the more sensitive method used in this 
study. Even when applying the approximately 5-fold multiplication factor mentioned earlier to 
the 4-HPPH concentrations found in this study, they would still fall below the brain LLOQ of 
Yarragudi et al.204. Despite this, the LLOQ of plasma in that study was reported to be 185 ng/mL 
and based on the same logic, should have been quantifiable, but perhaps a lack of brain 
concentrations led to a decision to omit an incomplete data set.  
A final additional experiment which could have contributed to the discussion of intranasal 
phenytoin delivery would have been an equivalent dose administered systemically by 
intravenous injection to track the fate of systemically absorbed compound compared to that 
delivered directly to the brain and the effect on seizures compared with intranasal microparticle 
delivery. In other words, it must be considered that increased levels of phenytoin in the brain at 
120 minutes could have been a reflection of accumulation over time following absorption into 
the systemic circulation rather than direct intranasal delivery. Given the suspected confounding 
effect of ethanol in the MEST test, however, and its significant presence in the commercial 
intravenous formulation, such a study was not performed in this Chapter. Yarragudi et al.204, 
whose focus was purely pharmacokinetics, did perform this experiment at time points up to 60 
minutes (Figure 3.4) which can be used as an indicator of what would have been expected in 
terms of tissue levels of phenytoin. It was reported that brain concentrations were significantly 
and consistently lower than intranasal after an intravenous dose at 60 minutes, despite plasma 
concentrations being significantly and consistently higher, and thus brain to plasma ratio being 
consistently low, therefore brain concentrations would not be expected to increase at 120 
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minutes to match those achieved by intranasal administration. The same can therefore be 
inferred for any phenytoin absorbed into the blood from the nasal passage. Furthermore, 
phenytoin was too low to be quantified in the olfactory bulbs after intravenous dose 
administration by Yarragudi et al.204, further supporting a direct delivery pathway in the case 
of intranasal administration. As a final comment, concentrations of 4-HPPH in the brain from 
the intravenous study of Yarragudi et al.204 would also have been useful to further interrogate 
the data discussed above suggesting that 4-HPPH may also have been directly delivered to the 
brain through an intranasal pathway by providing a direct dose comparison.  
Despite all of the evidence above to support phenytoin delivery from microparticles eliciting a 
peak anti-seizure effect at 120 minutes, the blank microparticles (without phenytoin) 
experiment at this time point exhibited an interesting variability in responses in individual rats 
(Figure 3.19) which, while far from revealing a statistically significant effect on seizure 
threshold was unexpected and is worth discussing as the reasons for it were unclear. No data 
exists, to this author’s knowledge, to suggest that the polymer would have an acute 
pharmacological effect on seizure threshold. Therefore, even though the amount of TSP 
administered was slightly higher than in the phenytoin microparticles study (given that the 
phenytoin mass was replaced with TSP), this is unlikely to have contributed to the outcome.  
Furthermore, considering the 1000 Dalton (Da) limit proposed for good nasal absorption231–233, 
the size of the TSP molecules (720-880 kilodaltons (kDa))207 seems to preclude the possibility 
that they could even be taken up through an intact nasal mucosa to reach the brain, as opposed 
to phenytoin which is well below this limit (252 Da).  Any effect therefore would have to have 
been locally mediated and happen to coincide with the peak brain concentrations of phenytoin. 
All of this seems less and less likely when considering that phenytoin microparticles had no 
significant effect at 60 minutes, yet contained 75% of the TSP dose of the blank microparticles.    
So if there was no effect from the microparticles, attention must be directed to the seizure model 
and the technical limitations that could have led to such a finding. While the validation in 
Chapter Two seemed promising, variability appears to have arisen and limited some of the 
subsequent studies in this Chapter. By looking at the data from a different perspective (i.e. 
comparing overall percentage of HLE in saline vs phenytoin groups as shown in Appendix K), 
it can be seen that the values for the blank microparticles trial are very similar (28 vs 22%) 
supporting a lack of real effect, whereas the trend towards a lower incidence of HLE is more 
evident in the phenytoin microparticles groups at 120 minutes (28% vs 11%) and 180 minutes 
(33% vs 12%) supporting a true effect which was supported by pharmacokinetic data. 
Furthermore, the p values derived from Prescott’s test, while not endowing statistical 
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significance on any of the results, other than upon pooling, offer a far greater statistical 
probability of the phenytoin microparticles having a true effect (p = 0.3647 (120 minutes) and 
p = 0.1412 (180 minutes) compared with p = 1 for blank microparticles, the latter effectively 
suggesting there is no possibility that the apparent effect of TSP microparticles is real based on 
the data available. Furthermore, while the anti-seizure percentage difference in the blank 
microparticle study is numerically larger than the pro-seizure effect (60% vs 13%), the number 
of rats in each group only differed by one (Appendix L).  
It is worth discussing a few general limitations of the MEST study design which became 
apparent here in its application to test an intranasal delivery system. Firstly, variability in 
batches of rats used for determining the CC50 threshold meant the threshold was calculated to 
have much wider confidence limits in the rats which participated in the later microparticle trials 
(120 and 180 minutes) and the resulting experimental response after saline reflected more of a 
CC30, limiting the resolution for detecting drug effects compared with earlier experiments. It is 
possible that variation in ages and weights within studies (Appendix A and B) and mixtures of 
different genetic backgrounds may have led to the variability in this first stage and the difficulty 
in the estimating the CC50 in a number of groups. A future suggestion would be to employ rats 
that are as homogenous as possible, something which could not be strictly controlled in this 
study as the author was not able to personally breed the animals. Nonetheless, at least the study 
design allowed for the experiment to be continued with lower resolution rather than producing 
only CC50 thresholds with confidence intervals too large to meaningfully compare as may have 
occurred with the traditional design.   
Another consideration is that because the CC50 was determined separately for each batch of 
rats, the stimulation current was different in each experiment which could possibly have led to 
variability in responses based on the current rather than the time point after treatment or the 
presence or absence of phenytoin. For instance, it could be argued that because the stimulation 
current was slightly lower for blank microparticles (56 mA) compared with phenytoin 
microparticles at 120 minutes (62 mA), that the blank microparticle rats could have been more 
susceptible to intra-subject variations in threshold due to extra-experimental variables (e.g. 
response to isoflurane, social cues, stress). This might have contributed to the changes seen in 
both pro- and anti-seizure directions while the overall difference in the groups was very small 
as discussed above. Overall, the statistically calculated CC50 values determined in all of the 
MEST experiments in this Chapter were not found to be statistically different from one another 
(Appendix M). The experimentally determined CC50 values after saline administration, on the 
contrary, showed that different batches did appear to have different CC50 values; the ones with 
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around 30% HLE after saline suggesting a higher stimulation current would have been optimal 
to achieve 50% HLE. In this context, and given that the saline trials for both blank and 
phenytoin microparticles showed approximately 30% HLE, the 8 mA difference in stimulation 
current between the experiments was probably not a significant contributor to variability. 
Perhaps the real orchestrator of variability was simply whether there was any anti-seizure drug 
present or not. In the cases where phenytoin was present, the effect on seizure threshold was 
decidedly anti-seizure regardless of the stimulation currents used (63, 62 and 54 mA for 60, 120 
and 180 minutes respectively) the magnitude of which complemented brain drug 
concentrations, while when it was not, there seemed to be more room for extra-experimental 
variables to have a significant influence.  
 
3.7 Conclusions 
This Chapter used the seizure model established in the previous Chapter to evaluate tamarind 
seed polysaccharide microparticles as an intranasal delivery system for phenytoin. A peak anti-
seizure effect of the drug was identified at 120 minutes after microparticle administration, 
suggesting the microparticles to be a fairly slow-acting, but sustained anti-seizure drug delivery 
system with potential for future application in the regular dosing of phenytoin. As well as this, 
these experiments were also an evaluation of the seizure model to detect the more subtle effects 
of phenytoin that were expected after delivery by the nasal route at much lower doses. In this 
respect, it succeeded in that pharmacodynamic data was obtained that complemented 
pharmacokinetic studies of phenytoin concentrations in the plasma and brain. In addition, the 
simultaneous monitoring of the drug’s major metabolite, 4-HPPH, offered an interesting insight 
into intranasal trafficking of phenytoin and supported the argument that a direct route to the 
brain was being exploited. Interestingly, accumulation of phenytoin in the olfactory bulbs was 
not observed and, if anything, the brain distribution was weighted slightly towards the 
brainstem, suggesting an alternative pathway to the commonly referenced passage through the 
olfactory neurons. Lastly, the importance of histological studies as an essential component of 
intranasal drug delivery studies was emphasised by the comparison of the biocompatible 
phenytoin microparticles with an evidently incompatible ethanol-containing phenytoin control 
solution. Overall, the results supported the application of the seizure model as a screening tool 
to gauge the effects of intranasally delivered anti-seizure drugs, setting the necessary 
foundations for an investigation into a compound with untested activity.  
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Chapter Four      
 
On the Intravenous and Intranasal Delivery of 
Oleoylethanolamide and its Effect on Seizures 
                                                                                              
 
4.1 Introduction 
Having explored the delivery of an existing ASD through the nose in Chapter Three with some 
encouraging results, this Chapter now heads further towards the unknown in the investigation 
of oleoylethanolamide (OEA). OEA is an endogenous molecule which is hypothesised to have 
an anti-seizure effect234, but this has not so far been tested or reported on in the literature. A 
likely reason for the lack of investigation into the effects of OEA is the rapid in vivo hydrolysis 
it is subject to after systemic administration by Fatty Acid Amide Hydrolase (FAAH), which 
limits its therapeutic utility235. Despite this, it has been reported to show neuroprotective effects 
in other conditions including stroke236,237 and Parkinson’s disease238.  
The hypothesis that OEA could have an anti-seizure effect is based primarily on the effects 
reported from structurally related molecules in the N-acylethanolamide (NAE) class, 
palmitoylethanolamide (PEA)239,240 and anandamide (AEA)241 (Figure 4.1). In the case of 
anandamide, the ED50 (effective dose in 50 % of animals) in the MES test was unable to be 
measured up to a dose of 300 mg/kg i.p., highlighting the significance of its short plasma half-
life due to FAAH hydrolysis235,242. When combined with the FAAH inhibitor 
phenylmethylsulfonyl fluoride, anandamide still exhibited a fairly high ED50 of 50 mg/kg i.p.  
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(at a time of peak effect of 20 minutes)241, but it was able to demonstrate an anti-seizure effect. 
As acknowledged by the authors, however, it is debatable whether the effect seen was entirely 
due to the exogenously administered anandamide or a generalised FAAH inhibition resulting 
in an increase in endogenous levels and effects of NAEs. Interestingly, the ED50 of 
palmitoylethanolamide (PEA) determined in the MES test in another study239 was much lower 
(9.2 mg/kg i.p. with a time of peak effect of 2 hours). While the longer time to peak effect may 
be explained by poor absorption due to precipitation at the injection site (as noted by the 
authors), the reason for the lower ED50 is less clear. It could be related to an alternative site of 
anti-seizure action at which PEA is more potent or allosteric (as it does not act at cannabinoid 
receptors like anandamide242,243), a lower affinity for FAAH244 or perhaps the so-called 
‘entourage effect’ whereby it acts indirectly by decreasing FAAH metabolism of other NAEs 
such as anandamide242. Notably, it also did not induce any neurological impairment up to a dose 
of 250 mg/kg, highlighting a potentially significant benefit to the investigation of naturally 
biocompatible endogenous molecules as therapeutics when considering the marked role that 
intolerable adverse effects play in the failure of epilepsy treatments.  PEA has also been tested 
in chemically-induced seizures (e.g. pentylenetetrazole test) and found to suppress the tonic, 
but not the clonic, components of the seizures239,240.  Furthermore, one of these studies also 
showed PEA to be largely ineffective in amygdala-kindled animals and suggested a possible 
selective action on brainstem compared to forebrain circuits or that perhaps the molecular 
substrates of tonic and clonic seizures were differentially affected by NAEs240.   
 
Figure 4.1. OEA and structurally related molecules AEA and PEA. 
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The main mechanism of action proposed for the neuroprotective effects of OEA is peroxisome 
proliferator-activated receptor alpha (PPARα) agonism, although it is thought to act at other 
receptors as well242,245. It should be noted that PEA also acts at the PPARα receptor, but is 
markedly less potent (EC50 = 3 µM vs 120 nM for OEA) and the activity of AEA at the receptor 
remains a matter of debate242. Interestingly, other drugs with reported PPARα agonist activity 
have demonstrated anti-seizure effects246–248, including the clinically-used anti-seizure drug, 
valproic acid249–253. Furthermore, a consequence of the ketogenic diet, a commonly used adjunct 
for managing drug-resistant epilepsy, is increased levels of polyunsaturated fatty acids, which 
also act as PPARα agonists and it has been postulated that this may play a role towards its 
efficacy254. This has been further substantiated by a study which found no added benefit from 
combining fenofibrate, a PPARα agonist, and the ketogenic diet on increasing seizure threshold 
in the PTZ test, compared to each treatment alone, suggesting a possible common pathway 
(Figure 4.2). This phenomenon is, however, a chronic effect. While a change in gene 
transcription resulting from PPARα agonism is the most widely accepted hypothesis for the 
effects of OEA, it is inherently slow, meaning other non-genomic pathways are likely to elicit 
the rapid effects that have been reported with acute administration in other conditions236–
238,245,255. Non-genomic actions have also been associated with PPARs, however, and it has been 
suggested that effects may be achieved through ligand-bound PPARα stimulating the activity 
of tyrosine kinases (Tyr Kin), which, in turn, phosphorylate surface-expressed nicotinic 
acetylcholine receptors (nAChR) and reduce their response to agonists242,256 (Figure 4.2) 
thereby modulating excitation and potential seizure pathways257.  
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Figure 4.2. Schematic diagram of the mechanism of PPARa activation by OEA leading to non-genomic 
(rapid) and genomic (slow) effects. Figure adapted with permission from Pistis & Melis242.  FAAH = 
fatty acid amide hydrolase; Tyr Kin = tyrosine kinase; P = phosphate; nAChR = nicotinic acetylcholine 
receptor; PPAR = peroxisome proliferator-activated receptor; PPRE = peroxisome proliferator 
response element; RXR = retinoid X receptor; 2-AG = 2-arachidonoyl glycerol; TZD = 
thiazolidinediones; AEA = anandamide; OEA = oleoylethanolamide.  
 
As a means to potentially overcome the challenge of hydrolysis, as well as provide a 
physiologically suitable aqueous vehicle for administration of poorly soluble OEA, Younus et 
al.258 recently reported the incorporation of OEA into self-assembling liquid crystalline lipid 
nanoparticles called cubosomes (with an encapsulation efficiency of >99%) which will be 
utilised as a delivery system for OEA in this Chapter. The structure of a cubosome can be 
described as a continuous negatively-curved lipid bilayer twisted around two non-intersecting 
water channels to form a structure with cubic symmetry (Figure 4.3)259. A cubosome has a very 
large surface area for its size and contains both hydrophilic and lipophilic regions, permitting 
the encapsulation of hydrophilic, amphiphilic or lipophilic additives. A surface stabiliser is 
necessary to prevent aggregation between the particles260,261. Cubosomes can be classified 
according to the three periodic minimal surfaces shown in Figure 4.3C262. In general, the Ia3d 
structure has been proposed to form at low hydration levels, transitioning to the Pn3m and then 
Im3m structure with increasing hydration and lessening negative curvature of the bilayer. The 
third structure, Im3m, also tends to form as a result of structural disruption by the incorporation 
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of other molecules above a certain concentration261,263-264 and exhibits a larger lattice spacing263.  
It is this form which the OEA cubosomes used in this Chapter assume upon production258.  
 
Figure 4.3. The internal structure of cubosomes. (A) Cryogenic transmission electron microscopy 
(Cryo-TEM) image of an OEA cubosome (scale bar = 200 nm), (B) Fast Fourier Transform of the image 
in A to reveal the internal cubic symmetry of the particle and (C) Schematic diagrams of the three 
possible internal structures of cubosomes: primitive (Ia3d), gyroid (Im3m) and diamond (Pn3m). Panels 
and B adapted with permission from Younus et al.258 Copyright American Chemical Society. Panel C 
adapted from Chen et al.265 with permission.  
 
The self-assembly and maintenance of the cubosome structure is a factor of the geometric 
properties of the component molecules and their surrounding environment; particularly features 
such as solvent concentration and temperature, the modification of which may lead to dynamic 
changes in the internal structure to form alternative self-assembled lipid structures such as 
hexosomes or liposomes260 (Figure 4.4). A critical, but so far infrequently studied, implication 
of this is the effect of complex biological media on cubosomes, which must inevitably be 
elucidated if systemic administration is to be an end application. Of particular note, a previous 
study has reported the transformation of basic phytantriol cubosomes to hexosomes on exposure 
to blood plasma266, which it was speculated may have implications for systemic delivery of 
OEA cubosomes in this Chapter.  
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Figure 4.4. Relationship between cubosomes and other commonly studied self-assembling lyotropic 
liquid crystalline structures, liposomes and hexosomes. Adapted with permission from Huang and 
Gui267(published by the Royal Society of Chemistry), Rizwan and Boyd260, Rizwan et al.268, Boyd et al.269 
(Copyright American Chemical Society) and Bibi et al.270 
 
The premise of this approach is that OEA is co-formulated into the cubosome with a non-
hydrolysable lipid, phytantriol, based on the hypothesis that both the tortuous structure and the 
presence of this second lipid will aid in shielding OEA from degradation and allowing it to 
reach its target site in the brain. Younus et al.271 showed an in vitro resistance of the particulate 
OEA to FAAH hydrolysis but in vivo stability and brain delivery has not yet been studied. It is 
hypothesised that OEA will remain in a particulate form as it travels through the plasma or via 
the nose to the brain, allowing protection of OEA in vivo. This could perhaps be augmented by 
the adsorption of a protein corona to cover the surface of the nanoparticles, as has been 
described for similar drug delivery systems elsewhere272–274 and supported by the present 
author’s own unpublished extracurricular studies.  
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This Chapter sets out to evaluate whether administering OEA through the nose (and potentially 
avoiding the systemic circulation) could deliver it via this direct route to the brain and elicit an 
anti-seizure response. Given the unproven effects of OEA on seizures, however, it starts by 
investigating the systemic (intravenous) administration of cubosomal OEA. This permits 
exploration of the effect of the OEA cubosomes on seizures in two key ways. Firstly, in the 
absence of potentially confounding anaesthetic (an unavoidable limitation to intranasal studies) 
and secondly, after administration via a route which guarantees the OEA enters the blood 
circulation at a dose which could be expected to show an anti-seizure effect in the absence of 
rapid hydrolysis and following successful brain delivery. To complement this, the Chapter also 
investigates the pharmacokinetics of 13-Carbon-labelled OEA (13C-OEA) delivered 
intravenously in cubosomes through the development of an LC-MS analytical method and 
studies the time-resolved in vitro structural stability of OEA cubosomes in plasma utilising 
small angle X-ray scattering (SAXS). To conclude the Chapter, the effects of intranasal OEA 
cubosomes on MEST seizure threshold and nasal epithelial integrity are determined.  
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4.2 Aims 
The overall aim of this Chapter was to use the seizure model developed in Chapter Two and 
Chapter Three to investigate a potential anti-seizure effect of the endogenous 
endocannabinoid-like molecule, OEA, using cubosomes as a drug delivery platform. To 
achieve this, the following objectives were set:  
 
 Determine if OEA (in cubosome form) has an effect on seizure threshold after systemic 
(intravenous) administration. 
 Develop and validate an LC-MS method to detect 13C-labelled OEA in rat plasma, brain 
and liver tissue. 
 Determine the plasma, brain and liver tissue levels of 13C-OEA after systemic 
administration as cubosomes to determine whether any pharmacodynamic effect seen 
(or not seen) could be attributable to chemical stability (or instability) of OEA.   
 Evaluate the in vitro structural stability of OEA cubosomes in rat plasma to determine 
whether any pharmacodynamic effect seen (or not seen) and any chemical stability (or 
instability) might be attributable to structural stability (or instability) of OEA 
cubosomes.  
 Evaluate the acute histological impact of OEA cubosomes on the rat nasal epithelium 
and determine a suitable dose for administration via the nose. 
 Determine if OEA (in cubosome form) has an effect on seizure threshold after intranasal 
administration. 
 Evaluate the histological impact of OEA cubosomes on the rat nasal epithelium in 
seizure test subjects after a three day period. 
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4.3 Hypotheses 
 OEA will have an anti-seizure effect in the MEST seizure test after systemic 
(intravenous) administration, as reported for structurally similar NAEs in the related 
MES model.  
 13C-OEA will exhibit a longer plasma half-life/resistance to degradation in plasma when 
administered as cubosomes compared with a 13C-OEA control solution. 
 OEA cubosomes will distribute and accumulate to some extent in the liver, given their 
size and previous reports on lipid nanoparticles accumulating there due to the presence 
of fenestrated blood vessels.  
 OEA cubosomes will undergo structural changes on exposure to blood plasma which 
could play a role in their ability to protect OEA from hydrolysis and deliver it to the 
brain. 
 OEA cubosomes can be intranasally administered without disrupting the integrity of the 
olfactory epithelium.  
 OEA will elicit an anti-seizure effect after intranasal administration in cubosomes. The 
nose may offer a more direct route to the brain for OEA, thereby allowing a more rapid 
onset of effects and decreasing pre-target degradation in the systemic circulation 
allowing dose reduction. 
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4.4 Materials & Methods 
4.4.1 Materials 
Oleoylethanolamide (OEA) was purchased from Toronto Research Chemicals (Canada).  
Deuterated oleoylethanolamide (d4-OEA) was purchased from Cayman Chemical (USA). 
13C-
Oleoylethanolamide (13C-OEA) was kindly synthesised and provided by Callaghan Innovation, 
New Zealand. Phytantriol (3,7,11,15-Tetramethyl-1,2,3-hexadecanetriol) was purchased from 
A & E Connock (England). Dimethyl sulfoxide (DMSO) (≥99.5%, plant cell culture tested), 
Polysorbate 80 (Tween 80®), propylene glycol (PG), formic acid (for mass spectrometry, 
~98%) and phosphate-buffered saline sachets (pH 7.4) were purchased from Sigma Aldrich 
(New Zealand). EMSURE® Chloroform for analysis was purchased from Merck (Germany). 
Acetonitrile (ACN) (LiChrosolv®), Methanol (MeOH) (LiChrosolv®), tert-Butyl Methyl Ether 
(TBME) (LiChrosolv®) and Ethanol (EMSURE®) were purchased from Lab Supply (New 
Zealand). All of these solvents were liquid chromatography grade. Male Wistar rat plasma, 
brain and liver tissue for LC-MS method validation and standard preparation was obtained in-
house from control rats administered saline treatments. Male Wistar rat plasma for SAXS 
experiments was kindly provided by Monash Institute of Pharmaceutical Sciences, Victoria, 
Australia. All water used in this study was ion exchanged, distilled and passed through a Milli-
Q water purification system (Millipore, USA). 
4.4.2 Animals 
All procedures involving animals were approved by the University of Otago Animal Ethics 
Committee pursuant to Animal Use Protocols 08/16, 65/16 and 130/18. Male Wistar rats 
sourced from the Hercus Taieri Resource Unit were used in all experiments. Specific weights 
and ages of animals over the course of the experiments can be found in Appendix B and N. 
Animals were housed under laboratory conditions in the Hercus Taieri Resource Unit for the 
duration of the experiment.   
4.4.3 Preparation of OEA Treatments 
4.4.3.1 Preparation of OEA Cubosomes, Dispersion and Solution 
Cubosomes for intranasal histopathology and pharmacodynamic MEST experiments were 
prepared with 30% OEA (stabilised with Polysorbate 80®) as described previously by Younus 
et al.271 OEA was added to a 20 mL glass vial along with phytantriol so that it constituted 30% 
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w/w of the total lipid. In addition, propylene glycol (sufficient to achieve 5% w/v in the final 
dispersion) and a surface stabiliser (Polysorbate 80®) (sufficient to achieve 0.3% w/v in the 
final dispersion) were added and the mixture was dissolved in excess chloroform. The 
chloroform was evaporated fully from the vial using a Buchi Rotavapor R-210 (Buchi, USA) 
at a pressure of 300 kPa (generated by a Buchi V-850 vacuum controller with V-700 vacuum 
pump) in a 45 ºC water bath (Buchi B-491). Subsequently, Milli-Q® water, pre-heated to 45ºC, 
was added to the vial (in sufficient volume to give a final total lipid concentration of 20 mg/mL 
(2% w/v)), followed by a monolayer of 4 mm diameter soda lime glass beads. The vial was 
immediately vortexed for 10 minutes at 35 Hz. A free OEA suspension for use in the intranasal 
histopathology experiments was produced using the same method, but without the addition of 
the cubosome-forming lipid, phytantriol. 
For the intravenous pharmacokinetic experiment, the same method was followed, but with 13C-
OEA (kindly synthesised and provided by Callaghan Innovation, New Zealand) replacing OEA 
and the OEA content of the cubosomes being reduced to 10% w/w of total lipid due to limited 
availability of the carbon-labelled compound. 13C-OEA control solution was prepared by 
dissolving 13C-OEA in DMSO and ethanol, then diluting this mixture with Milli-Q water to 
give a final composition of 10% DMSO, 40% ethanol and 50% water. The concentration of 
13C-OEA in both the control solution and the cubosome dispersion was 2 mg/mL. 
For the SAXS experiments, cubosome dispersions were prepared at a concentration of 20 
mg/mL lipid with 0% (phytantriol only), 10% and 30% OEA content (w/w total lipid) using the 
same method described above.  
4.4.3.2 Dynamic Light Scattering (DLS) 
Particle size and polydispersity index (PDI) of cubosome dispersions was measured using a 
Malvern ZetaSizer Nano® (ATA Scientific, Australia) in order to validate that the formulations 
to be used were comparable to those previously reported (published258 and unpublished data). 
A sample of cubosome dispersion was diluted to a concentration of approximately 0.2 mg/mL 
(10 µL of dispersion added to 1 mL of water) total lipid in Milli-Q water and placed in a 
disposable cuvette to measure size (Z-average) and polydispersity index. Three sets of size 
measurements, each comprising 10 runs, were performed for each formulation at 25 °C and a 
scattering angle of 173 º.  
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4.4.4 Drug Administration 
For the intravenous pharmacodynamic MEST study with OEA, rats were injected with a 7.5 
mg/kg dose of OEA cubosomes through a lateral tail vein using a 0.3 mL or 0.5 mL insulin Lo-
dose syringe (BD Biosciences, New Zealand) at a pre-determined time point before MEST 
stimulation. Isoflurane anaesthesia was not performed prior to drug administration in this 
experiment as, unlike intranasal administration, intravenous administration was able to be 
performed on conscious animals, therefore allowing the removal of the anaesthesia as a 
potential confounding variable from this experiment.  
For the intravenous pharmacokinetic study with 13C-OEA, rats were injected with a 1 mg/kg 
dose of 13C-OEA in cubosomes or solution through a lateral tail vein using a 0.3 mL insulin Lo-
dose syringe (BD biosciences) at a pre-determined time point before euthanasia.   
For the intranasal studies, OEA cubosomes and OEA suspension were administered using the 
Rat Intranasal Catheter Device following isoflurane anaesthesia as described in Chapter 
Three. For initial dose screening studies, the concentration of each was equivalent to 6 mg/mL 
OEA. For the subsequent MEST experiments, the cubosome dispersion was diluted to a 
concentration of 1.5 mg/mL OEA (5 mg/mL w/v total lipid). The volume administered was 
kept constant at 20 µL.  
4.4.5 Behavioural Analysis in Intranasal Dose Determination Studies 
Behaviour was monitored for 60 minutes after administration of the OEA cubosomes and 
suspension for any potential signs of nasal irritation such as frequent sneezing, noisy breathing, 
red (porphyrin) discharge, nose-rubbing or general signs of pain/discomfort (with reference to 
the Rat Grimace Scale275).  
4.4.6 Tissue Collection and Histological Processing 
In 13C-OEA pharmacokinetic studies, rats were euthanised after one of four time points (15, 30, 
60 or 90 minutes) following the injection. Trunk blood was collected in a 6 mL blood tube 
coated with sodium heparin (BD Biosciences, New Zealand) at the time of euthanasia and 
centrifuged immediately for 10 minutes at 2000 G (Sigma 1-6 compact centrifuge, Sigma, 
Germany) to obtain plasma, then aliquoted and frozen immediately on dry ice before transfer 
to a -80 °C freezer. The brain and liver were immediately dissected, rinsed in PBS (pH 7.4), 
blotted on filter paper, weighed, and then frozen on dry ice.  
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In intranasal studies, nasal tissues were collected at 60 minutes after drug administration in the 
initial dose screening experiments and at either 60 minutes or three days after administration to 
determine effects of the formulation on the nasal epithelium of rats in the pharmacodynamic 
MEST experiments. As described in Chapter Three, rats were euthanased by guillotine 
decapitation and after removal of the brain, eyes, lower jaw and excess skin and tissue around 
the nasal passage were removed from the skull. A blunt needle was inserted 0.5 cm into the 
posterior nasopharyngeal duct and used to flush the nasal passage with 10 mL of 10% neutral 
buffered formalin. Subsequently, the nasal passage was fixed in 50 mL of NBF for 48-72 hours. 
The fixed nasal passage was then decalcified in 10% EDTA (pH 7.2) for two to three weeks, 
sliced coronally into blocks, as per published methods83,150 and embedded in paraffin wax. A 
microtome (Leica Jung RM 2025, Leica Biosystems, Australia) was used to cut 5 µm sections 
from region III which were subsequently deparaffinised, stained with haemotoxylin and eosin, 
and cover-slipped with DPX mounting medium. Sections were imaged on an Aperio ScanScope 
(Leica Biosystems, Australia). Images were analysed using Aperio ImageScope v12.2.2.5015 
software (Leica Biosystems, Australia). 
4.4.7 Maximal Electroshock Stimulation Threshold Test 
The MEST experiments were performed in accordance with the stimulation procedure outlined 
in Chapter Two. Intranasal studies followed the cross-over study design used in Chapters 
Two and Three, while the study design for the intravenous experiments was modified to allow 
screening at multiple time points after drug administration in a single batch of rats (Figure 4.5). 
It was hypothesised that the dose and systemic route of delivery of OEA should be sufficient to 
demonstrate an effect in a smaller group than in intranasal studies, if one was to be seen. The 
modified design also allowed the exclusion of potential confounding that might exist if washout 
of cubosomes and their respective components from the body after intravenous administration 
was inadequate, as no information is currently available on their clearance or effects on seizure 
threshold.  
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Figure 4.5. Study design for intravenous OEA cubosome experiments. 
 
As in the cross-over design, a total of three stimulations were delivered to each rat, no less than 
48 hours apart. For the first stimulation, the “up and down” method was used to estimate the 
CC50 for HLE in the group, as described in Chapter Two. For the second stimulation, all rats 
were stimulated at the calculated CC50 without any prior treatment and their baseline response 
recorded. Prior to the third stimulation, rats were randomly divided into three groups, each 
consisting of a 50% proportion of rats that had shown HLE at the CC50. Each group was 
assigned a time point (15, 30 or 60 minutes), then OEA cubosomes were intravenously 
administered and each rat was stimulated at the CC50 at their assigned time point after drug 
treatment to determine their response. Statistical comparisons were made between responses 
using the sign test.  
4.4.8 Small-Angle X-ray Scattering  
SAXS is a technique used to elucidate the internal structure of liquid crystalline nanoparticles 
in a sample, allowing the predominant mesophase to be elucidated260. It was used in this Chapter 
to study the in vitro time-resolved stability of the internal structure of OEA cubosomes upon 
incubation with rat plasma to simulate stability after the intravenous administration that was 
performed in the pharmacokinetic and pharmacodynamic experiments. Experiments were 
conducted on the small-angle X-ray scattering/wide-angle X-ray scattering (SAXS/WAXS) 
beamline at the Australian Synchrotron (Victoria, Australia) during beamtime granted for 
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Proposal 13722. Samples were prepared in a clear 96-well plate and mounted vertically in a 
temperature-controlled holder maintained at 25 ºC or 37 ºC in the beam path. Measurements 
were taken with a photon energy of 13 kilo electron volts (keV). The detector was a Pilatus 1 
M (170 mm × 170 mm). A sample-to-detector distance of 1.6 m and a scattering vector (q) 
range of 0.0126 to 0.62 were used.  
The cubosome samples measured primarily included OEA-phytantriol cubosomes stabilised 
with Polysorbate 80 and containing OEA proportions of 10% and 30% w/w of total lipid, as 
well as phytantriol only cubosomes as a control to examine how OEA affected the outcome. 
Other cubosome formulations of indirect relevance to this Chapter were simultaneously studied 
and data from selected samples is provided in Appendix O of this thesis in order to supplement 
the experimental discussion of this Chapter. Initial measurements of cubosome dispersions 
were taken at 25 ºC to validate that the expected cubic mesophase existed in the samples before 
any temperature change or exposure to rat plasma. To determine the time-resolved stability of 
cubosomes upon incubation in rat plasma the procedure was as follows. Cubosomes or Milli Q 
water (control) in 100 µL aliquots were added to the wells. An aliquot of 100 µL of rat plasma 
or Milli Q water (control) was then added to each well and triturated gently using a multi-
channel pipette. The plate was then loaded into the holder in the beam path. Measurements were 
taken from 30 minutes after mixing to allow temperature equilibration in the holder, then at 10 
minute intervals from 30-60 minutes, 15 minute intervals from 60-180 minutes and 30 minute 
intervals thereafter over the course of seven hours. The two-dimensional diffraction patterns 
recorded on the Pilatus detector were reduced to one-dimensional intensity versus q profiles 
using Scatterbrain software provided by the Australian Synchrotron. The data was analysed by 
indexing Bragg peaks for known liquid crystalline structures276 and lattice parameter 
dimensions calculated over time using known relationships from the d-spacings.  
4.4.9 Liquid Chromatography Mass Spectrometry (LC-MS) Method for Analysis of 13C-
OEA in Plasma, Brain and Liver 
4.4.9.1 Extraction and Sample Preparation 
Frozen brains and livers were homogenised after adding 2 mL/g (based on wet weight 
determined after washing in PBS and blotting with filter paper at the time of dissection) of ice 
cold Milli Q water and allowing to sit on ice for 5 minutes prior to homogenisation on ice with 
a tip sonicator (UP50H Ultrasonic Processor, hielscher Ultrasound Technology, Germany) (1 
cycle, 100% amplitude). The homogenate was aliquoted into 1.7 mL ultra clear microtubes 
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(Axygen, USA) and frozen at -80 °C again. Aliquots of 100 µL were made in quadruplicate at 
this stage and the rest were around 1 mL. Plasma was thawed on ice and prepared without 
dilution, except for four samples, which were diluted with blank plasma in order to be 
quantifiable within the standard range.  
The 100 µL aliquot was taken out of the freezer and 5 µL of the internal standard (d4-OEA), 
and 5 µL of methanol (solvent) added as it thawed. Once possible, this was vortexed, then 200 
µL chilled ACN was added. This mixture was sonicated briefly, then 800 µL chilled TBME 
was added and it was sonicated briefly again, then vortexed briefly. It was then centrifuged at 
17,200 G for 20 minutes at 4 °C (Prism™ R Microcentrifuge, Labnet International, Inc., USA).  
The samples were taken into a precooled tray, then 800 µL of the supernatant was taken and 
transferred to a new tube. These tubes containing the supernatant were then evaporated to 
dryness in a centrifugal evaporator (Thermo Savant Speed Vac®, Thermo Fisher Scientific, 
New Zealand) until dry (4-10 hours, depending on the tissue type). A 200 µL volume of 
methanol was then added to each tube and it was briefly sonicated and vortexed to reconstitute. 
A brief centrifugation (10,000 revolutions per minute (rpm) for 1 second) followed to ensure 
all liquid was moved to the bottom of each tube. Samples were then pipetted into the top of a 1 
mL syringe (BD Biosciences, New Zealand) and filtered through a 13 mm Nylon 0.22 µm 
syringe filter (Microanalytix, New Zealand) into a 250 µL or 100 µL insert (PP BM insert with 
bottom spring case (Phenomenex, USA)) in a 2 mL clear glass vial (Thermo Fisher Scientific, 
New Zealand). Samples were stored at 4 °C until analysis.   
4.4.9.2 Standard Preparation 
The stock solution for 13C-OEA standard preparation was produced by dissolving 13C-OEA 
powder in methanol at a concentration of 1 mg/mL. The stock solution for d4-OEA was 
provided as a 1 mg/mL solution in ethanol. Serial dilution of these solutions in methanol was 
performed to achieve the desired standard concentrations. To prepare standard samples for 
analysis, aliquots of standard solutions (5 µL) were mixed with blank plasma, brain or liver 
homogenate aliquots (100 µL) in place of the 5 µL of blank methanol added to the unknown 
samples, as described above. The extraction procedure was the same from that point forward. 
Standards covered a range of 0.39 to 25 ng/mL for plasma and 1.17 to 75 ng/g for brain and 
liver tissue. Quality control samples were prepared alongside standards at concentrations within 
the relevant ranges.  
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4.4.9.3 LC-MS Analysis  
Samples were analysed using an Agilent 1290 HPLC system (G4226A autosampler, LC binary 
SL pump, TCC SL (Agilent, USA)) connected to an AB Sciex QTRAP 5500 mass spectrometer 
with Turbo Spray ion source (Sciex, USA). Parameters were optimised to detect the compounds 
of interest as shown in Table 4.1.   
Table 4.1. Optimised parameters for compound analysis. 
Entrance potential (V) 10 
Curtain gas (psi) 10 
Collision gas Medium 
Ionspray voltage (V) 5500 
Temperature (ºC) 600  
Ion source gas 1 (psi) 40 
Ion source gas 2 (psi) 40 
 
Figure 4.6 shows the molecular structures and molecular masses of the compounds analysed as 
well as the expected fragmentation in positive ion mode.  
 
Figure 4.6. Molecular structures of (A) OEA (Mw = 325.3 g/mol) and (B) OEA-d4 (Mw = 329.3 g/mol). 
The asterisks in (A) indicate possible sites of the single 13C carbon on each molecule of 13C-OEA (Mw = 
327.3 g/mol). The expected predominant fragmentation point in positive ion mode to produce the 
[M+H]+ ethanolamine ion is shown by yellow arrows.  
 
The following ions were monitored in MRM mode (positive ionisation) using the optimised 
parameters shown in Table 4.2.  
Chapter Four: On the Intravenous and Intranasal Delivery of OEA and its Effect on Seizures 
144 
Table 4.2. MRM optimised parameters for ions monitored. 
Q1 Q3 Time 
(msec) 
ID DP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
326.206 62.000 150.0 OEA 166 23 12 
330.255 66.000 150.0 OEA-d4 71 21 18 
327.201 63.000 150.0 13C-OEA 111 21 10 
 
Mobile phase A consisted of 0.1% formic acid in Milli Q water. Mobile B was 0.1% formic 
acid in 2:1 Acetonitrile:Methanol. Analysis was performed at a flow rate of 0.6 mL/min by 
injecting 5 µL of sample into a Kinetex EVO 5 µ 100 Å C18 (150 x 2.1 mm) column (fitted 
with a 4 x 2.0 Gemini-NX C18 SecurityGuard Cartridge) (Phenomenex, USA) in gradient 
mode, maintained at 40 °C. Starting pressure was approximately 2530 psi. The gradient was 
started at 20% A, 80% B and increased to 5% A, 95% B over 1.67 minutes, held there until 10 
minutes for cleaning, then returned to 20% A, 80% B at 10.7 minutes and allowed to re-
equilibrate until 12 minutes. Eluent was allowed to flow to the MS detector for the first 2.0 
minutes for compound elution, then was diverted to waste until 3.7 minutes, then allowed to 
flow to the detector again until 12.0 minutes to re-equilibrate. 90% methanol in Milli Q water 
was used for needle cleaning between samples (10 seconds). Draw speed and eject speed were 
200 µL /min. All three compounds eluted simultaneously at 1.64 minutes. The auto-sampler 
was kept at a temperature of 4 °C during analysis.  
4.4.9.4 Data analysis 
Data was collected in Analyst® software (Sciex, USA) and analyte/internal standard ratio was 
used to construct calibration curves and analyse the data in Microsoft Excel (Microsoft, USA). 
Standard curves were plotted in GraphPad Prism® (GraphPad, USA) for presentation in this 
thesis. The use of 13C-OEAwas intended to clearly differentiate the exogenously administered 
compound from the endogenous 12-Carbon oleoylethanolamide (12C-OEA). However, the 12C-
OEA was found to produce an ion pair with the same mass to charge ratio (m/z) as the 13C-
OEA (327/63), which was attributed to the formation of an [M+2H]2+ ion (327/63) by 12C-OEA. 
This pseudo background signal was found to occur as a consistent proportion of the 12C-OEA 
signal (4-6%) and was therefore able to be corrected for using Equation 4.1 and the Analyte/IS 
ratio subsequently calculated using Equation 4.2. Data was compared statistically with t-tests 
and one-way analysis of variance (ANOVA) (with post-hoc Tukey’s test) as appropriate, with 
p < 0.05 considered statistically significant. 
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Equation 4.1. Calculation of corrected 13C-OEA intensity. 
 
Equation 4.2. Calculation of corrected analyte/IS ratio.  
Ratio (Analyte/IS) = Corrected 13C-OEA intensity 
OEA-d4 intensity 
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4.5 Results 
4.5.1 Pharmacodynamic Evaluation of Intravenous OEA cubosomes 
The first study in this Chapter used the MEST model to determine whether OEA cubosomes 
had an effect on seizure threshold after intravenous administration. The design was modified 
slightly from that used in the intranasal studies, as described in the Methods section, as a more 
pronounced effect was hypothesised to occur after intravenous administration, so less 
sensitivity was required. As shown in Figure 4.7, the CC50 of the group was found to be 63 mA 
(95% CI: 38-105 mA) (Figure 4.7A). Upon subsequent stimulation at this current after no 
treatment, only 43 % of the rats displayed HLE (Figure 4.7B). This suggested a slight 
underestimation of the true CC50, however, this was able to be corrected prior to the drug 
treatment test with this study design by dividing the rats into three time point sub-groups in 
which 50% of rats in each group had shown HLE at the CC50 (Figure 4.7C). FLE was seen in 
100% of rats at the CC50 in all groups.  
 
Figure 4.7. CC50 calculation (A) and baseline (B and C) data for the intravenous OEA cubosome MEST 
experiment. Responses after no treatment are shown for the full group (B) and the sub-groups that were 
used to test at different time points (C).   
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As shown in Figure 4.8, no statistically significant anti-seizure effect (or pro-seizure effect) was 
observed in the MEST test after intravenous administration of a single dose of OEA cubosomes 
(7.5 mg/kg OEA). Furthermore, there was no trend to suggest an underlying effect, as there was 
in Chapter Three. At 15 minutes, a 25 % reduction in the incidence of HLE occurred, while 
at 30 minutes, a 40 % reduction in incidence occurred, but so did a 20 % increase in rats which 
had not displayed it in the baseline study. Finally, at 60 minutes, a 25 % increase in the incidence 
of HLE was observed. No change in the incidence of FLE was seen.  
 
 
Figure 4.8. Effect of intravenous OEA cubosomes (7.5 mg/kg OEA) on HLE (black) and FLE (grey) at 
the group CC50 current 15 minutes (n=4 and 8 respectively; p = 0.32), 30 minutes (n=5 and 10 
respectively; p = 0.56) and 60 minutes (n=4 and 7 respectively; p = 0.32) after treatment administration. 
Data is presented as percent change in response with respect to no treatment in the same rats. Animal 
numbers and the method used to calculate the percentage difference are shown in Appendix C. Note that 
FLE is not visible in the above Figure as no change was found in this experiment.  
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4.5.2 Validation of an LC-MS Method for Measuring Tissue 13C-OEA Concentrations 
in Plasma, Brain and Liver Tissue  
4.5.2.1 Specificity 
As described above, the use of 13C-OEA to study the pharmacokinetics of the exogenously 
administered OEA was intended to clearly differentiate it from background endogenous levels 
of OEA, however, a background signal at the same m/z ratio as the 13C-OEA ion pair 
complicated the determination of specificity. Preliminary studies attributed this signal to the 
formation of an [M+2H]2+ ion and determined that it was a consistent proportion (4-6%) of the 
OEA signal and could therefore be corrected for using blank samples run within each assay 
(Figure 4.9).  
 
 
Figure 4.9. Blank tissue samples of rat plasma (A), liver homogenate (B) and brain homogenate (C) 
spiked with the same concentration of internal standard (d4-OEA) (red). Background endogenous OEA 
signal (blue) is shown along with the proportionately increasing pseudo-background 13C-OEA signal 
(green).  
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The optimised method parameters allowed resolution of clear peaks representing the analyte 
13C-OEA and internal standard OEA-d4 (Figure 4.10), as well as background OEA (Figure 4.9) 
so that the correction to the background 13C-OEA signal could be made. The compounds eluted 
consistently at 1.64 minutes in all matrices.  
 
 
Figure 4.10. Representative chromatograms of 13C-OEA (green) and OEA-d4 (red) in rat plasma (A), 
rat liver homogenate (B) and rat brain homogenate (C). Note that original chromatogram data has been 
re-plotted using GraphPad Prism® to enhance clarity. The 13C-OEA concentration in these 
chromatograms is 6.25 ng/mL for plasma and 18.8 ng/mL for brain and liver tissue due to dilution of 
the latter two, however all represent the same concentration in the actual sample. Accordingly, the 
internal standard (OEA-d4) concentration is 12.5 ng/mL for plasma and 37.5 ng/g for brain and liver 
tissue.  
 
4.5.2.2 Sensitivity   
To determine the sensitivity of the assay, standard curves were produced by plotting mean 
analyte/internal standard ratio values against concentration and fitting to second order 
polynomial (quadratic) equations. The standard curve was validated in triplicate on three 
separate days (Figure 4.11). Accuracy and precision for all concentration values was found to 
be within the acceptable range of ± 15% and the fit of the curve maintained an R2 value of 
≥0.9998 (Appendix P).  
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Figure 4.11. Standard curves of 13C-OEA in rat plasma (A), brain homogenate (B) and liver homogenate 
(C). Data shown are the mean values (± SD) of the standards prepared and measured in triplicate on 
three different days. The relationship between analyte concentration and analyte/internal standard ratio 
was best modelled by fitting second order polynomial (quadratic) curves to the data as shown on the 
graphs.   
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4.5.2.3 Accuracy and Precision 
The inter-day and intra-day accuracy and precision of the assays, based on quality control 
samples, are shown in Table 4.3 and Table 4.4. Variability was within the acceptable range of 
± 15% for all assays.  
 
Table 4.3. Inter-day accuracy and precision of 13C-OEA quantification in rat plasma, brain and liver 
tissue based on quality control samples. 
Matrix 
Nominal 
conc  
(ng/mL  
or ng/g) 
Inter-day (n=3) 
Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
Plasma 
0.78 0.72 92.3 3.7 
7.5 7.29 97.2 2.6 
20 20.1 100.7 1.4 
Brain 
2.34 2.27 97.2 2.3 
11.3 10.8 95.3 5.1 
30 29.1 97 4.2 
60 63.5 105.8 3.1 
Liver 
2.34 2.09 89.2 4.7 
11.3 10.0 88.8 4.1 
30 27.4 91.2 5.7 
60 56.5 94.2 3.8 
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Table 4.4. Intra-day accuracy and precision of 13C-OEA quantification in rat plasma, brain and liver tissue based on quality control samples.    
Analyte Nominal 
conc 
(ng/mL 
or ng/g) 
                   Intra-day 1 (n=3)                     Intra-day 2 (n=3)                    Intra-day 3 (n=3) 
Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
 Mean  
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
 Mean      
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
Plasma 0.78 0.71 90.3 2.2  0.70 89.0 6.5  0.75 95.6 3.7 
 7.5 7.30 97.3 2.4  7.10 94.7 5.2  7.48 99.8 3.0 
 20 20.3 101.4 3.2  19.8 98.7 3.5  20.3 101.5 3.6 
Brain 2.34 2.23 95.3 3.9  2.33 99.5 4.8  2.26 96.5 4.0 
11.3 10.5 92.9 2.1  11.4 101.1 3.3  10.4 92.1 6.4 
30 28.4 94.7 3.8  30.5 101.6 4.0  29.1 94.6 2.5 
60 63.8 106.4 2.6  65.3 108.9 3.5  63.5 102.3 3.2 
Liver 2.34 2.04 87.1 2.8  2.02 86.0 5.4  2.20 93.7 4.5 
11.3 10.5 93.0 2.3  9.73 86.5 3.3  9.88 87.8 3.9 
30 28.9 96.2 4.1  27.4 91.3 7.8  25.8 85.8 6.6 
60 58.7 97.8 2.8  54.4 90.7 2.5  56.4 94.0 2.1 
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4.5.3 Pharmacokinetic Evaluation of OEA Biodistribution and In Vivo Stability 
Cubosomes formulated with 13C-OEA were used to determine biodistribution and biological 
stability of 13C-OEA after intravenous administration.  
4.5.3.1 13C-OEA Cubosome Dispersion Characterisation 
Dynamic-light scattering was used to determine the average size and polydispersity of the 
cubosome dispersion used for the in vivo experiments (Table 4.5). These parameters were found 
to be comparable to those reported previously258 suggesting that the 13C-OEA formulation was 
representative of cubosome dispersions formulated with 12C-OEA. The 13C-OEA stock 
available was very limited, so more intensive characterisation (e.g. with SAXS) was not 
possible.  
Table 4.5. Particle characteristics of the cubosomes dispersion used for the experiments (10% 13C-OEA-
phytantriol cubosomes stabilised with Tween 80). Data shown is the average ± standard deviation of 
triplicate measurements taken from the duplicate samples that were able to be taken from the stock 
dispersion at the end of the in vivo experiment. 
 Zeta average 
(d.nm) 
PDI 
10% 13C-OEA-phytantriol 
cubosomes-Tween 80 
133 ± 2 0.216 ± 0.013 
 
4.5.3.2 Pharmacokinetic Analysis 
The plasma, brain and liver tissue concentrations of 13C-OEA after intravenous administration 
as cubosomes or control solution, along with the respective brain/plasma and liver/plasma ratios 
are shown in Figure 4.12. Variability within some groups was quite significant, making 
interpretation of trends difficult. Despite not being statistically significant, average plasma 13C-
OEA concentrations (Figure 4.12A) trended towards decreasing over time after administration 
of control solution, as was to be expected following intravenous administration. Concentrations 
following cubosomes trended towards fluctuating a bit more. Interestingly, the concentration 
of 13C-OEA did not fall below the LLOQ at any point up to 90 minutes suggesting a persistence 
of low levels of the molecule in the plasma after administration of either formulation. With 
respect to differences between cubosomes and control solution at each time point, the only 
statistically significant difference was found at 90 minutes after administration, with cubosome 
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13C-OEA concentrations being lower than those after control solution, contrary to what was 
hypothesised. This same difference is suggested by the trends at earlier time points as well and 
the decreasing p values suggest it became gradually more significant over time.  
Brain concentrations (Figure 4.12B) showed a similar trend, although many values were below 
the LLOQ in these samples and were zeroed for analysis in the Figure. The data including the 
values below the LLOQ is shown in Appendix Q for transparency and a general agreement 
with the plasma trends supports the credibility of the measurements, despite them not being 
able to be quantified within the specified limits of the LC-MS assay. As could be expected, the 
average brain/plasma ratios (Figure 4.12D) showed a similar trend towards a slightly higher 
ratio of 13C-OEA in the brain after control solution compared with cubosomes, however all 
ratios were below 0.2 indicating that neither exogenous formulation led to a particularly good 
accumulation of 13C-OEA in the brain compared with plasma.  
Liver concentrations (Figure 4.12C) showed a similar trend, but no significant differences were 
found between cubosomes and control at any time point in this data set. This was also true for 
the liver/plasma ratio (Figure 4.12E), however, the trend over time was more interesting here 
in that the average ratio increased at 60 minutes after administration of cubosomes, but not 
control solution, to produce the only statistically significant difference within a formulation 
type over time in any of the data. Hence, the distribution of cubosomal 13C-OEA to the liver 
was greater than to the brain, the former exhibiting a significant elevation at 60 minutes which 
persisted until 90 minutes, although it never exceeded 1.0.  
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Figure 4.12. Pharmacokinetics of 13C-OEA in rats up to 90 minutes after intravenous administration of  
cubosomes (13C-OEA 10% w/w with phytantriol) (blue) or control solution (orange) at a concentration 
of 2 mg/mL. (A) Plasma concentration, (B) Brain concentration, (C) Liver concentration, (D) Brain to 
plasma ratio, (E) Liver to plasma ratio. Values represent means and error bars represent standard 
deviation. Values below the LLOQ of the assay are presented and analysed as zeroes. P-values are 
shown for comparison between cubosomes and control solution at a given time point (two-tailed t-test) 
and between each of the formulations over the different time points (one-way ANOVA). With respect to 
the latter, coloured bars (matched to the symbol colour) represent statistically significant differences 
determined by post-hoc analysis (Tukey’s).  
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4.5.4 Small Angle X-ray Scattering (SAXS) Evaluation of Structural Kinetics in Plasma 
SAXS was used to evaluate the in vitro structural stability of OEA cubosomes upon incubation 
in rat plasma at 37 ºC to supplement the pharmacokinetic and pharmacodynamic studies. 
Control measurements in the absence of plasma are presented in Figure 4.13. These were taken 
to confirm the initial cubosome structure of the nanoparticles prior to the experiment as well as 
to ascertain any potentially confounding effect of the raised temperature on them, as previous 
reports have presented data at ambient temperature only258,277. The consistent Bragg peak 
ratio276 of √2:√4:√6 shows that the Im3m structure of the cubosomes was unaffected, however, 
the lattice parameters all decreased slightly over the course of the experiment from 102.5, 105.8 
and 125.8 Å to 99.2, 105.2 and 119.4 Å for phytantriol, OEA 10% and OEA 30% cubosomes, 
respectively (Panels B to D).  
The effect of plasma incubation on the OEA cubosomes (0%, 10% and 30% OEA) is presented 
in Figure 4.14. All of the cubosomes (Panels B to D), regardless of OEA content, rapidly 
transformed into hexosomes after in vitro incubation in plasma, as indicated by the appearance 
of Bragg peaks with a spacing ratio of 1:√3:√4. An initial disappearance of the cubic phase was 
seen at the first measurement in all samples which can be interpreted as a reduction in the 
intensity of the cubic phase below the background signal, while the intensity of the hexagonal 
phase subsequently increased towards exceeding the background signal as a result of the 
relative change in the concentration of each particle type. Further evidence of this is provided 
in Appendix R which shows the effect of incubating cubosomes at different plasma 
concentrations in order to effectively slow the transition to a rate at which it could be observed. 
The emergence of the hexagonal peaks appeared to take slightly longer (75 minutes compared 
to 50 minutes) in the 30% OEA formulation (Panel D), suggesting that a greater proportion of 
OEA was associated with a delayed transformation. Also interesting was that the lattice 
parameters of the hexosomes at 420 minutes (at which the samples were deemed to have 
equilibrated) were different for each formulation (58.8, 60.0 and 64.3 Å), increasing with the 
proportion of OEA, as was the case for the original cubosome formulations mentioned earlier. 
This suggested that OEA remained associated with the particles during the transition rather than 
the possibility of it being exchanged for other plasma lipids. The control data of water mixed 
with plasma (Panel A) confirms that no other liquid crystalline structures were present in plasma 
in the absence of the added dispersion that could have contributed to the result.  
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Figure 4.13. SAXS studies of OEA cubosomes in 50% Milli Q water incubated at 37 ºC for 420 minutes. 
Plots from left to right show data for Milli Q water, Phytantriol-Tween 80 cubosomes, 10% OEA-
Phytantriol-Tween 80 cubosomes and 30% OEA-Phytantriol-Tween 80 cubosomes. The blue plots 
represent the initial measurement for each sample at ambient temperature. Subsequent measurements 
start at 30 minutes after mixing for consistency with plasma samples (10 minutes after placing in the 
temperature-controlled holder) and were taken at 10 minute intervals from 30-60 minutes, 15 minute 
intervals from 60-180 minutes and 30 minute intervals from 180-420 minutes. LP = lattice parameter.  
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Figure 4.14. SAXS studies of OEA cubosomes in 50% rat plasma incubated at 37 ºC for 420 minutes. 
Plots from left to right show data for Milli Q water, Phytantriol-Tween 80 cubosomes, 10% OEA-
Phytantriol-Tween 80 cubosomes and 30% OEA-Phytantriol-Tween 80 cubosomes. The orange plots 
represent the appearance of the hexagonal phase. Measurements start at 30 minutes after mixing and 
were taken at 10 minute intervals from 30-60 minutes, 15 minute intervals from 60-180 minutes and 30 
minute intervals from 180-420 minutes. LP = lattice parameter.  
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4.5.5 Cubosome Nasal Toxicity Evaluation: Preliminary Histological Screening   
The intention of the second part of this chapter was to investigate whether the nasal route 
offered any advantage to the delivery of OEA to the brain by offering a potential direct route 
avoiding the complex barriers of the systemic circulation, as were demonstrated in the results 
above. The first step towards achieving this aim was to study the effect of OEA cubosomes on 
the nasal epithelium in order to select an appropriate dose for testing.  Representative images 
of the effects of OEA cubosomes on the olfactory epithelium at its maximum concentration 60 
minutes after administration are shown in Figure 4.15. In the cubosome trial, there is clear 
damage to the integrity of the epithelium at the maximum dose of cubosomes, as indicated by 
degeneration, loss of apparently anuclear, necrotic cells and accumulation of debris and exudate 
in the lumen (Panel E). Free drug suspension (at an equivalent concentration of OEA) was also 
tested to elucidate the potential cause of the damage from the cubosomes, the images of which 
are also shown in Figure 4.15, Panels C and F.  In comparison to the control nostril (Panel C), 
blood vessels appear to be dilated in the lamina propria suggesting inflammatory irritation and 
the epithelium appears uneven with some minor cell exfoliation (Panel F), but this is not on the 
scale seen with the cubosomes. This suggests the damage was primarily attributable to the 
presence of the cubosomes or the cubosome-forming lipid, phytantriol, rather than any other 
formulation component.  
Behaviour after intranasal administration was recorded to supplement histological data. The 
most significant behaviour noted after administration of the highest dose (20 mg/mL dispersion) 
was a frequent narrowing of the eye on the side the nostril the formulation was administered to, 
likely due to the discomfort of the liquid in the upper nasal passage. This was not seen after 
saline administration or the control dispersion, however, suggesting it was not purely related to 
the presence of liquid and that the cubosome dispersion at this concentration was indeed irritant. 
Note that the powder in Chapter Three also did not have this effect. A small amount of 
porphyrin discharge was noted coming out of the treated nostril about 15 minutes after 
administration of the cubosomes, along with some sneezing and nose twitching further 
supporting that this dose was unsuitable for intranasal administration.  
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Figure 4.15. Representative histological images of the olfactory epithelium of rats 60 minutes after 
intranasal administration saline (D), OEA cubosome dispersion at the maximum concentration of 20 
mg/mL total lipid (E), or equivalent concentration of free OEA suspension (F). The corresponding 
panels on the left (A-C) show the control (untreated) nostril of each rat. Scale bars = 50 µm. Arrows in 
panel E indicate degeneration, loss of anuclear, necrotic cells and accumulation of debris and exudate 
in the lumen. Arrows in panel F indicate uneven areas of the epithelium and some minor cell exfoliation. 
 
In order to determine a dose that was suitable, two further concentrations were tested; 10 mg/mL 
and 5 mg/mL (Figure 4.16). A disruption of the epithelium compared with control was still 
evident at 10 mg/mL (Panels A and C), albeit lesser, but not at 5 mg/mL (Panels B and D). 
Observation of subject behaviour after administration was consistent with this finding, so the 
latter dose was selected for use in subsequent studies. 
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Figure 4.16. Representative histological images of the olfactory epithelium of rats 60 minutes after 
intranasal administration of OEA cubosome dispersions at concentrations of 10 mg/mL and 5 mg/mL 
total lipid. Panels A and B show the untreated epithelium in the control nostril and panels C and D show 
the epithelium in the nostril exposed to the cubosome dispersion. Scale bars = 50 µm. 
 
4.5.6 Evaluation of Pharmacodynamics of OEA Cubosomes After Intranasal 
Administration  
To determine whether OEA cubosomes had an effect on seizure threshold after intranasal 
administration, MEST trials were conducted with the aim of testing three time points; 15, 30 
and 60 minutes after administration. The earlier time points were investigated as the in vivo 
time scale of protection of OEA from hydrolysis in cubosomes after intranasal administration 
was uncertain, but hypothesised to fall within this range.  
The CC50 and control responses to stimulation for these studies are shown in Figure 4.17. The 
rats in the 60 minutes group had a calculated CC50 of 66 mA (18 – 240 mA) (Figure 4.17A), 
which translated to 39 % of rats exhibiting HLE after intranasal saline administration in the 
experimental control data (Figure 4.17B). The determination of the CC50 at earlier time points 
presented a more complex situation as the residual effect of the isoflurane anaesthetic was found 
to be significant. This meant that at the 15 minute time point, a series of eight rats stimulated 
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from 50 mA up to 132 mA yielded no cases of HLE rendering the CC50 indeterminable (Figure 
4.17C).  The remaining nine rats in the group were therefore used to estimate the CC50 at the 30 
minute time point instead (Figure 4.17D). While the influence of isoflurane was still evident at 
this time point, a CC50 of 76 mA (39 – 148 mA) was able to be calculated and used for 
subsequent studies, however only 12 % of saline-treated rats subsequently exhibited HLE 
(Figure 4.17E) which heavily supressed the resolution for detecting an anti-seizure effect of 
OEA. All saline-treated rats in both groups displayed FLE after all stimulations.   
 
 
 
Figure 4.17. Determination of the CC50 and baseline response to stimulation at the CC50 in the batches 
of rats that participated in the study of intranasal OEA cubosomes (7.5 mg/mL OEA). Experimental data 
from the up and down method is shown for 60 minute (A), 15 minute (C) and 30 minute (D) time points, 
where “X” represents HLE and “O” represents no HLE. The CC50 was indeterminable at 15 minutes, 
so only the baseline responses of the rats when stimulated at the calculated CC50 60 minutes (B) and 30 
minutes (E) after intranasal saline administration are shown. The black bar represents the percentage 
of rats which exhibited HLE at the calculated CC50 and the grey bar represents those which exhibited 
FLE (with or without HLE).  
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As shown in Figure 4.18, no significant anti-seizure (or pro-seizure) effect was observed in the 
MEST test after intranasal administration of a single dose of OEA cubosomes at 30 minutes (p 
= 1) or 60 minutes (p = 0.93). At 60 minutes, a 29 % reduction in the incidence of HLE was 
observed, while at 30 minutes, a 33 % reduction was observed. These results were effectively 
nullified however, by an increase in the incidence of HLE (11% and 7% respectively) which 
was also observed at each time point. No change in the incidence of FLE was seen.  
 
Figure 4.18. Effect of intranasal OEA cubosomes on HLE (black) and FLE (grey) at the group CC50 
currents 30 minutes (n=4 and n=17 respectively) and 60 minutes (n=9 and n=17 respectively) after 
treatment administration. Data is presented as percent change in response with respect to intranasal 
saline treatment in the same rats. Animal numbers and the method used to calculate the percentage 
difference are shown in Appendix C. Note that FLE is not visible in the above Figure as no change was 
found in this experiment.  
 
4.5.7 Evaluation of the Histological Effects of OEA Cubosomes on the Nasal Mucosa of 
Tested Animals  
Nasal tissue from animals that participated in the seizure studies was histologically processed 
in order to examine the integrity of the olfactory epithelium throughout the experiment (Figure 
4.19). Interestingly, a slight disruption to the epithelium was noted 60 minutes after 
administration of OEA cubosomes at 5 mg/mL (Panel B) which was not detected in the earlier 
dose optimisation studies. This was, however, minor and at three days after treatment (Panel 
D), it can be seen that the epithelium was once again comparable with that after saline 
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suggesting that no significant detrimental effects resulted from the intranasal administration of 
the formulation.  
 
 
Figure 4.19. Representative histological images of the olfactory epithelium of rats that participated in 
the 60 minute MEST studies with OEA cubosomes. Images show short-term effects of the formulation 
on the olfactory epithelium in rats stimulated at 60 minutes after administration of saline (A) and OEA 
cubosomes (B) and longer-term effects at three days after administration of saline (C) and OEA 
cubosomes (D). Scale bars = 50 µm.  
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4.6 Discussion 
Our lab group has previously reported formulation of OEA cubosomes with two different steric 
stabilisers; Poloxamer 407 and Polysorbate 80 (more commonly known by their respective 
trade names Pluronic F127® and Tween 80®). The latter were chosen for use in this Chapter as 
Polysorbate 80 has been suggested to enhance the delivery of cubosomes, as well as alternative 
nanoparticles, to the brain258,277–280. Azhari et al.281 showed an increase in fluorescence in the 
zebrafish brain after administration of phytantriol cubosomes stabilised with Tween 80® 
compared with control and other stabilisers, while the present author’s own extracurricular 
study of selachyl alcohol cubosomes stabilised with Tween 80® showed an enhanced in vivo 
delivery of drug to the brain compared with selachyl alcohol hexosomes stabilised with Pluronic 
F127® (unpublished data).  Furthermore, Younus et al.271 studied the in vitro hydrolysis of OEA 
cubosomes formulated with Tween 80® and Pluronic F127®, as mentioned earlier, and reported 
that both protected the OEA equally well from hydrolysis compared with control.   
This Chapter began by investigating the pharmacodynamic effects of OEA cubosomes in the 
MEST seizure model after intravenous administration in order to determine if OEA had an 
effect on seizure threshold as hypothesised. The intravenous route was chosen as the OEA could 
be administered directly into the systemic circulation without ambiguity, at a dose that an ASD 
would be likely to show some effect99. The idea was that if an effect on seizures was seen, the 
data could act as a positive control for the effect of OEA, similar to the role played by the 
intravenous phenytoin trial in Chapter Two. In light of the discussion of anti-seizure effect 
screening in Chapter One, it was initially considered that our seizure model may not be able 
to detect the effects of OEA (being an untested molecule with an uncertain mechanism), but 
based on previous studies showing positive results of NAEs in the MES model239,241, it was 
expected that an effect of OEA should be detected by the MEST model, assuming that the 
mechanism was similar.  The result of this trial, however, was that no clear effect of OEA was 
seen.  
The simplest conclusion from this would be that OEA does not have an effect on seizure 
threshold after intravenous administration. To be more specific, one might say that it does not 
have an acute effect on seizure threshold after a single intravenous dose of 7.5 mg/kg in 
cubosome form, which opens up a realm of possibilities.  Firstly, it could be that the dose level 
tested (limited by the volume of injection and concentration of the cubosome dispersion) was 
inadequate to exert an anti-seizure effect. It is true that previous studies of NAEs have used 
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much higher doses (between 25 and 300 mg/kg), but they did not employ protective drug 
delivery systems to subvert hydrolysis like in this study. Nonetheless, given that this was a 
MEST test (which tested very close to the seizure threshold) rather than a supramaximal MES 
test (as was used in the previous NAE studies and is used in standard ASD screening), some 
noticeable effect on threshold would probably be expected if the molecule exhibited clinically 
relevant anti-seizure properties. Next, repeated dosing was not tested in this study and it could 
be that the effects of OEA might only be noticeable after chronic administration. This theory 
could be substantiated by the relatively slow genomic mechanisms proposed for OEA action242 
and the potential link to the ketogenic diet discussed earlier254. However, the trials of the other 
aforementioned NAEs suggested an acute effect was possible239–241, which could lend more to 
dose being the major contributor to the lack of effect seen in this study.  
The other major possibility, and a reason the dose might not have been adequate, was that the 
cubosomes may not have protected OEA from hydrolysis and/or delivered it to the brain, 
thereby depriving OEA of the chance to have an anti-seizure effect. As mentioned earlier, 
neither of these parameters had been investigated in vivo prior to this study. Given that this 
Chapter was, in essence, a study of a new drug delivery system, further studies were conducted 
to evaluate the likelihood that the inadequate delivery of OEA was the cause of the negative 
result. If this was the case, it might be something which could be improved upon (for example, 
by exploring a direct intranasal route to the brain to bypass the systemic circulation, as was 
planned for later in the Chapter) in contrast to the possibility that OEA simply had no 
pharmacological anti-seizure action which would make it useless for this application.  
The first study performed looked at the pharmacokinetics of OEA administered in cubosomes. 
As OEA is an endogenous molecule, it is already present at varying levels in plasma and body 
tissues, so a carbon-labelled isotope of the molecule (13C-OEA) formulated into cubosomes was 
used to track the exogenously administered compound. The concentration of 13C-OEA was 
measured in the plasma into which it was injected, the brain to which it was targeted and finally 
the liver, which is thought to be a potential generic site of lipid nanoparticle accumulation282,283. 
A control solution was also tested to provide the baseline pharmacokinetics of exogenously 
administered 13C-OEA for comparison.    
As shown in Figure 4.12, the result was that 13C-OEA appeared to be rapidly degraded in 
plasma, brain and liver by the time points tested, the first of which was 15 minutes, as in the 
pharmacodynamic study. At a glance this seems to strongly support the speculation above that 
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the reason no anti-seizure effect was seen was because the OEA was being rapidly degraded, 
despite the hypothesised protection afforded to it by the cubosome structure. In contrast to the 
in vitro assay of Younus et al.271, the cubosomes were found to offer no additional protection 
against hydrolysis compared with the same control solution and there was even a suggestion 
that hydrolysis was increased by the cubosome formulation. The variability in the results 
however meant that this trend was generally not statistically significant. Despite not exhibiting 
superiority to control solution with regards to protection from hydrolysis, the cubosomes at 
least provided non-inferior 13C-OEA concentrations in an aqueous formulation, unlike the 
heavily organic-solvent based control.  
Out of all the body compartments studied, the highest concentrations of 13C-OEA were found 
in the plasma at all time points. While this is perhaps not surprising given that the 13C-OEA 
was administered intravenously, it suggested that accumulation in the brain (as desired) or the 
liver (as hypothesised, but not desired) was not significant. One must consider that it is possible 
the 13C-OEA was rapidly delivered to either of these tissues, but was equally rapidly hydrolysed 
before the first time point of 15 minutes. In this respect, it would have been interesting to 
investigate levels of the labelled hydrolytic product of 13C-OEA as well, namely 13C-
ethanolamine as deduced from the predominant m/z of the synthesised 13C-OEA (Figure 4.6), 
but a labelled standard was unavailable. Detection with LC-MS would also likely have been a 
complex task, given the low molecular weight of ethanolamine and its potential to be rapidly 
conjugated to other lipid molecules in tissues. An alternative explanation for the results above 
could be preferential distribution to other tissues that were not analysed. This would, however, 
seem less likely in light of the abovementioned data indicating that Tween 80®-stabilised 
cubosomes are effective at delivering drug to the brain and other studies describing non-specific 
liver accumulation of lipid nanoparticles due to the enhanced permeability and retention (EPR) 
effect282,283.  
Overall, trends in the data were difficult to describe conclusively due to inter-subject variability. 
The design of this study necessitated the use of individual rats for each time point in order to 
obtain plasma, brain and liver for analysis at the designated time point after 13C-OEA 
administration. This introduced potential for variability due to individual rat characteristics 
such as capacity to metabolise 13C-OEA and the way the cubosomes would be processed in 
vivo. Also important is that each data point represented an individual tail vein injection (a 
technically difficult procedure), so the dose that was successfully injected into the circulation 
may have varied. To eliminate these variables, a suggestion for similar studies in the future 
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would be to attempt analysis at all time points (and additional earlier ones) in each animal for 
plasma and brain. For plasma, this would involve cannulation of the tail vein and blood 
sampling at the desired time points. Brain would represent a more complex set up, for instance 
involving microdialysis, which would require some expertise in the procedure. Such a method 
would also reduce the quantity of 13C-OEA required, allowing higher doses of cubosomes to be 
explored, such as that equivalent to the dose used in the pharmacodynamic study which may 
also have an influence on the pharmacokinetics, as the current analysis is based on an 
assumption of linear pharmacokinetic behaviour between 1 mg/kg and 7.5 mg/kg doses.  
The analytical method for measuring 13C-OEA itself had some complexities. What should have 
been a straightforward LC-MS assay was slightly complicated by a background signal for the 
13C-OEA ion pair. This signal was found to be consistently proportional to the background OEA 
(i.e. 12C-OEA) signal intensity which was present to varying degrees in all the tissues analysed 
(Figure 4.9). Preliminary experiments (data not shown) determined that the background signal 
was also found at the same proportion in a solution of commercially synthesised OEA (≥98% 
purity). Therefore, it was concluded that it was most likely to be due to production of the 
[M+2H]2+ ion of OEA in the mass spectrometer, rather than a true background presence of 13C-
OEA. In further support of this, in order to give this m/z signal, background 13C-OEA molecules 
would have to consistently constitute a 13C atom on the ethanolamine portion of the molecule, 
as was determined to be the case for the synthesised compound. Furthermore, they would have 
to be present in a consistent proportion to OEA in all tissues and commercially synthesised 
product. All of this seems unlikely given the natural abundance of 13C in the environment is 
estimated to be only 1%284. Nonetheless, it was impossible to prove in this study, as the blank 
tissues always contained background OEA.   
Despite this complication, the consistent proportion of the signal allowed a correction to be 
applied to the data (Equation 4.1) which yielded a reproducible analytical method with 
satisfactory confidence limits down to the lowest concentration possible with this limitation 
(Appendix P). To produce a simpler method for any future studies that may occur, the 
recommendation of this author would be to explore firstly whether a different mass 
spectrometer would lead to different ionisation patterns and removal of the background signal 
and secondly whether 13C-OEA could be synthesised with the 13C label on the oleic acid portion 
of the molecule, rather than the ethanolamine portion which would be expected to produce an 
alternative ion pair (i.e. m/z = 327/62 rather than 327/63) that would not overlap with the 
[M+2H]2+ ion of OEA. Furthermore, with reference to the discussion above, simultaneously 
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measuring the hydrolytic by-product 13C-oleic acid might also be possible to further study the 
contribution of degradation.  
The quantitative data discussed above had some limitations. Whether it was due to technical 
complexities, method limitations, hydrolysis or distribution, brain concentrations, and 
sometimes liver concentrations, were frequently below the lower limit of quantification of the 
method. The data to which this applies is treated as zeroes in Figure 4.12 as they could not be 
quantified within the limits of the assay, however, a presentation of the actual measured values 
is provided in Appendix Q for transparency to the reader.  
It is worth considering how technical limitations may have contributed to the results of this 
experiment. At each time point there was an unavoidable delay between euthanasia of the 
animal and freezing of the tissue due to the need for dissection and centrifugation of plasma. 
This meant the tissues were somewhere between body and room temperature for up to 10 
minutes post-mortem before being frozen with dry ice. In this time, hydrolytic enzyme activity 
may well have continued, reducing the concentration of 13C-OEA in the tissues. The multiple 
time point experiment suggested above for future studies may provide an advantage in 
overcoming this, as it could allow more rapid freezing after sampling. Furthermore, sampling 
from a live animal would avoid the rapid increases in NAE concentrations reported after 
euthanasia285 which could also have had an influence on the result and likely contributed to the 
high intensity background OEA signal found in the brain (Figure 4.9) as suggested by the wide 
range of endogenous OEA levels reported in post-mortem brains286–288. Another point where 
further enzymatic degradation may have occurred post-mortem was the necessary sample 
thawing during preparation for LC-MS analysis. Samples were kept on ice wherever possible 
during this process, however, so enzyme activity is less likely to have had a major influence at 
this point.   
Finally, the characteristics of the cubosomes themselves must be considered. The nanoparticles 
have not been formulated with 13C-OEA to date and while the isotope should have theoretically 
demonstrated the same physicochemical properties as regular OEA, it was possible that small 
differences in behaviour could have occurred, as has been reported for isotopic variants of other 
compounds289,290. To assess formulation characteristics, particle size and PDI were measured 
and found to be similar to that reported by Younus et al.258, suggesting the formulation was 
representative of the previously reported OEA cubosome dispersion. The structure of the 
particles was unable to be verified by SAXS or Cryo-TEM due to very limited sample 
availability and the formidable cost of obtaining more of the compound, so the preservation of 
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particle structure remains unconfirmed when interpreting the results of this study. The second 
consideration regarding the particles is that due to the limited availability of the compound, the 
cubosomes tested in the pharmacokinetic study comprised only 10% OEA compared with the 
30% OEA cubosomes used in the pharmacodynamic study, which one may argue could have 
affected their representation of the intravenous behaviour of the cubosomes in the latter. 
Considering that Younus et al.271 reported greater in vitro protection of OEA from hydrolysis 
by 10% OEA cubosomes compared with 30% OEA cubosomes (unpublished data), the 
evidence so far would seem to suggest that the pharmacokinetic data would, if anything, provide 
an overestimation of the protective effect of the OEA cubosomes in the pharmacodynamic 
study. SAXS data from this Chapter which looked at the structural stability of both types of 
cubosomes during in vitro incubation with rat plasma suggested that their behaviour was 
comparable, as is discussed next.   
SAXS data showed that both the 10% and 30% OEA cubosomes used in the abovementioned 
intravenous studies rapidly transform into hexosomes after in vitro incubation in rat plasma 
(Figure 4.14). Control studies (Figure 4.13) showed that this was not related to the increased 
incubation temperature, which only had the effect of slightly decreasing the average lattice 
parameter of the cubosomes, as has been reported elsewhere for phytantriol cubosomes 
stabilised with Pluronic F127® 290–295. This raises the question of whether this structural 
transition might be at least in part the cause of the apparent poor delivery of OEA to the brain 
and protection from hydrolysis in the plasma. The hexagonal phase is typically associated with 
sustained drug release given that it is thought to be a ‘closed’ structure relative to the ‘open’ 
structure provided by cubosome water channels268,296. This would lead one to think that perhaps 
transformation to a hexagonal particle might be an aid to the protection of OEA, but the 
pharmacokinetic studies in this Chapter do not seem to agree with that.  
The first consideration is whether the structural transition could be due to the OEA in the 
cubosome being accessed by enzymes and hydrolysed to oleic acid. Previous studies have 
shown that formulation of phytantriol cubosomes with >10% oleic acid induces a structural 
transition to hexosomes at neutral pH297. Pluronic F127® was the stabiliser used in the 
referenced study, but the phenomenon has been replicated in this author’s own lab with Tween 
80® stabilised cubosomes to show the same effect induced by the charged oleic acid increasing 
negative curvature of the phytantriol bilayer (unpublished data). While a reasonable theory, it 
is undermined by two other elements of the data – firstly, phytantriol cubosomes alone (in the 
absence of OEA) also undergo the same transition to hexosomes in plasma (Figure 4.14) and 
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secondly, 30% OEA cubosomes appear to undergo the transition at a slightly slower rate than 
10% which is opposite to what might be expected due to the higher proportion of OEA.  
The apparent decrease in the rate of cubosome transformation to hexosomes in plasma with 
increasing OEA composition could possibly be explained by the relative curvature of the 
cubosome bilayers. All structures exhibit an Im3m symmetry, which emanates from a less 
negatively curved lipid bilayer due to the insertion of the oleoyl chain of Tween 80® 277. Upon 
addition of OEA, the lattice parameter of the cubosomes increases as the bilayer becomes even 
less negatively curved upon the incorporation of more oleoyl chains from more OEA 
molecules258. From this, it can be inferred that in order to transition to the state of high negative 
curvature that is the hexagonal phase, a greater change is needed in the less curved bilayer 
containing more OEA and hence more time. We can also infer another finding from the slower 
rate of transition with increased lattice parameter in support of the above paragraph in that the 
transition is likely not due to hydrolysis of OEA to oleic acid. This is because larger water 
channels would theoretically allow greater access to enzymes and a greater rate of hydrolysis 
and transition to the hexagonal phase (unless of course the emergence and relative effect on the 
bilayer of oleic acid was outweighed by the lesser negative curvature of the bilayer) as described 
by Younus et al. in vitro271.  
It should be noted that in order to achieve sufficient resolution of SAXS data, it was necessary 
to measure samples at a concentration of only 50% plasma relative to cubosome dispersion, as 
has been reported previously266. This means that while the data shows the relative structural 
kinetics of the different cubosomes, the actual time scale over which such transformations 
would occur would be much faster in 100% plasma in vivo298,299 and could be expected to have 
taken place within the time range at which pharmacodynamic and pharmacokinetic testing took 
place. This concept is illustrated with supplementary data in Appendix R which was obtained 
with phytantriol Tween 80® cubosomes and shows the effect of changing plasma concentration 
on the rate of transformation, but not the actual outcome. Structural instability may therefore 
have played a role in the apparent ineffectiveness of OEA cubosomes at protecting OEA and 
delivering it to the brain in this study and further investigation into the causes of the structural 
instability and how it may be prevented would no doubt be an interesting avenue of future 
research.  
As an entry point, a parallel study performed with OEA cubosomes stabilised with Pluronic 
F127® (the other OEA formulation characterised by Younus et al.258) is shown in Appendix O. 
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It also demonstrated a transition of cubosomes on incubation with plasma, however not to 
hexosomes, but a single broad peak which was not able to be unequivocally classified. Certainly 
though, the dispersion did not maintain the organised internal structure of cubosomes or 
hexosomes, suggesting that this stabiliser may be less effective compared with Tween 80® in 
maintaining the structural stability of intravenously administered liquid crystalline 
nanoparticles. It must be noted that the results are in contrast to previously reported data on 
phytantriol-Pluronic F127® cubosomes studied in human plasma which transformed into 
hexasomes266. While the source of plasma immediately appears as a potential explanation for 
the difference, it must also be considered that the phase homogeneity of the original cubosome 
formulation in the study was questionable. Whatever the case, these studies indicate that the 
appetite for discovering how to control the structural stability of liquid crystalline nanoparticles 
in biological media must continue to grow in an attempt to optimise and translate such delivery 
systems successfully in the future.   
The second part of this Chapter investigated intranasal delivery of OEA cubosomes and ended 
up holding more weight than was hypothesised. It was initially thought that an anti-seizure 
effect of some degree would be observed after intravenous treatment with OEA cubosomes, but 
it was not, and the in vivo and in vitro studies into intravenous delivery of these nanoparticles 
unveiled a number of complexities. At the centre of these was the important question of whether 
inadequate protection or inadequate delivery (or both) was the cause of this failure. Hence, 
attention was shifted to the nose, as a potential method to deliver OEA to the brain while 
bypassing the route through the plasma and across the blood-brain barrier. Use of cubosomes 
as a delivery system was still important here due to the poor solubility of free OEA in aqueous 
vehicles and the constrictive volume limitations for intranasal dosing.  
The results of the intranasal OEA cubosomes MEST studies, however, presented their own 
complexities. The initial study at 60 minutes after administration had a less than optimal, but 
still acceptable, 39 % of saline-treated rats displaying HLE at the statistically determined CC50, 
however, the effect of drug treatment was inconclusive with small changes in the incidence of 
HLE in each direction, which were expectedly not statistically significant (p = 0.93). From this 
it could only be concluded that if there was an effect of OEA, it seemed to rapidly abate by 60 
minutes. Subsequently, an attempt was made to check for a rapid onset effect from the OEA, 
but it was here that a major limitation was encountered in the form of confounding by the 
anaesthetic isoflurane. At 15 minutes after administration, a clear anti-seizure effect of the 
anaesthetic was evident, despite the rats having appeared to have regained function, so much 
so that it was not possible to determine the CC50 (Figure 4.17C). While a small number of rats 
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showed HLE at 30 minutes after administration, enabling a CC50 of 76 mA to be calculated 
(Figure 4.17D), this current was higher than that encountered in any other study in this thesis 
indicating that the effect of isoflurane was still significant. The results of the drug trial looked 
very similar to that at 60 minutes, and were likewise insignificant, but the particularly poor 
resolution due to the confounding meant that the outcome could not provide an adequate answer 
to the question at hand. As discussed in Chapter One, almost all studies report the use of 
anaesthesia of some sort in order to administer intranasal anti-seizure treatments to the olfactory 
region of the nasal cavity. Therefore, at this stage of science, it is difficult to see how such a 
procedure could be performed without it in order to credibly test rapid effects after intranasal 
delivery to the olfactory region in a simple screening model such as that used in this thesis. 
Nonetheless, it would be a very useful tool for future studies to investigate and should be 
addressed in order to increase the quality of the intranasal anti-seizure drug delivery literature.  
The OEA cubosomes used in this Chapter were found to clearly disrupt the olfactory epithelium 
at the highest concentration (Figure 4.15E), meaning the dispersion had to be diluted to optimise 
it for nasal administration. Unfortunately, the volume limitation of the nasal cavity meant that 
dilution could not be compensated for by increasing volume, so total dose had to be reduced. 
The data once again support the argument raised in Chapter One and Chapter Three that the 
effect of any intranasal formulation or delivery system on the nasal epithelium should be 
histologically evaluated and raises the call to the field of pharmaceutical sciences to ensure 
quality data is presented alongside any pharmacokinetic or efficacy studies as a fundamental 
means of validation.  
The intranasal histology study of this Chapter is also interesting from the perspective of 
cubosome toxicity to cells, which the current literature assesses heavily through the use of in 
vitro cell lines293,300–303, but with little consideration as to how this translates in vivo. The closest 
studies found to those in this thesis are those which examine corneal histology of glyceryl 
monooleate (GMO) based cubosomes304,305, but only a single concentration of cubosomes, 
much lower than those used in this Chapter, is tested (or at least selectively presented) in each, 
offering scarce room for comparisons to be made. The comparison to a control suspension 
containing all components but the essential cubosome-forming lipid phytantriol (Figure 4.15F) 
suggested that either the cubosomes themselves or the phytantriol were the major cause of 
epithelial disruption rather than the other components of the dispersion. This is supported by 
supplementary histological data from preliminary testing of phenytoin-loaded selachyl alcohol 
cubosomes presented in Appendix I for which the effect was similar. This data, based on 
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cubosomes formed from an alternative lipid along with in vitro cell toxicity studies of the free 
lipids, phytantriol and selachyl alcohol, by Younus et al.271 suggest the cubosome structure 
itself to be the key cause of cell toxicity/epithelial disruption. The mechanism of this toxicity 
remains uncertain, but is likely due to a fusogenic mechanism of interaction between the 
negatively curved bilayers of the nanoparticles and the plasma membranes of the cells306,307 
which would obviously have a concentration limit above which it would be expected to become 
majorly disruptive. Tan et al.303 have reviewed the subject in more detail and concluded that 
current literature suggests that greater negative curvature seems to reduce cell toxicity (i.e. 
toxicity would be expected to be in the order of hexagonal < Pn3m cubic < Im3m cubic) due to 
a lower degree of lipid mixing with the cell membrane. This would imply that perhaps Pn3m 
cubosomes (e.g. OEA-phytantriol cubosomes stabilised with Pluronic F127® 258 or hexasomes 
(e.g. phenytoin-loaded selachyl alcohol hexosomes stabilised with Pluronic F127®, as 
characterised by Younus et al.271) may be more suitable for delivering higher concentrations 
(and therefore higher doses) of the therapeutics intranasally. However, unpublished in vitro cell 
toxicity studies carried out by the present author and Younus et al.271 have not found a difference 
between these formulations and the ones tested in this Chapter, so whether a difference would 
be seen in vivo remains questionable.   
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4.7 Conclusions 
This Chapter applied the seizure model from the previous Chapters to the investigation of a 
formulated endogenous compound with untested anti-seizure activity, oleoylethanolamide. The 
primary findings suggest that OEA (at least in cubosome form) does not exhibit acute anti-
seizure activity after intravenous administration at the dose tested. However, the subsequent 
chemical and structural stability studies of 13C-OEA and OEA cubosomes respectively present 
ample evidence to suggest that the delivery of OEA cubosomes to the brain via the systemic 
circulation is complex. They support that it could have been subject to confounding from a 
range of different variables which it was not possible to tease out within the constraints of this 
Chapter. Intranasal delivery was therefore of particular interest as an alternative means to 
deliver OEA directly to the brain and bypass the systemic challenges altogether, however, these 
investigations were met with significant challenges of their own. Firstly, histology revealed that 
unlike the microparticles in the previous Chapter, the dose of cubosomes that could be 
administered to the nose was limited by concentration as well as volume. Secondly, testing for 
rapid effects on seizure threshold after intranasal administration (i.e. time points less than 60 
minutes after administration) was impeded by the lingering anti-seizure effects of the isoflurane 
anaesthesia that was necessary to deliver the dose to the animals. This rendered the MEST study 
inconclusive and highlighted a need for development of new intranasal administration methods 
for pre-clinical testing of such hypotheses. To conclude, the evidence at hand suggests that OEA 
cubosomes are not likely to be a useful anti-seizure treatment, at least after acute administration, 
but further investigation into the complexities behind these results will confirm whether this 
judgement is justified. It will also confirm whether OEA cubosomes themselves can maintain 
the required stability to be useful for intravenous or intranasal treatment of other conditions.
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Chapter Five 
 
Summary & Future Directions 
                                                                                           
Epilepsy is the most common serious neurological disorder3, affecting up to 50 million people 
worldwide4. Despite decades of international research towards developing new 
pharmacological treatments and the current availability of over 22 anti-seizure drugs (ASDs)6, 
approximately 30% of patients are still classified as “drug-resistant”7. Investigation of new 
strategies to support the ability of ASDs to offer sustained seizure freedom and tolerability is 
critical to addressing this troubling statistic. This thesis aimed to explore delivery of ASDs 
through the nose, a somewhat alternative approach to ASD treatment which has been gaining a 
lot of traction in recent years, especially in light of proposed direct nose-to-brain delivery 
pathways that bypass the hurdles of the systemic circulation33,82. Due to the physical limitations 
of the nasal cavity22,94, pharmaceutical formulation strategies are intimately relevant to the 
successful exploitation of this route of delivery and form the basis of the investigations in this 
thesis.    
 
Chapter One introduced the topic of intranasal delivery of anti-seizure drugs from the link 
between the nose and seizures, to pathways to the brain, to current rudimentary formulations in 
clinical use. It then proceeded to a discussion of animal seizure models and their theoretical 
application to studying intranasal seizure treatments, following by a critical discussion of 
methodology and outcomes reported in the more exploratory ventures in the literature to date. 
Upon this foundation, the experimental component of the thesis aimed to develop a relatively 
simple screening model capable of detecting intranasal effects in Chapter Two. It aimed to 
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then use that to explore firstly, a drug delivery system carrying the pharmacokinetically 
troublesome anti-seizure drug phenytoin in Chapter Three and secondly, a delivery system 
carrying an endogenous molecule, oleoylethanolamide, with potential, but previously 
unstudied, anti-seizure action in Chapter Four.  
Chapter Two proposed the development of a new cross-over study design based on the MEST 
test for assessing the effects of intranasal drug therapy on seizure threshold. As discussed in the 
preamble to that Chapter, the MEST test has been frequently used in the 
literature15,98,99,101,172,174,308, but the template of two subsequent “up and down” stimulation trials 
left room for improvement with regards to achieving the aims of this study. The expectation 
that the effects of intranasally delivered drugs may be more localised and subtle than those seen 
after systemic administration meant that modifications were necessary to aim for the highest 
sensitivity and lowest variability possible while still maintaining a fairly simple screening 
procedure. The modified design clearly detected the anti-seizure effect of phenytoin after 
intravenous administration with respect to the two key outcomes, HLE and FLE, and this was 
supported by measurement of brain and plasma levels which were in line with other reports in 
the literature175–177,187,188. Importantly, isoflurane administration 60 minutes prior to stimulation 
did not appear to introduce any confounding effect between phenytoin and control that could 
have decreased the resolution for detecting anti-seizure effects. This was an important 
prerequisite for the following studies as anaesthetics are currently necessary to reliably and 
ethically perform intranasal administration to the olfactory region in rats, as discussed in 
Chapter One, so any effect of them on seizure tests must be minimised in order to obtain 
unambiguous results. A further important consideration for any seizure model is the impact on 
animal welfare. This was closely evaluated for this procedure and determined to be minimal, 
supporting the continued use of the model in the subsequent experiments.  
Chapter Three proceeded to apply the seizure model to its intended purpose of evaluating an 
intranasal delivery system carrying phenytoin. The aim was both to evaluate the anti-seizure 
efficacy of tamarind polysaccharide-based phenytoin microparticles, an intranasal delivery 
system previously designed and characterised by Yarragudi et al.204, as well as to test the 
capabilities and limitations of the model in detecting anti-seizure effects following the 
intranasal delivery of the known ASD phenytoin. With regards to evaluating the phenytoin 
microparticles as an intranasal anti-seizure drug delivery system, this study was particularly 
unique in that it is the first to the author’s knowledge of an intranasal dry powder (anti-seizure) 
delivery system being administered and evaluated as a dry powder as opposed to being 
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suspended in a liquid before administration146 to facilitate administration to animals, which no 
doubt affects the behaviour of the particulate delivery system. Furthermore, this study 
holistically addressed histological safety, pharmacokinetics and pharmacodynamics, as 
opposed to other in vivo studies of ASD delivery systems in the literature that encompassed 
only selected elements and carried avoidable limitations making them hard to draw conclusions 
from, as discussed in detail in Chapter One.  
The modified MEST study design proved proficient at detecting intranasal anti-seizure effects, 
with a peak effect being identified at 120 minutes after administration which correlated with 
peak brain levels of phenytoin. As was seen in Chapter One, most studies of intranasal anti-
seizure delivery systems aim to use the direct nose-to-brain route to achieve rapid effects for 
rescue therapy. The data in this Chapter, however, shows the microparticles to be a fairly slow-
acting, but sustained anti-seizure drug delivery system more suitable for the potential 
application of regular dosing of phenytoin which presents the utility of the nose-to-brain route 
for the treatment of seizures from a different perspective. The implementation here would most 
likely be as a means to deliver the phenytoin effectively to keep seizures suppressed, while 
bypassing the pharmacokinetic pitfalls that mar its systemic use, thereby increasing tolerability 
and simplifying dosing.  
A further area of interest is whether the direct intranasal delivery of phenytoin, which 
theoretically bypasses multi-drug transporters at the blood brain barrier, could be applied in 
cases of drug resistance attributed to multi-drug transporter overexpression. As discussed in 
Chapter One and Chapter Three, many studies have been performed to explore the multi-
drug transporter hypothesis of resistance in the past two decades9,122,133,174,201–203 and phenytoin, 
as a model drug, has been at the centre. The phenytoin-resistant kindled rat in particular was 
extensively characterised and presents an interesting future model in which the utility of the 
microparticles might be studied to ascertain whether the anti-seizure effect of phenytoin can be 
rekindled in animals which have developed resistance to the systemically administered drug. 
This is, however, a model of focal epilepsy, so preliminary studies would be recommended to 
investigate regional brain distribution to the focus (i.e. the amygdala).  
In addition to the efficacy data, the results of this Chapter supported the previous claim by 
Yarragudi et al.204 that delivery of phenytoin from the microparticles followed a direct route 
from the nasal passage to the brain.  This was reflected in the relative plasma and brain 
concentrations of phenytoin, but also supplemented by going a step further and studying the 
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presence of its major metabolite, 4-HPPH, which was found to be elevated in the brain above 
the low percentage expected after systemic administration. The study of 4-HPPH also offered 
the suggestion that phenytoin was being partially metabolised by the nasal epithelium and the 
sustained release mechanism of the microparticles may therefore have facilitated direct 
transport to the brain through metabolite-induced inhibition of phenytoin metabolism229. This 
was an interesting incidental finding and suggested that future studies may be able to harness 
the approach to allow more in depth study into the delivery of ASDs via the nasal passage by 
also considering their metabolites. 
Interestingly, in the studies of Chapter Three, the direct brain delivery of phenytoin did not 
appear to be primarily mediated through pathways associated with the olfactory bulbs. While 
previous studies have suggested intranasal trafficking of anti-seizure drugs through the 
olfactory bulbs138,140,141, the data of this Chapter was to the contrary and in agreement with that 
presented by Yarragudi et al.204 in that olfactory bulb concentrations were never higher relative 
to the main brain after microparticle administration (or for that matter, phenytoin control 
solution) and if anything, generally appeared to be lower. The present study, however, also 
studied brainstem concentrations of phenytoin and found an apparent elevation in this region. 
This finding, combined with the discussion of current literature in Chapter One, suggested a 
brainstem-associated bulk intranasal transport pathway (e.g. bulk flow peripheral to trigeminal 
neurons) to be the most likely mechanism which led to direct, but widespread brain delivery of 
phenytoin.   
A final notable finding from Chapter Three concerns the importance of histological sampling 
as an essential component of intranasal drug delivery studies. Chapter One discussed the lack 
of regard for this in the current literature and the suggestion in a review by Kozlovskaya et al.91 
that fractions of drug reportedly delivered intranasally to the brain in many studies were so high 
that they implied a breach of physiological barriers due to formulation constituents. The 
credibility of this claim was seen experimentally in Chapter Three through the comparison of 
the biocompatible phenytoin microparticles with an evidently incompatible ethanol-containing 
phenytoin control solution which caused significant epithelial disruption and emphasised the 
need for quality histological studies to accompany all future investigations into intranasal drug 
delivery to ensure safety. The similarities between rodent and human nasal epithelia mean 
preclinical studies in rodents offer an ideal opportunity to screen histologically and optimise 
dosage and formulation at this early stage, while validating claims of direct intranasal delivery.  
Tissues can easily be obtained as a by-product from animals undergoing pharmacokinetic or 
efficacy experiments so future researchers should not be excused from having to present this 
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data.  The data presented by Yarragudi et al.204 and subsequently in Chapter Three supports 
the compatibility of phenytoin microparticles with the nasal epithelium and encourages future 
studies with this delivery system such as those mentioned earlier regarding seizure prevention 
in a more complex animal model, as well as tolerability of blank tamarind seed polysaccharide 
microparticles in human subjects.  
Overall, the results of Chapter Three supported the use of the MEST seizure model as a 
screening tool to ascertain the effects of intranasally delivered anti-seizure drugs, so Chapter 
Four subsequently aimed to investigate a molecule with hypothesised, but previously untested 
activity. That molecule was oleoylethanolamide, an endogenous bioactive lipid of the N-
acylethanolamide class with reported neuroprotective properties236–238 that has recently been 
formulated into a nanoparticulate dispersion of cubosomes by Younus et al.258 to improve 
solubility and stability.  Other N-acylethanolamides have shown anti-seizure activity in MES 
studies in the literature239,241, so it was hypothesised that OEA would too, simultaneously 
providing a demonstration of the proposed benefits of formulating it into cubosomes. This 
result, however, was not to be found.  
The study began with an investigation of intravenously administered OEA cubosomes. This 
route was chosen to provide a positive control of the effects of OEA on seizures, such as that 
provided by intravenous phenytoin in Chapter Two, prior to intranasal studies. Unlike similar 
molecules (PEA and AEA) which have demonstrated an effect in the supramaximal MES 
test239,241, OEA failed to show any significant effect (pro- or anti-seizure) in the submaximal 
threshold MEST test used in this study. It was therefore concluded that OEA, at least in 
cubosome form and at the dose tested, does not exhibit an acute effect on seizure threshold after 
intravenous administration. A couple of future directions immediately emerge upon stating this 
conclusion, namely whether the cubosome dispersion could be concentrated further or modified 
to increase the dose of OEA delivered or whether chronic administration of OEA cubosomes 
might be the key to uncovering anti-seizure effects of OEA, both of which were discussed in 
Chapter Four. Furthermore, the recent cubosome formulation of another NAE, 
linoleoylethanolamide (LEA), by Younus et al.271 offers another avenue for MEST screening 
studies.  
To provide a more wholesome foundation for directing such future studies, however, 
pharmacokinetic and structural stability analyses were subsequently conducted in Chapter 
Four to determine whether the lack of effect from OEA could be explained by the OEA 
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pharmacokinetic profile or a potential change in the environmentally malleable self-assembled 
cubosome structure. What was found opened up possibilities for a further range of future studies 
to tease out the complexities of the results. Pharmacokinetic studies with 13C-OEA cubosomes 
suggested that the lack of effect may have been due to a lack of delivery of OEA to the brain 
after intravenous administration. However, it was unclear whether this was due to a rapid 
hydrolysis and a failure of the cubosomes to protect the OEA or a preferential distribution to 
other body compartments due to a failure of the cubosomes to target the brain. The former 
suggestion would be in disagreement with the in vitro findings of Younus et al.271, while the 
latter would differ from the present author’s extracurricular in vivo studies with phenytoin 
cubosomes which did suggest the cubosomes facilitated drug delivery to the brain. However, 
the delivery of intact cubosomes was not proven here and the different lipid used (i.e. selachyl 
alcohol) may have influenced its success (unpublished data). Methodological limitations may 
also have played a role, as was discussed in Chapter Four along with some suggested 
improvements. In particular, it is suggested that future studies be carried out which take samples 
of plasma (and brain if possible) concentrations in single animals over time, rather than the time 
point allocated groups in this study in order to eliminate intra-subject variability between time 
points in the pharmacokinetic profile and remove the effects of potential dosing errors and post-
mortem NAE concentration changes. Also worth investigating would be the effect of stabiliser 
on the fate of OEA administered in cubosomes as  Younus et al.271 reported a slight (though 
statistically insignificant) increase in protection of OEA in Pluronic F127® cubosomes in vitro 
compared with Tween 80® when exposed to FAAH which could possibly have in vivo 
relevance.  
To complicate matters further, in vitro SAXS studies indicated that the OEA cubosomes 
stabilised with Tween 80® rapidly transformed into a hexosomes upon contact with blood 
plasma which offered a further possible explanation for why the cubosomes seemed to be 
unsuccessful at delivering the OEA systemically. While hexosomes are not considered to be 
ineffective drug delivery systems296,303,309, the change in structure raises questions about the 
stability and retention of OEA in the particles and the effect this may have on biological 
distribution as work to date has characterised these only with respect to cubosomes 
(unpublished data). As a starting point for further investigations, it is suggested that a study 
could be conducted whereby OEA cubosomes are incubated for a short time with plasma, then 
separated from it again using a size exclusion column, as in another of the present author’s 
extracurricular studies investigating protein adsorption to cubosomes (unpublished data), and 
the retention of OEA in the nanoparticles measured. Furthermore, studies might then be 
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performed to compare the in vitro stability of the hexosomes against FAAH to that reported by 
Younus et al.271 for the unexposed cubosomes. In light of the suggested pharmacokinetic studies 
with Pluronic F127®-stabilised OEA cubosomes above, similar studies might also be performed 
on the ambiguous-phased particles into which this type of cubosomes transformed, as was 
shown in Appendix O, to see how this alternative transformation influences the protection and 
delivery of OEA. As a more extensive continuation of this thread, studying what actually causes 
the transformation of cubosomes to hexosomes would be of great interest to the field of self-
assembling lipid nanoparticles, not only with respect to OEA cubosomes, but also pure 
phytantriol cubosomes, as this could allow such mechanisms to be manipulated and exploited 
as has been the case for dispersions in gastrointestinal fluids310. 
In the context of this thesis, investigations then proceeded to explore if intranasal delivery could 
offer a means of delivering OEA directly to the brain and bypassing the systemic challenges 
altogether. The first obstacle in this study was presented by histology which showed that the 
dose of OEA dispersion that could be administered safely (i.e. without disrupting the olfactory 
epithelium) to the test animals was limited by concentration as well as volume and required 
dilution of the maximum possible with the presently characterised formulation. This was a 
setback compared with the powder formulation in Chapter Three for which the dose seemed 
to be limited only by how much powder could be administered from the insufflator. While 
powder would obviously reach a limit too, based on the safe volume of the nasal cavity it could 
occupy without impeding breathing, this delivery system was clearly more compatible than the 
cubosomes with the nasal epithelial cells. Further experiments confirmed that the cubosomes 
themselves appeared to be the cause of the disruption, rather than the individual components of 
the formulation. The testing of intranasal cubosomes has been reported before (though not for 
seizure treatment)311, but the present study is the first to the author’s knowledge to report a 
toxicity to the nasal epithelium independent of lipid type. This is somewhat surprising given 
the extensive attention given to the in vitro study of cubosome toxicity to various cell types as 
discussed in Chapter Four and stresses that quality histological data should be a fundamental 
means of validation of in vivo studies in the pharmaceutical sciences literature, especially with 
regards to direct nose-to-brain delivery for which it is intimately relevant. Furthermore, it offers 
an in vivo perspective on cubosome tolerability by cells which would do well to be expanded 
on in future studies and compared with in vitro dose-response findings to ascertain 
translatability of the data modelled in this setting and, if appropriate, use it to screen and 
optimise formulations further for interaction with the nasal epithelium. For instance, as 
discussed in Chapter Four, current literature suggests hexosomes might be more suitable for 
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higher dose nanoparticle administration303, so modification of the phase of the OEA dispersion, 
perhaps by introducing a molecule to induce negative curvature (e.g. tocopheryl acetate312) 
could be explored and trialled in vivo.  
Despite the above findings, dilution of the dispersion allowed a histologically safe dose of OEA 
cubosomes to be determined and this was used to test for an effect on seizure threshold. A 
reliable, but non-significant, result was only obtainable at 60 minutes after administration as it 
became evident that the effect of the anaesthetic isoflurane on seizures (which was necessary 
to allow deep intranasal administration) was significant at earlier time points of 15 and 30 
minutes after administration and clouded the experimental outcome. This was not entirely 
unexpected given the discussion of the limitations posed by the need for anaesthetics in 
Chapter One, and though it was hoped the crossover study design and short duration of 
anaesthetic used in the present investigations may have offered some reprieve, this was not the 
case. It therefore remains an important issue for future pre-clinical studies to navigate should 
the study of rapid intranasal anti-seizure effects wish to progress. In the meantime, perhaps 
more attention should be given to administration of longer-acting anti-seizure drugs and 
delivery systems as regular dosing instruments, as in Chapter Three, or to testing compounds 
after chronic administration via the nose which could still be studied using the present methods 
and could be more relevant to the mechanism of action of OEA, as proposed earlier in 
discussion of intravenous studies. An intranasal pharmacokinetic study with 13C-OEA may also 
shed some light on the timescale and pathway of the passage of OEA from the nose to the brain 
and be of use in guiding future work. Additionally, pharmacodynamic studies of OEA in other 
neurological conditions in which it is proposed to be effective (e.g. stroke and Parkinson’s 
disease236–238), specifically those with measurable outcomes which are not so easily affected by 
anaesthetics, may provide a better initial evaluation of the potential of cubosomes to deliver 
OEA intranasally and whether investigations into its utility as a seizure treatment are worth 
pursuing. In light of the results obtained, Chapter Four had to conclude that OEA cubosomes 
appeared to be ineffective at influencing seizure threshold after acute administration by the 
intranasal route at the maximum non-disruptive dose. Whether this was due to a complete lack 
of efficacy of OEA, an inadequate maximum deliverable dose based on volume and 
concentration limitations, or the inability to see through the confounding of the anaesthetic 
remain questions to be investigated by the future studies discussed and provide a foundation for 
other studies investigating intranasal OEA.   
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Overall, this thesis has achieved its aim of establishing a model for testing intranasal ASD 
delivery and fundamentally evaluating the potential for delivery of ASDs through the nose to 
the brain using the selected particulate formulation strategies of microparticles and cubosomes. 
From the critique of the emerging intranasal field laid out in the opening review, to the practical 
implementation and challenges of the subsequently designed experiments, to the enticing 
follow-on questions summarised in this Chapter which are yet to be answered, the author hopes 
this text has stimulated critical thought and provided some sturdy groundwork on which future 
science can be built. 
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Appendices 
 
Appendix A: Weight progression of rats over the course of all seizure studies in Chapter 
Three. Days of stimulation are indicated by red arrows.  
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Appendix B: Average age (±SD) of rats over the course of each of the seizure experiments.   
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Appendix C: Results of all MEST experiments presented in terms of the number of rats 
displaying a result. Black bars represent a change in HLE response, while grey bars 
represent no change in HLE response between trials.  Details of the calculation method 
for the percentage differences presented in the Chapters are also given.  
 
Anti-seizure effect was determined by the ability of the treatment to prevent HLE:  
Anti-seizure effect (%) = Cases of drug preventing HLE (i.e. saline = HLE, drug = no HLE) 
(black) / (all cases of HLE both times (no anti-seizure effect) (grey) + cases of drug preventing 
HLE (i.e. saline = HLE, drug = no HLE) (black)) x 100 
Pro-seizure effect was determined by ability of the treatment to cause HLE: 
Pro-seizure effect (%) = Cases of drug causing HLE (i.e. saline = no HLE, drug = HLE) (black) 
/ (all cases of no HLE (i.e. no pro-seizure effect) (grey) + cases of drug causing HLE (i.e. saline 
= no HLE, drug = HLE) (black) x 100 
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Appendix D: Chromatograms from the validation of the specificity of the phenytoin and 
4-HPPH LC-MS Method. A = solvent (methanol), B = Plasma blank, C = Plasma LLOQ 
concentration, D = Brain blank, E = Brain LLOQ concentration.  
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Appendix E: Intraday variability in phenytoin and 4-HPPH standard curves.  
Analyte Nominal 
conc 
(ng/mL) 
Intraday 1 (n=3)  Intraday 2 (n=3)  Intraday 3 (n=3) 
R2 Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
 R2  Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
  R2  Mean     
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
 Plasma 
Phenytoin 7.81 0.9999 7.3 93.6 4.0  0.9998 6.8 87.3 4.8  0.9999 7.4 94.9 3.5 
 15.6  15.0 95.8 3.2   14.7 94.2 6.4           16.0 102.3 1.3 
 31.3  32.1 102.6 2.2   32.5 104.1 9.4           29.6 94.7 3.1 
 62.5  61.6 98.6 3.7   64.3 102.8 7.0          64.0 102.5 0.5 
 125  126 100.8 1.4   124 98.9 7.6          129 103.3 4.7 
 250  251 100.3 2.6   251 100.3 2.9         271 108.3 0.6 
4-HPPH 7.81 0.9999 7.5 95.6 5.3  0.9992 8.3 106.7 0.9  0.9996 8.1 103.9 6.6 
 15.6  16.2 103.4 1.7   15.1 96.9 3.4   15.1 96.4 4.7 
 31.3  31.8 101.7 5.1   27.0 86.5 5.9   30.4 97.1 3.9 
 62.5  60.9 97.4 0.6   62.4 99.9 3.0   60.5 96.7 5.5 
 125  126 100.8 4.1   126 100.5 4.2   129 102.9 2.6 
 250  252 100.8 2.3   242 96.9 3.9   253 101.3 0.7 
 Brain 
Phenytoin 23.4 0.9998 24.2 103.1 5.0  0.9996 22.8 97.1 4.0  0.9999 22.1 94.5 4.8 
 46.9  48.1 102.6 4.9   48.4 103.2 4.6           47.1 100.6 4.6 
 93.8  93.2 99.4 5.7   90.1 96.1 3.1           98.5 105.1 10.7 
 188  181 96.5 4.7   197 105.3 2.0          185 98.8 4.6 
 375  378 100.9 4.0   367 97.9 1.8          371 99.0 3.1 
 750  745 99.3 2.5   739 98.6 0.8         742 98.9 1.0 
4-HPPH 23.4 1 23.4 99.7 5.1  0.9998 22.5 96.1 3.0  0.9999 21.9 93.4 2.6 
 46.9  48.9 104.4 4.8   48.9 104.2 3.3   48.4 103.3 2.4 
 93.8  94.6 100.9 3.6   93.3 99.6 2.0   100.7 107.4 5.6 
 188  185 98.9 4.5   197 104.9 3.2   190 101.3 0.6 
 375  380 101.3 2.5   374 99.7 1.8   377 100.4 2.7 
 750  755 100.7 3.2   759 101.2 2.5   759 101.2 0.9 
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Appendix F: Phenytoin concentrations matched to individual response of each phenytoin-
treated rat in the second treatment trial of the validation experiment in Chapter Two. 
 
 
 
Rat 
Phenytoin Concentration Response 
Plasma 
(µg/mL) 
Brain  
(µg/g) 
 
HLE FLE Other 
  1* 2.1 3.4 No Yes Clonus 
2 5.0 6.1 No No Audiogenic-like 
3 6.0 6.5 No No Audiogenic-like 
  4* 5.5 6.2 No No Short clonus 
5 7.3 9.3 No No Audiogenic-like 
6 7.8 7.3 No No Audiogenic-like 
7 7.2 7.7 No No Very short clonus 
8 7.5 8.4 No No Very short clonus 
9 7.9 7.8 No No Audiogenic-like 
*Invalid response in one MEST trial, so this animal was excluded from the pharmacodynamic 
data analysis. Note: The rat which displayed FLE as presented in the pharmacodynamic data 
did so in the second stage of the experiment (i.e. the first treatment trial), so plasma and brain 
phenytoin concentrations were not taken and are therefore not presented in the above table.  
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Appendix G: Average mass of phenytoin (or equivalent of TSP) delivered from intranasal 
insufflator in microparticle experiments. 
 
 
Experiment 
Average phenytoin (or 
phenytoin equivalent mass) 
delivered (±SD) (mg) 
PHT MPs 60 min 1.7 (±0.4) 
PHT MPs 120 min 1.6 (±0.6) 
PHT MPs 180 min 1.5 (±0.5) 
Blank MPs 120 min 1.5 (±0.3) 
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Appendix H: Brainstem and olfactory bulb intra-day standard curve accuracy and 
precision for quantification of phenytoin and 4-HPPH.  
             Brainstem  
Analyte Nominal 
conc  
(ng/g) 
Intraday (n=3) 
Mean 
(ng/g) 
Accuracy 
(%) 
Precision 
(CV%) 
Phenytoin 23.4 22.1 94.1 2.7 
46.9 47.5 101.1 3.1 
93.8 95.4 101.8 4.7 
 187.5 187.5 100.0 0.5 
 375 371 99.0 1.9 
 750 744 99.2 1.2 
4-HPPH 23.4 21.1 90.0 2.2 
 46.9 47.9 102.1 1.8 
 93.8 97.3 103.8 2.1 
 187.5 192.0 102.4 3.6 
 375 369 98.4 4.0 
 750 747 99.6 5.9 
         Olfactory bulbs  
Analyte Nominal 
conc  
(ng/mL) 
Intraday (n=3) 
Mean 
(ng/g) 
Accuracy 
(%) 
Precision 
(CV%) 
Phenytoin 23.4 23.7 101.3 4.1 
46.9 48.0 102.4 2.4 
93.8 93.8 100.0 3.8 
 187.5 182.5 97.3 2.5 
 375 380 101.2 3.5 
 750 744 99.2 0.2 
4-HPPH 23.4 23.6 100.8 0.8 
 46.9 46.7 99.7 0.9 
 93.8 93.8 100.1 4.4 
 187.5 184 98.3 1.8 
 375 378 100.9 3.2 
 750 754 100.5 3.0 
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Appendix I: Histological effect of selachyl alcohol-based phenytoin cubosomes 50 mg/mL 
(w/w lipid) or equivalent phenytoin suspension on the olfactory mucosa of rats. 
Dispersions consisted of 0.5 mg/mL phenytoin, 0.75% w/v Polysorbate 80 and 12.5% w/v 
propylene glycol with or without 5% w/v selachyl alcohol. Control nostril (A, B, C) and 
treatment nostril (D, E, F) are shown for saline, phenytoin cubosomes and phenytoin free 
drug suspension respectively.  
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Appendix J: Calculation procedure used to prepare stock solutions for phenytoin and 4-
HPPH standards for LC-MS.  
To make standards in plasma and brain using 5 µL aliquots of stock solution: 
 
Plasma:  
 
Concentration of standard stock solution (ng/mL) =  
Desired standard concentration in plasma (ng/mL) x (100 µL/1000 µL) x (1000 µL/5 µL 
aliquot of stock solution)    
 
e.g. Desired 50 ng/mL standard conc in plasma x 0.1 mL plasma aliquot x (1000 µL/5 µL 
aliquot of stock solution) = 1000 ng/mL stock solution 
 
Brain: 
 
Concentration of standard stock solution (ng/mL) =  
Desired standard concentration in brain (ng/g) x (1 g/3 mL homogenate) x (100 µL/1000 
µL) x (1000 µL/5 µL aliquot of stock solution)    
 
e.g. Desired 150 ng/g standard conc in brain x (1g/3mL homogenate) x 0.1 mL brain 
homogenate aliquot x (1000 µL/5 µL aliquot of stock solution) = 1000 ng/mL stock solution 
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Appendix K: Percentage of HLE and FLE in individual MEST treatment groups.  
Experiment %HLE after 
saline 
%HLE after 
drug treatment 
Phenytoin 25mg/kg IV (60 min) 57 0 
Phenytoin microparticles (60 min) 55 46 
Phenytoin microparticles (120 min) 28 11 
Phenytoin microparticles (180 min) 35 12 
Blank microparticles (120 min) 28 22 
Phenytoin control solution IN (60 min) 61 22 
OEA cubosomes IV (15 min) 57 43 
OEA cubosomes IV (30 min) 50 40 
OEA cubosomes IV (60 min) 50 62.5 
OEA cubosomes IN (30 min) 13 18 
OEA cubosomes IN (60 min) 39 28 
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Appendix L: Prescott’s test tables with two-tailed p-values for all MEST experiments.  
Phenytoin microparticles (60 minutes); p=0.8 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 1 3 0 4 
Drug → Saline 0 6 0 6 
Total 1 9 0 10 
 
Phenytoin microparticles (120 minutes); p=0.3647 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 3 6 0 9 
Drug → Saline 1 7 1 9 
Total 4 13 1 18 
 
Phenytoin microparticles (180 minutes); p=0.1412 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 2 6 0 8 
Drug → Saline 0 7 2 9 
Total 2 13 2 17 
 
Pooled phenytoin microparticles (60, 120, 180 minutes); p=0.016 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 6 15 0 21 
Drug → Saline 1 20 3 24 
Total 7 35 3 45 
 
Blank microparticles (120 minutes); p=1 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 1 7 1 9 
Drug → Saline 1 6 2 9 
Total 2 13 3 18 
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Intranasal phenytoin control solution (60 minutes) – HLE; p=0.0136 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 2 7 0 9 
Drug → Saline 0 4 5 9 
Total 2 13 5 18 
 
Intranasal phenytoin control solution (60 minutes) – FLE; p=1 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 1 8 0 9 
Drug → Saline 0 9 0 9 
Total 1 17 0 18 
 
Intravenous phenytoin 25 mg/kg (60 minutes) – HLE; p=0.0035 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 6 1 0 7 
Drug → Saline 0 5 2 7 
Total 6 6 2 14 
 
Intravenous phenytoin 25 mg/kg (60 minutes) – FLE; p=0.0006 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 7 0 0 7 
Drug → Saline 0 1 6 7 
Total 7 1 6 14 
 
OEA cubosomes (i.n.) (30 minutes); p=1 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 0 8 0 8 
Drug → Saline 1 7 0 8 
Total 1 15 0 16 
 
OEA cubosomes (i.n.) (60 minutes); p=0.93 
Sequence HLE 1st time 
only 
HLE or No 
HLE both 
times 
HLE 2nd time 
only 
Total 
Saline → Drug 0 8 0 8 
Drug → Saline 0 6 1 7 
 Total 0 14 1 15 
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Appendix M: Comparison of baseline log CC50 values (±SD) between MEST experiments.  
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Appendix N: Weight progression of rats over the course of all seizure studies in Chapter 
Four. Days of stimulation are indicated by red arrows. 
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Appendix O: Control and rat plasma SAXS studies of OEA cubosomes stabilised with 
Pluronic F127®. Arrows show the relative peak positions of the Pn3m cubic phase. For the 
plasma data, the phase was not able to be identified.  
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Appendix P: Intraday variability in 13C-OEA standard curves from LC-MS method validation.  
Analyte Nominal 
conc 
(ng/mL) 
Intraday 1 (n=3)  Intraday 2 (n=3)  Intraday 3 (n=3) 
R2 Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
 R2  Mean 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
  R2  Mean     
(ng/mL) 
Accuracy 
(%) 
Precision 
(%CV) 
Plasma 
13C-OEA 0.39 1 0.40 102 1.2  1 0.39 99.1 1.8  0.9997 0.35 90.1 6.1 
 0.78  0.78 99.3 1.4   0.78 99.3 0.9   0.76 97.9 5.7 
 1.56  1.52 97.4 5.3   1.55 99.1 4.0   1.55 99.4 4.7 
 3.13  3.16 101.3 0.6   3.19 102.1 1.3   3.14 100.4 6.1 
 6.25  6.25 100.0 1.3   6.18 98.9 4.2   6.59 105.4 3.3 
 12.5  12.4 99.3 1.2   12.5 99.9 0.8   12.3 98.0 6.0 
 25  24.8 99.1 0.4   24.9 99.5 1.3   25.0 100.2 5.0 
Brain 
13C-OEA 1.17 1 1.18 101.1 9.8  0.9998 1.11 95.0 8.9  0.9999 1.21 103.5 1.3 
 2.34  2.40 102.4 1.2   2.27 96.9 5.3   2.35 100.4 8.9 
 4.69  4.63 98.8 6.4   4.82 102.8 7.8   4.79 102.1 2.2 
 9.38  9.26 98.8 1.4   9.43 100.5 4.7   9.13 97.4 1.4 
 18.8  18.8 100.0 2.9   19.5 104.1 6.2   19.2 102.2 5.8 
 37.5  37.5 99.9 2.3   37.0 98.6 1.8   37.3 99.5 2.6 
 75  74.8 99.7 0.7   75.2 100.3 4.9   75.1 100.2 2.3 
Liver 
13C-OEA 1.17 0.9998 1.00 85.1 7.5  1 1.09 93.1 8.0  1 1.13 96.7 5.5 
 2.34  2.29 97.7 4.3   2.35 100.3 2.0   2.31 98.4 1.5 
 4.69  4.73 100.9 3.6   4.68 99.8 2.0   4.74 101.1 1.2 
 9.38  9.74 103.9 0.9   9.54 101.8 3.0   9.47 101.1 3.9 
 18.8  19.4 103.7 1.5   19.1 102.0 2.8   19.0 101.1 4.6 
 37.5  37.0 98.7 1.0   37.4 99.7 0.9   37.3 99.4 1.5 
 75  75.6 100.9 4.8   75.7 100.9 2.5   75.0 100.0 0.2 
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Appendix Q: Pharmacokinetic analysis of 13C-OEA (Figure 4.12) including values below 
the lower limit of quantification of the LC-MS assay (unfilled symbols), as measured and 
calculated by extrapolation of the model. 
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Appendix R: SAXS studies of phytantriol-Tween 80® cubosomes incubated at 37 ºC in 
different concentrations of plasma at 5 min (A) and 60 min (B) to allow observation of the 
Im3m cubosome to hexasome transformation. A 100 µL aliquot of cubosome dispersion 
was added to 100 µL of rat plasma pre-diluted with phosphate buffered saline (PBS) pH 
7.4 to between 1 and 8 times its original concentration. For the control, rat plasma was 
replaced with PBS alone. Emergence of the hexasome peaks are indicated by arrows.  
 
 
 
 
 
 
 
 
 
